Annu. Rev. Med. 2008.59:1-12. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-01
ARI
7 December 2007
13:33
The FDA Critical Path Initiative and Its Influence on New Drug Development∗ Janet Woodcock1 and Raymond Woosley2 1
Center for Drug Evaluation and Research, US Food and Drug Administration, Rockville, Maryland 20857; email:
[email protected]
2
The Critical Path Institute, Tucson, Arizona 85721; email:
[email protected]
Annu. Rev. Med. 2008. 59:1–12
Key Words
The Annual Review of Medicine is online at http://med.annualreviews.org
biomarkers, biomarker qualification, clinical trials
This article’s doi: 10.1146/annurev.med.59.090506.155819
Abstract
c 2008 by Annual Reviews. Copyright All rights reserved 0066-4219/08/0218-0001$20.00 ∗ The U.S. Government has the right to retain a nonexclusive, royalty-free license in and to any copyright covering this paper.
Societal expectations about drug safety and efficacy are rising while productivity in the pharmaceutical industry is falling. In 2004, the US Food and Drug Administration introduced the Critical Path Initiative with the intent of modernizing drug development by incorporating recent scientific advances, such as genomics and advanced imaging technologies, into the process. An important part of the initiative is the use of public-private partnerships and consortia to accomplish the needed research. This article explicates the reasoning behind the Critical Path Initiative and discusses examples of successful consortia.
1
ANRV334-ME59-01
ARI
7 December 2007
13:33
INTRODUCTION
Annu. Rev. Med. 2008.59:1-12. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
In 2004, the US Food and Drug Administration (FDA) launched the Critical Path Initiative, a project that is intended to improve the drug and medical device development processes, the quality of evidence generated during development, and the outcomes of clinical use of these products. Why would a regulatory agency be involved in such a modernization effort? FDA’s mission is to protect and promote the health of the public. With respect to drugs, biological products, and medical devices, this translates into ensuring reasonable product safety while also facilitating the translation of scientific innovations into commercial products. The ongoing tension between these two objectives results in assertions that FDA requirements are stifling innovation, and simultaneously that FDA standards are too low. The thesis of the Critical Path Initiative is that scientific advances in the development process are the best way to resolve these conflicts to the satisfaction of most parties and to the benefit of the public. Although the initiative concerns all regulated medical products, this review discusses Critical Path in the context of drug development.
BACKGROUND Rising Expectations about Drug Development In 1962, congressional amendments to the Food, Drug, and Cosmetic Act created for the first time a requirement that drugs be scientifically shown to be effective before they could be marketed (a requirement for safety had been in effect since 1938). During the 1960s–1980s, drug developers, the academic community, and regulators worked to develop and refine ways to design, conduct, and analyze randomized controlled clinical trials that could produce the needed evidence. Many important advances in pharmacotherapy (e.g., cardiovascular therapies, psychiatric drugs, anti-infectives, and cancer treatments) 2
Woodcock
·
Woosley
were introduced during this era. However, the evidence generated in drug development programs was still somewhat limited. For example, dose-response information was usually scanty, often few women were studied, data on long-term use (even for chronically administered drugs) were lacking, evaluations of subgroups such as patients with renal or hepatic insufficiency were not conducted, and data on drug-drug interactions were not available. From the mid-1980s through the 1990s, as an increasing number of drug therapies became available, the FDA as well as the international regulatory community established the expectation that such information would be obtained during most drug development programs. Therefore, modern development programs usually are much more extensive and contain many more clinical studies and patient exposures than was usual in 1960–1985. Despite these advances, there remains a great deal of uncertainty about the performance of drugs that are new to the market. Data from long-term use are still usually limited. Current drug development programs cannot detect drug-related adverse outcomes that represent a small increase in frequency of a problem that is already common in the treated population (e.g., ischemic cardiovascular events). Technologies to predict the occurrence of rare, catastrophic side effects are not available. Additionally, despite attempts to make the results of clinical trials more generalizable, the patients enrolled in trials do not reflect the full range of the population or treatment situations that occur in practice. As a result, new safety issues are often identified only after drugs enter the market. Nevertheless, in the past decade, aggressive marketing techniques have led to immediate uptake and widespread use of many new drugs, combined with a general expectation that their performance is well understood over a wide range of clinical situations. In particular, many members of the public believe that if prescription products are advertised on television, they must be safe. The increasing
Annu. Rev. Med. 2008.59:1-12. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-01
ARI
7 December 2007
13:33
recognition of this problem has led to calls for larger trials and longer patient exposures prior to drug marketing. Not only drug development but also medical practice has become increasingly complex since the 1962 amendments. For many diseases, multiple subgroups and disease stages have been defined, and numerous therapeutic options exist. Drug development programs are rarely designed to answer the questions posed by evidence-based medicine and by insurers: What therapeutic option has the best outcomes in various patient groups or, similarly, what option provides the best value? If comparative trials are performed premarket, they usually involve a demonstration of “noninferiority” in comparison with a single control drug. Increasingly, members of the health care community, as well as Congress, are calling for more of this information to be developed.
Problems with the Pharmaceutical Pipeline The pharmaceutical industry is facing a productivity crisis. Despite rising investment in pharmaceutical research and development, successful development of novel drugs is slowing (Figure 1). In fact, 2004 represented a 20-year low in introductions of new chemical entities (NMEs) worldwide (1). The same phenomenon has been observed in the United States, where the submission rate of new drug applications for NMEs has shown a downward trend in the past decade (2). Not surprisingly, the investment needed per successful NME has risen to an estimated $800 million or more (3, 4). This cost is driven by the high rate of clinical failure, estimated at 70%– 90% of candidates (5). The rising percentage of late-stage clinical failures, now ∼50% of compounds tested in phase 3 trials, is of particular concern. The high cost of successful drug development may discourage investment in more innovative, risky approaches, as well as in therapeutics for diseases that represent smaller markets. Additionally, the need
Global R&D spend ($bn)
Unique NMEs launched worldwide 70
70 R&D spend 60
60
NMEs
50
50
40
40
30
30
20
20
10
10 0
0 1994
1996
1998
2000
2002
2004
Figure 1 Comparison of global pharmaceutical industry research and development investment and global output of new molecular entities. Source: Hoekema A. 2007. Sharing risks and rewards—basis for a turnkey pharma-biotech alliance in osteoarthritis. Drug Disc. World Spring:54
to recoup this investment during the period of market exclusivity, prior to the introduction of generic copies, is an incentive for aggressive marketing techniques (6). However, rapid market uptake means that a large number of individuals may have already been exposed by the time a drug problem is discovered after marketing. Thus, rising societal demands for greater certainty about the outcomes of drug therapy are occurring at a time when the pharmaceutical industry is experiencing difficulty in sustaining innovation. These concurrent trends are a cause for significant concern, given the number of medical conditions that currently have unsatisfactory or no therapeutic options. The FDA, with its dual roles of protecting and promoting health, is charged with implementing policies that ensure that the benefits of new products will outweigh their risks, while simultaneously promoting innovations that can improve health. The challenges inherent to this mission drove the genesis of the Critical Path Initiative. www.annualreviews.org • The FDA Critical Path Initiative
3
ANRV334-ME59-01
ARI
7 December 2007
13:33
Expectations have been widespread that 30 years of significant public investment in biomedical research would produce an explosion of new therapies for previously untreatable or inadequately treated diseases. The failure of this surge to materialize has prompted extensive speculation on the cause of this “pipeline problem.” Many in the drug development community believe that genomics and other newer technologies are not yet sufficiently mature to reliably support drug development. Others blame industry business decisions or regulatory requirements. In 2004, the FDA published a White Paper entitled “Innovation or Stagnation: Challenges and Opportunities on the Critical Path to Medical Product Development” (7). While acknowledging that a combination of factors has likely led to the current drug development situation, this paper called attention to an important and
generally unrecognized problem: the lagging science of drug development. Drug development can be conceptualized as a process leading from basic research through a series of developmental steps to a commercial product (Figure 2). The FDA White Paper identified the “Critical Path” as a process beginning with identification of a drug candidate and culminating in marketing approval. Along the path to marketing, the product is subjected to a series of evaluations to predict its safety and effectiveness and to enable its mass production. Despite extensive investment in basic biomedical science over the past three decades, there has been very little change in the science of the development process. The sophisticated scientific tools used in drug discovery and lead optimization are generally not utilized in the preclinical and clinical development stages. Instead, traditional empirical evaluation is used in both animal and human testing. We are
Working in Three Dimensions along the Critical Path Prototype Design or Discovery
Preclinical Development
Clinical Development
Material Selection Structure Activity Relationship
In Vitro and Animal Testing
Human and Animal Testing
In Vitro and Computer Model Evaluation
In Vitro and Animal Models
Human Efficacy Evaluation
Physical Design
Characterization Small-Scale Production
Manufacturing Scale-up Refined Specifications
Basic Research
Safety
Dimensions
Annu. Rev. Med. 2008.59:1-12. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
FDA’S CRITICAL PATH INITIATIVE
Medical Utility
Industrialization
FDA Filing/ Approval & Launch Preparation Safety Follow Up
Mass Production
Figure 2 The critical path of drug development. First, a candidate drug emerges from a drug discovery program. The candidate must successfully complete a series of evaluations of its potential safety and efficacy and must be amenable to mass production. For each candidate finishing the pathway, 5000–10,000 are evaluated in the discovery phase. 4
Woodcock
·
Woosley
Annu. Rev. Med. 2008.59:1-12. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-01
ARI
7 December 2007
13:33
using the tools of the last century to evaluate this century’s advances. How did this situation come about? The FDA’s analysis, which has been generally accepted, is that “no one is charged” with improving developmental science. The National Institutes of Health (NIH) focus on innovative biomedical science, not the applied science of the development process; as a result, academia also concentrates on basic science. The pharmaceutical industry is concerned with developing innovative products. The FDA, as a regulator, is not charged with— nor is it funded for—improving the process, although it has been involved in such efforts. Additionally, the science needed is generally integrative “big science” that requires contributions from multiple disciplines and sectors and is not within the purview of a single investigator or firm. How is the evaluative science of development related to “translational science”? Translational science, which is also called “experimental medicine,” or simply “clinical pharmacology” in the case of drug development, involves moving a scientific innovation from the laboratory into early clinical studies (8). Improvement in this part of the process is an essential step in modernizing drug development.
THE CRITICAL PATH PROGRAM FDA’s 2004 Critical Path White Paper generated considerable discussion and debate among drug and device developers, academics, and patient advocacy groups. Over 100 groups submitted comments on the paper. After extensive consultation with numerous stakeholders, FDA issued the “Critical Path Report and List” in 2006 (9). This report enumerated leading areas for scientific improvement in the development process: development and utilization of biomarkers; modernizing clinical trial methodologies and processes; the aggressive use of bioinformatics, including disease modeling and trial simulation; and improvement in manufactur-
ing technologies. It also contained the “2006 Critical Path Opportunities List,” 76 discrete projects that, if completed, could improve product development and subsequent use. A number of these projects are now being undertaken, many in partnership with FDA (10).
Development and Qualification of New Biomarkers Development of new biomarkers was identified as the highest priority for scientific effort. Genomic, proteomic, and metabolomic technologies, as well as advanced imaging techniques, hold tremendous promise for generating new biomarkers that can reflect the state of health or disease at the molecular level (11). Although much prior discussion about the use of biomarkers in drug development has focused on surrogate endpoints for effectiveness, most uses of new biomarkers are not expected to involve surrogacy. For example, prediction of adequate safety is an essential part of drug development. Currently, preclinical safety testing involves traditional animal toxicology studies, as well as in vitro assays such as the Ames test. Animal toxicology tests are very useful for assessing safety for initial human testing; however, they often fail to uncover the types of toxicities seen after widespread human exposure. New technologies, such as gene expression assays in whole cell or animal systems, proteomics, or metabolomics, may provide much greater insight into the whole spectrum of pharmacologic effects of a candidate drug. Such technologies may also be useful in comparing the candidate’s effects (particularly off-target effects) to those of other drugs in its class or other drugs intended for similar uses (12). Drug developers are just beginning to use such technologies in the preclinical safety workup, and the clinical implications of such findings have not been worked out. The current scheme for clinical safety testing has also failed to incorporate recent scientific advances. Human safety during drug development is primarily evaluated on an www.annualreviews.org • The FDA Critical Path Initiative
5
ARI
7 December 2007
13:33
observational basis from subjects exposed in the various developmental trials. The markers used to assess potential human toxicity are also assays that have been available for decades, e.g., clinical chemistries and hemograms. Few explanatory studies are carried out to determine the mechanism of an observed side effect, and assays to predict rare side effects are not available. Despite premarket exposure of thousands of subjects, serious side effects are frequently uncovered after marketing. New types of biomarkers may provide opportunities for prevention or early detection of these adverse events. The current problems with predicting and evaluating drug efficacy could also be ameliorated by using biomarkers. Many drug efficacy problems stem from the extreme variability of human disease response. New biomarkers can improve diagnosis, define disease subsets that may differ in response, define individual variability in the drug’s molecular target, and provide an early readout of response to therapy (11). For example, both in vitro diagnostics and imaging techniques are expected to provide additional information about disease subsets. This is already beginning to happen in cancer, where gene expression assays are being used to supplement histologic and clinical assessments of tumors, e.g., evaluating the likelihood of recurrence and the need for adjuvant therapy. For disorders such as psychiatric conditions that are currently diagnosed by clinical symptoms, it is hoped that genetic or imaging markers may help to distinguish biologically based subsets. A related type of biomarker is one used to predict treatment responsiveness. Many new cancer therapies target a specific molecule or cellular pathway. Genetic, proteomic, or other molecular assays that assess target status within a tumor may be used to predict responsiveness to a targeted drug. This is the strategy used with the drugs trastuzumab (Herceptin®) and imatinib (Gleevec®). Interindividual drug target heterogeneity due to genetic polymorphisms may be important in diseases other than cancer. Using biomarkers to classify patients by
Annu. Rev. Med. 2008.59:1-12. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-01
6
Woodcock
·
Woosley
disease type or response probability can improve drug development by reducing variability and increasing the size of the treatment effect. If the biomarkers are then incorporated into clinical practice, clinical variability can also be reduced. Decreasing interindividual differences in drug exposure is another strategy to reduce response variability. Recently, FDA has approved a number of assays for genetic polymorphisms in drug-metabolizing enzymes. Many marketed drugs are subject to polymorphic metabolism, leading to a wide range of exposures in the treated population (13). The safety and effectiveness of these drugs, as well as investigational drugs with variable metabolism, could be improved by using dose adjustments directed by genetic tests. The absence of practical processes to establish the clinical significance of a given biomarker has severely limited the use of existing biomarkers in drug development and the clinic. The return on investment for diagnostic test manufacturers is seldom sufficient to enable extensive clinical trials, and investigational drugs are rarely developed in concert with new diagnostic tests. To address these issues, FDA and other stakeholders have established the concept of biomarker qualification, which means determining the clinical significance of the biomarker in a specific context (14). For example, a genetic test might be qualified to identify a subset of disease for the purpose of trial enrollment. The quantity of data needed for qualification depends on the intended use, and most uses require far less data than would be required to establish a surrogate endpoint for efficacy. Because the development and qualification of new biomarkers will benefit many parties, consortia have been formed for this purpose. “The Biomarker Consortium” (http:// www.biomarkersconsortium.org) at the Foundation for NIH (FNIH) is a leading example. Initiated by federal partners NIH, FDA, and Center for Medicare and Medicaid Services (CMS), along with private sector organizations PhRMA (the pharmaceutical
ANRV334-ME59-01
ARI
7 December 2007
13:33
Annu. Rev. Med. 2008.59:1-12. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
manufacturers’ trade organization) and BIO (the Biotechnology Industry Organization), the consortium now has multiple industrial, academic, and patient group members. It is funding biomarker qualification trials for fluorodeoxyglucose-positron emission tomography (FDG-PET) scanning in non-Hodgkin’s lymphoma and lung cancer and is evaluating a number of additional proposals.
CLINICAL TRIAL MODERNIZATION Other areas in urgent need of improvement are the design, conduct, and analysis of clinical trials during drug development. This part of the Critical Path Initiative includes establishing standards for clinical trial data and its management; fully automating trial process and data management; improving the clinical trial quality management system; and modernizing FDA oversight of the clinical trial process. Significant progress in data standardization has been achieved by the clinical trial standards organization, the Clinical Data Interchange Standards Consortium (CDISC) (http://www.cdisc.org). Working with the National Cancer Institute (NCI), FDA has adopted a number of CDISC standards for regulatory submissions. Currently, a CDISC initiative called Clinical Data Acquisitions Standards Harmonization (CDASH), organized to develop standards for case report forms, is ongoing (15). Additionally, FDA is working with the NIH to harmonize and simplify various investigator reporting requirements. Over the past several years, FDA has been modernizing its oversight of clinical trials, has held several public meetings, and has issued guidance and draft regulations. Many parties are interested in improving the consistency, quality, and reliability of clinical trials while reducing the paperwork burdens (16). Discussions about forming a public-private partnership to accomplish these objectives are also ongoing.
BIOINFORMATICS One of the greatest scientific flaws in the current process of medical product development is its failure to produce generalized knowledge despite a huge investment in data generation. For example, FDA holds the world’s largest collection of animal test data and correlated human trial data, but most of this information is unusable in its current form, except to document a specific development program. As a result, opportunities for major improvement are missed. Under the Critical Path Initiative, stakeholders are beginning to take advantage of these opportunities. For example, FDA and various partners have created a standard for a digital electrocardiogram (ECG) recording, and FDA requested that ECG data submitted to it be in this format. At the same time, a data warehouse to hold the ECG data was established. Since that time, >500,000 digital ECGs have been added to the warehouse, and a collaboration with Duke University has been established for overall data analysis (17). This resource may help scientists efficiently evaluate candidate drugs for adverse cardiac repolarization effects, a concern that is currently addressed (somewhat less than satisfactorily) by extensive clinical testing. As data standards for regulatory submissions are implemented, processes and protocols to utilize the data for research purposes without compromising proprietary interests need to be developed. One important use of such data will be to construct quantitative models of disease processes, incorporating what is known about biomarkers, clinical outcomes, and the effects of various interventions. These models can then be used for trial simulations, to better design appropriate trials and clinical outcome measures (18). Although the FDA has constructed several disease models, this work is in its early stages and will require extensive partnerships. However, there is little doubt that such quantitative approaches constitute the future of product development and assessment.
www.annualreviews.org • The FDA Critical Path Initiative
7
ANRV334-ME59-01
ARI
7 December 2007
13:33
DRUG MANUFACTURING
Annu. Rev. Med. 2008.59:1-12. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Perhaps surprisingly, the manufacturing of pharmaceuticals suffers from the problems of drug development in general. Many drug manufacturing processes are characterized by inefficiency, waste, and neglect of modern process control technologies. Thus, the pharmaceutical manufacturing sector would also benefit from incorporation of new science and technology. FDA is spearheading these changes through its Pharmaceutical Quality for the 21st Century Initiative (19).
CONSORTIA INVOLVED IN CRITICAL PATH ACTIVITIES After FDA’s 2004 call for public-private collaborations, scientists at several universities created programs to work with FDA to conduct the needed research. Despite limited funding, these programs have been able to make significant progress addressing projects called for in the 2006 Critical Path Opportunity List. Investments in programs created by the University of Arizona, Duke University, Massachusetts Institute of Technology (MIT), and the University of California at San Francisco are beginning to produce results (see Sidebar). The first to respond, the University of Arizona, offered to create a nonprofit research and education institute dedicated solely to work with FDA on the Critical Path
ACADEMIC CONTRIBUTIONS TO DRUG DEVELOPMENT SCIENCE The Center for Biomedical Innovation at MIT (CBI), the Center for Drug Development Sciences (CDDS) at the University of California, San Francisco, and the Duke Clinical Research Institute (DCRI) are examples of university-based centers that are making major contributions to the regulatory sciences. Because of their broad access to outstanding scientists in the academic community, they are important resources for companies that are developing medical products, and they train the innovative leaders.
8
Woodcock
·
Woosley
Initiative. The Arizona community (state and local governments, business, and philanthropic groups) saw this opportunity to partner with FDA as a way to leverage the state’s $2 billion investment in biotechnology. In early 2004, with a planning grant from the state, the FDA, the University of Arizona, and SRI International (a nonprofit corporation, formerly Stanford Research Institute) agreed to create the Critical Path Institute (C-Path). C-Path is envisioned as a neutral third party, without financial support from the regulated industry. Because of C-Path’s neutral funding and its mission to focus on process, not products, FDA can actively participate in the work without concerns about conflicts of interest. C-Path’s strategy is to invite stakeholders to join consortia in which they can work with the FDA to improve the process of medical product development. The University of Arizona and SRI committed “in kind” support, predominantly the time and effort of their scientists. The FDA agreed to participate under a Memorandum of Understanding. C-Path was incorporated in January 2005 and began initial operations in July 2005 with a $10 million, five-year commitment from the City of Tucson, Pima County, regional municipalities, and private foundations in Arizona (http://www.C-Path.org). C-Path has approximately 20 employees working with the FDA and industry scientists on the projects listed in Table 1. These projects were selected using three specific criteria. The first and essential requirement is that there be champions for the project within the FDA. Also, there must be two or more companies willing to work together on the project, and there must be a source of external funding that is independent of commercial interests. The projects focus on precompetitive aspects of drug development, e.g., preclinical toxicology. The first consortium formed by C-Path, the Predictive Safety Testing Consortium (PSTC), was announced in March 2006 by Secretary of Health and Human Services Michael Leavitt. Since then, the PSTC has
ANRV334-ME59-01
Table 1
ARI
7 December 2007
C-Path Institute projects (http://www.C-Path.org)
Development gap
Annu. Rev. Med. 2008.59:1-12. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
13:33
C-Path process
C-Path project
Deliverables
Inconsistent technical methods employed across the industry
Create consortium and process for sharing and validation of methods
Predictive Safety Testing Consortium (PSTC)
New FDA guidances to improve and accelerate preclinical safety testing Increased safety of new drugs
Drugs, devices, and diagnostics developed separately. New cancer drugs only 10%–20% effective
Create cross-industry and cross-agency (FDA/NIH/CMS) collaborations to evaluate multiple technologies
Lung cancer diagnostics validation clinical trial with NCI, FDA, and industry
Test to predict lung cancer response Change drug label Model for future drug/diagnostic products
Drugs and diagnostics developed separately. Warfarin side effects cost ∼$1 billion/year and only half (2 million) of patients who need warfarin get treatment
Create cross-industry and cross-agency (FDA/NIH/CMS) collaborations to evaluate multiple technologies
Genomic-based dosing for warfarin, clinical trial with NHLBI, FDA, and industry
Reduce adverse events Increase indicated warfarin treatment Change warfarin label: recommend genetic test Model for future pharmacogenetic clinical trials
High failure rate of clinical trials
Create consortium of orphan disease foundations
Create disease model registries (Nieman-Pick C, valley fever, adrenal cancer)
Template for disease model-based clinical trial design and fewer failed drug development programs
grown from an initial eight to 15 global pharmaceutical companies that are sharing their preclinical methods and data for tests of nephrotoxicity, hepatotoxicity, vascular injury, and carcinogenicity. In this consortium, methods developed by one company that appear to best predict drug toxicity are verified by experiments performed by a second company. Over 160 scientists are participating, including 25 scientists from the FDA and its European counterpart, the EMEA, who participate in the meetings and discussions as advisors. The methods that are cross-validated by the companies are expected to eventually provide the scientific basis for regulatory guidance to be issued by the FDA and the EMEA. A goal of C-Path projects is to integrate new and advanced technologies into medical product development, especially those that accelerate pathways for innovative diagnostic tests and therapies. For example, C-Path’s project with the FDA and the University of Utah examines genetic tests for improved war-
farin dosage selection. The goal is to provide the scientifically based pathway for simultaneous development of drugs and genetic tests to improve a drug’s safety or effectiveness. Another of C-Path’s projects, the Molecular Assays and Targeted Therapeutics (MATT) project, is being conducted by a collaboration among the FDA, the NCI, and the CMS. MATT’s goal is to define a more rapid and efficient process for integrated development of drugs, diagnostics, imaging, and other technologies that work together to help patients with cancer. The project is exploring a regulatory path by examining the utility of diagnostics and drugs that could enable targeted therapy of non-small-cell lung cancers that overexpress the epidermal growth factor receptor. C-Path’s Disease Model Registry (DMR) for orphan drugs (i.e., drugs intended for diseases affecting <200,000 persons in the United States) addresses the rising failure rate during the later phases of drug development. The overall goal of this project is to evaluate www.annualreviews.org • The FDA Critical Path Initiative
9
ARI
7 December 2007
13:33
methods and technologies that could improve understanding of the natural history of diseases and thereby identify clinical trial designs and methods that are more informative and have a greater chance for success. C-Path is creating the functional infrastructure for DMR and bringing together patients, the FDA’s Office of Orphan Product Development, care providers, researchers, foundations, and commercial entities to help generate the data standards and scientific evidence needed to support the efficient testing of new treatments for patients with orphan diseases. This work will also have relevance to personalized medicine because, similar to the situation with orphan diseases, the smaller marker size and the high cost of product development expected for personalized medicine have deterred investment in this new approach. The DMR will serve as a virtual control group, enabling developers to identify the optimal endpoints for clinical trials and thereby increase the likelihood of success in clinical trials. The DMR technology will also make possible online tracking of clinical outcomes, an essential element of newer innovations such as adaptive trial designs. The novel aspects of these C-Path projects are the core neutral funding and the scientifically qualified team leaders of the consortia. C-Path brings together scientists from highly competitive companies and then maintains a productive environment through modern project management techniques. Continued participation by the consortium members depends on the rewards they receive for the investment of time and effort. These rewards are expected to be science-based regulatory standards enabled by the work of the consortium, which define a development process that has the greatest possible efficiency and safety. The future of the Critical Path Initiative is increasingly secure because the many stakeholders in medical product development have come to recognize the value of and need for process improvement. They also recognize the importance of having a safe haven such as MIT’s Center for Biomedical Innovation
Annu. Rev. Med. 2008.59:1-12. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-01
10
Woodcock
·
Woosley
or a neutral third party such as C-Path where members of the pharmaceutical industry and the FDA can work as scientists and not be inhibited by their usual roles as regulators and regulated. Likewise, industry scientists are finding it very rewarding to share with their competitors their knowledge and experiences, especially their failures, in precompetitive areas of development. Therefore, it is likely that the work of the critical path will continue indefinitely. What is not yet clear is where it will take place and how it will be coordinated. The NIH is increasingly involved in critical path projects. The NCI collaborates with the FDA through the Oncology Biomarker Qualification Initiative (OBQI). The National Heart, Lung, and Blood Institute has been working with the FDA to coordinate studies of the genetic testing of warfarin. However, tremendous potential remains for the NIH to play an important role in providing FDA with the data and scientific information needed to improve medical product development. Examples include the NIH roadmap initiatives, the facilities of the National Center for Research Resources, and the growing network of Clinical Translational Research Awards. These are almost all devoted to translational science and have the potential to interface directly with some of the 76 projects on the 2006 Critical Path Opportunities List. An additional opportunity to maximize the efficiency and impact of critical path research is being explored through increasing collaborations between FDA and Agency for Healthcare Research and Quality (AHRQ) scientists. AHRQ’s Centers for Education and Research on Therapeutics are working closely with the FDA to define the optimal approach for active surveillance and postmarketing evaluation of safety and effectiveness of medical products. Ongoing application of new surveillance techniques that are enabled by more widespread use of electronic health records should complement the improved understanding of drugs obtained prior to marketing. It is hoped that electronic records–based surveillance will
Annu. Rev. Med. 2008.59:1-12. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-01
ARI
7 December 2007
13:33
result in rapid detection and analysis of unanticipated outcomes after the products are widely used, so that knowledge can be gained efficiently throughout the entire product life cycle. As of this writing, the US Congress is considering the FDA Revitalization Act. This legislation would create the Reagan-Udall Institute, a foundation established to advance FDA’s mission, that would engage in critical path research. Legislation being introduced in the House of Representatives would authorize funding for the FDA to create multiple critical path public-private partnerships. The European Commission is in the final stages of approving the Innovative Medicines Initiative, a
partnership among the pharmaceutical industry, the European Union, and academia that would conduct research relevant to drug development, with funding divided equally between government and industry. The need for critical path research is not likely to end. Scientific advances will continue to create methodological challenges in medicine that will require changes in the way we develop new products. Ideally, a systematic approach to process improvement will become part of the fabric of translational research. A major question is whether the Critical Path Initiative can maintain its momentum and substantively contribute to improved drug development.
SUMMARY POINTS 1. The productivity of the pharmaceutical industry has decreased and the costs of producing a novel medicine have been rising sharply. 2. Some members of the public are calling for medicines to be more extensively studied prior to approval. There is also concern in the United States about pharmaceutical prices. 3. FDA’s Critical Path Initiative is intended to improve drug development and reduce uncertainty by applying new scientific tools to the development process. 4. The applied research needed to develop these tools requires collaboration across multiple public and private entities and may be best accomplished by various consortia. 5. The C-Path Institute was set up specifically to facilitate and conduct such research, and it has a number of important projects under way.
DISCLOSURE STATEMENT Dr. Woodcock directs the Critical Path Initiative at FDA. Dr. Woosley is president of the Critical Path Institute.
LITERATURE CITED 1. CMR International. 2005. Pharmaceutical R&D Factbook. Epsom, Surrey, UK: Cent. Med. Res. Intl. 2. 2006. Research and Development in the Pharmaceutical Industry: A CBO Study. Washington, DC: Congr. Budget Off. 3. DiMasi JA, Hansen H, Grabowski HG. 2003. The price of innovation: new estimates of drug development costs. J. Health Econ. 22:151–85 4. Adams CP, Brantner VV. 2006. Estimating the cost of new drug development: Is it really 802 million? Health Aff. 25:420–28 www.annualreviews.org • The FDA Critical Path Initiative
11
ARI
7 December 2007
13:33
5. CMR International. 2006/2007. Pharmaceutical R&D Factbook, Ch. 5, p. 2. Epsom, Surrey, UK: Cent. Med. Res. Intl. 6. Wood AJJ. 2006. A proposal for radical changes in the drug approval process. N. Engl. J. Med. 355:618–23 7. US Food and Drug Administration. 2004. Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. http://www.fda.gov/oc/initiatives/ criticalpath/whitepaper.html 8. Wehling M. 2006. Translational science in medicine: implications for the pharmaceutical industry. Int. J. Pharm. Med. 20(5):303–10 9. US Food and Drug Administration. 2006. Innovation or Stagnation: Critical Path Opportunities Report and List. http://www.fda.gov/oc/initiatives/criticalpath/reports/ opp report.pdf 10. US Food and Drug Administration. 2007. Critical Path Opportunities Initiated During 2006. http://www.fda.gov/oc/initiatives/criticalpath/opportunities06.html 11. Woodcock J. 2007. The prospects for “personalized medicine” in drug development and drug therapy. Clin. Pharm. Ther. 81:164–69 12. Caskey CT. 2007. The drug development crisis: efficiency and safety. Annu. Rev. Med. 58:1–16 13. Huang SM, Goodsaid F, Rahman A, et al. 2006. Application of pharmacogenomics in clinical pharmacology. Toxicol. Mech. Methods 16:89–99 14. Lesko LJ. 2007. Paving the critical path: How can clinical pharmacology help achieve the vision? Clin. Pharm. Ther. 81:170–77 15. Clinical Data Interchange Standards Consortium (CDISC). 2007. CDISC and Industry Collaborative Group Lead FDA Critical Path Initiative Opportunity for Data Collection Standards. http://www.cdisc.org/news/PR33cdisccdashprojectfinal.pdf 16. Califf RM, Harrington RA, Madre LK, et al. 2007. Curbing the cardiovascular disease epidemic: aligning industry, government, payers, and academics. Health Aff. (Millwood) 26:62–74 17. Clabell CH, Noto TC, Krukoff MW. 2005. Clinical utility of the Food and Drug Administration Electrocardiogram Warehouse: a paradigm for the critical pathway initiative. J. Electocardiol. 38(Suppl.):175–79 18. Stanski DR. 2004. Model-Based Drug Development: A Critical Path Opportunity. http://www.fda.gov/oc/initiatives/criticalpath/stanski/stanski.html 19. US Food and Drug Administration—Center for Drug Evaluation and Research 2004. Pharmaceutical cGMPs for the 21st Century: A Risk-Based Approach, Final Report 2004. http://www.fda.gov/cder/gmp/gmp2004/GMP finalreport2004.htm
Annu. Rev. Med. 2008.59:1-12. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-01
12
Woodcock
·
Woosley
AR334-FM
ARI
18 December 2007
17:20
Annual Review of Medicine
Annu. Rev. Med. 2008.59:1-12. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Contents
Volume 59, 2008
The FDA Critical Path Initiative and Its Influence on New Drug Development Janet Woodcock and Raymond Woosley p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p1 Reversing Advanced Heart Failure by Targeting Ca2+ Cycling David M. Kaye, Masahiko Hoshijima, and Kenneth R. Chien p p p p p p p p p p p p p p p p p p p p p p p p 13 Tissue Factor and Factor VIIa as Therapeutic Targets in Disorders of Hemostasis Ulla Hedner and Mirella Ezban p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 29 Therapy of Marfan Syndrome Daniel P. Judge and Harry C. Dietz p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 43 Preeclampsia and Angiogenic Imbalance Sharon Maynard, Franklin H. Epstein, and S. Ananth Karumanchi p p p p p p p p p p p p p p p p p 61 Management of Lipids in the Prevention of Cardiovascular Events Helene Glassberg and Daniel J. Rader p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 79 Genetic Susceptibility to Type 2 Diabetes and Implications for Antidiabetic Therapy Allan F. Moore and Jose C. Florez p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 95 Array-Based DNA Diagnostics: Let the Revolution Begin Arthur L. Beaudet and John W. Belmont p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p113 Inherited Mitochondrial Diseases of DNA Replication William C. Copeland p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p131 Childhood Obesity: Adrift in the “Limbic Triangle” Michele L. Mietus-Snyder and Robert H. Lustig p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p147 Expanded Newborn Screening: Implications for Genomic Medicine Linda L. McCabe and Edward R.B. McCabe p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p163 Is Human Hibernation Possible? Cheng Chi Lee p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p177 Advance Directives Linda L. Emanuel p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p187 v
AR334-FM
ARI
18 December 2007
17:20
Genetic Determinants of Aggressive Breast Cancer Alejandra C. Ventura and Sofia D. Merajver p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p199 A Role for JAK2 Mutations in Myeloproliferative Diseases Kelly J. Morgan and D. Gary Gilliland p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p213 Appropriate Use of Cervical Cancer Vaccine Gregory D. Zimet, Marcia L. Shew, and Jessica A. Kahn p p p p p p p p p p p p p p p p p p p p p p p p p p p p p223 A Decade of Rituximab: Improving Survival Outcomes in Non-Hodgkin’s Lymphoma Arturo Molina p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p237
Annu. Rev. Med. 2008.59:1-12. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Nanotechnology and Cancer James R. Heath and Mark E. Davis p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p251 Cancer Epigenetics: Modifications, Screening, and Therapy Einav Nili Gal-Yam, Yoshimasa Saito, Gerda Egger, and Peter A. Jones p p p p p p p p p p p p267 T Cells and NKT Cells in the Pathogenesis of Asthma Everett H. Meyer, Rosemarie H. DeKruyff, and Dale T. Umetsu p p p p p p p p p p p p p p p p p p p p281 Complement Regulatory Genes and Hemolytic Uremic Syndromes David Kavanagh, Anna Richards, and John Atkinson p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p293 Mesenchymal Stem Cells in Acute Kidney Injury Benjamin D. Humphreys and Joseph V. Bonventre p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p311 Asthma Genetics: From Linear to Multifactorial Approaches Stefano Guerra and Fernando D. Martinez p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p327 The Effect of Toll-Like Receptors and Toll-Like Receptor Genetics in Human Disease Stavros Garantziotis, John W. Hollingsworth, Aimee K. Zaas, and David A. Schwartz p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p343 Advances in Antifungal Therapy Carole A. Sable, Kim M. Strohmaier, and Jeffrey A. Chodakewitz p p p p p p p p p p p p p p p p p p361 Herpes Simplex: Insights on Pathogenesis and Possible Vaccines David M. Koelle and Lawrence Corey p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p381 Medical Management of Influenza Infection Anne Moscona p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p397 Bacterial and Fungal Biofilm Infections A. Simon Lynch and Gregory T. Robertson p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p415 EGFR Tyrosine Kinase Inhibitors in Lung Cancer: An Evolving Story Lecia V. Sequist and Thomas J. Lynch p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p429 Adaptive Treatment Strategies in Chronic Disease Philip W. Lavori and Ree Dawson p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p443 vi
Contents
AR334-FM
ARI
18 December 2007
17:20
Antiretroviral Drug–Based Microbicides to Prevent HIV-1 Sexual Transmission Per Johan Klasse, Robin Shattock, and John P. Moore p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p455 The Challenge of Hepatitis C in the HIV-Infected Person David L. Thomas p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p473 Hide-and-Seek: The Challenge of Viral Persistence in HIV-1 Infection Luc Geeraert, Günter Kraus, and Roger J. Pomerantz p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p487
Annu. Rev. Med. 2008.59:1-12. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Advancements in the Treatment of Epilepsy B.A. Leeman and A.J. Cole p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p503 Indexes Cumulative Index of Contributing Authors, Volumes 55–59 p p p p p p p p p p p p p p p p p p p p p p p p525 Cumulative Index of Chapter Titles, Volumes 55–59 p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p529 Errata An online log of corrections to Annual Review of Medicine articles may be found at http://med.annualreviews.org/errata.shtml
Contents
vii
ANRV334-ME59-02
ARI
7 December 2007
12:18
Annu. Rev. Med. 2008.59:13-28. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Reversing Advanced Heart Failure by Targeting Ca2+ Cycling David M. Kaye,1 Masahiko Hoshijima,2 and Kenneth R. Chien3 1
Heart Failure Research Group, Baker Heart Research Institute, Melbourne, Victoria 8008, Australia; email:
[email protected]
2
Institute of Molecular Medicine, University of California, San Diego, La Jolla, California 92093-0346
3
Cardiovascular Research Center, Massachusetts General Hospital and Harvard Stem Cell Institute, Harvard Medical School, Richard B. Simches Research Centre, Boston, Massachusetts 02114; email:
[email protected]
Annu. Rev. Med. 2008. 59:13–28
Key Words
The Annual Review of Medicine is online at http://med.annualreviews.org
sarcoplasmic reticulum ATPase, phospholamban, excitation contraction coupling, gene therapy
This article’s doi: 10.1146/annurev.med.59.052407.103237 c 2008 by Annual Reviews. Copyright All rights reserved 0066-4219/08/0218-0013$20.00
Abstract Heart failure is a major cardiovascular disease, characterized by considerable morbidity and mortality. Despite major advances in the pharmacotherapy of heart failure, the options for patients with severe end-stage symptoms remain limited. However, recent developments in the identification of the molecular basis for the progressive nature of heart failure have identified a number of potentially important new therapeutic targets. In particular, key components of the cardiomyocyte calcium-handling pathway show characteristic changes in heart failure. A body of research examining the effect of restoration of these defects in experimental models of heart failure, whether in genetically engineered mouse models or by myocardial gene transfer, very strongly supports the calcium-handling pathway as a target for clinical intervention.
13
ANRV334-ME59-02
ARI
7 December 2007
12:18
INTRODUCTION
Annu. Rev. Med. 2008.59:13-28. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Heart failure (HF) is a complex, progressive pathophysiological condition that is triggered by an initial myocardial defect. Most commonly the initiating insult is myocardial infarction that causes loss of contractile elements of the heart. This loss increases the load on the remaining myocardium, ultimately leading to loss of contractile reserve and a clinical HF phenotype. It is increasingly recognized that a number of genetic defects are responsible for cardiomyopathy, either directly or in conjunction with other triggers for myocardial injury. Although several classifications for HF exist, based on clinical severity or physiology, the epidemiology of symptomatic HF is well quantified. It is generally estimated that symptomatic HF currently affects 0.4%–2% of the general population (1–3). It is well known that the incidence of symptomatic HF rises substantially with age, and for individuals over 65 years of age, the prevalence of HF has been reported to be 6%–10% (1, 4, 5). Beyond simple measures of the number of patients affected by HF, further data indicate the huge impact of HF on society, health care resources, and the economy. For example, HF is the major reason for 12–15 million medical practitioner contacts per year and for 6.5 million hospital days per year (6). In its more advanced stages HF is characterized by considerable disability, and mortality rates may exceed 50% per annum in the most advanced stages (7–9). Driven by these facts, considerable effort has been exerted during the past two decades to identify the mechanisms that contribute to HF and consequently represent viable targets for intervention. A vast body of clinical trial data has led to the generation of systematic guidelines for the management of HF (1).
14
Kaye
·
Hoshijima
·
Chien
FUNCTIONAL AND MOLECULAR PATHOPHYSIOLOGY OF HEART FAILURE Fundamentally, the physiological processes leading to the clinical profile of the patient with HF are often considered in regard to changes in the systolic and diastolic properties of the myocardium. These can be integrated with structural considerations including (a) the loss of myocytes, (b) alteration in the geometry of the heart (including cellular hypertrophy, the development of secondary mitral regurgitation, and a spherical shape), (c) the development of myocardial fibrosis, and perhaps most importantly (d ) reduction in myocardial contractility. Each of these processes contributes to the process of ventricular remodeling, a hallmark of HF. The loss of functioning contractile elements (i.e., cardiomyocytes) in the failing heart can come about in several ways. As indicated above, a substantial proportion of the burden of HF results from acute or chronic myocardial damage due to ischemia and/or infarction resulting in necrosis. It is noteworthy that myocardial necrosis can also result from several other processes, including drug toxicity (e.g., anthracyclines) and myocarditis. Perhaps of equal importance in the context of the chronically failing heart is cardiomyocyte loss via apoptosis. It is well known that the frequency of myocyte apoptosis is elevated in HF (10–12), and the mechanisms behind this are gradually becoming apparent. They probably include the effects of mechanical stress per se and increased local concentrations of neurohormones such as norepinephrine (acting via β-adrenergic receptors) and angiotensin II via the AT1 receptor (13–15). Cardiomyocyte hypertrophy is a key feature of ventricular remodeling in the early
Annu. Rev. Med. 2008.59:13-28. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-02
ARI
7 December 2007
12:18
phase of the transition to HF, and the extent of remodeling correlates well with clinical outcome (16, 17). State-of-the-art techniques including genomics, proteomics, and gene manipulation, using either transgenic models or somatic cell gene transfer, have been employed to investigate the complex, interconnected signaling pathways that drive hypertrophy (17a, 18). Key hypertrophic stimuli include angiotensin II and noradrenaline, so the utility of antagonists of the renin-angiotensin system and adrenergic nervous system can be well appreciated. Experimental studies using more specific smallmolecule inhibitors have demonstrated the capacity for modulation of the hypertrophic program, but these approaches have commonly been limited by a lack of cardioselectivity and consequent toxicity (18–23). Alterations in the structure of the cardiac extracellular matrix are another key feature of the remodeling heart. This is a dynamic process that results in the accumulation of extracellular matrix proteins, stimulated by cytokines and hormones including transforming growth factor β, aldosterone, and angiotensin II (24, 25). In conjunction with the deposition of matrix proteins, the degradation of the extracellular matrix by matrix metalloproteinases appears to be enhanced during cardiac remodeling (26), thereby favoring chamber dilatation. Together, the complex balance of increased collagen deposition and matrix turnover favors the development of interstitial fibrosis, further increasing wall stress and left ventricular diastolic pressure. It has been a key target of current and proposed therapies for HF (27–33).
Excitation-Contraction Coupling and the Failing Heart Excitation-contraction (EC) coupling (34, 35) is the sequence of cellular and molecular events that link the cellular action potential with contraction (Figure 1). In the myocardium, membrane depolarization causes the opening of voltage-dependent L-type
Ca2+ channels, resulting in the entry of a modest amount of Ca2+ . This process critically activates calcium release channels (ryanodine receptors, RyR) located immediately subjacent to the cell membrane, in the sarcoplasmic reticulum (SR), causing them to open and release a large amount of Ca2+ . The resulting large rise in the intracellular concentration of Ca2+ initiates contraction. Relaxation, an energy-requiring process, occurs by reaccumulation of Ca2+ into the SR via a specific pump, the SR Ca2+ -ATPase (SERCA). In the myocardium, the principal SERCA protein is the SERCA2a isoform (whilst SERCA1 is principally expressed in skeletal muscle). A closely associated protein, phospholamban (PLN), regulates SERCA2a activity in a manner that is dependent on its phosphorylation status (36, 37). In the dephosphorylated state, PLN exerts an inhibitory action on SERCA2a, slowing its enzymatic rate. When PLN is phosphorylated, classically at a serine residue located at position 16 by protein kinase A, the inhibitory action is lost, resulting in a net increase in SERCA activity. Physiologically, this situation typically occurs in the context of adrenergic activation with a resultant hastening of relaxation due to heightened SERCA activity. As indicated above, one of the major characteristics of the failing myocardium is depressed contractile reserve. Extensive studies using molecular biology, cell imaging, and gene manipulation have dissected in detail many of the mechanisms responsible for altered contractility. In particular, defects in the EC coupling process are a typical finding in both human HF and a variety of experimental models. Early studies (38–40) demonstrated a series of fundamental changes in intracellular Ca2+ handling, which reduced peak systolic Ca2+ concentration, elevated diastolic Ca2+ concentration, and prolonged the duration of the Ca2+ transient. Given considerable evidence (34) linking the amount of Ca2+ within the SR with contractility, particular emphasis has been placed on the role of SERCA in HF. Numerous studies have demonstrated
www.annualreviews.org • Reversing Ca 2+ Defects in Heart Failure
EC: excitationcontraction SR: sarcoplasmic reticulum SERCA: SR Ca2+ -ATPase PLN: phospholamban
15
ARI
7 December 2007
Annu. Rev. Med. 2008.59:13-28. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-02
12:18
Figure 1 Key components of the cardiac excitation-contraction system and potential therapeutic targets. Ca2+ enters the cardiomyocyte via L-type Ca2+ channels, triggering release of Ca2+ from the sarcoplasmic reticulum (SR) via the ryanodine release channel (RyR), which is further regulated by the FK binding protein (FKBP). Removal of Ca2+ from the cardiomyocyte is principally mediated via uptake into the SR via the SR Ca2+ -ATPase (SERCA), which is regulated by phospholamban (PLN) depending on its state of phosphorylation. Extrusion of calcium via the Na+ -Ca2+ exchanger (NCX) also occurs. Regulation of several steps via protein kinase A (PKA) and CaM kinase are shown. βAR, beta adrenoceptor.
reductions in the mRNA and protein levels of SERCA2 are evident in the failing heart (41–44), and these findings are supported by biochemical studies confirming the presence of reduced SERCA enzymatic activity (45). In conjunction with these studies, changes in the pattern of PLN expression have also been suggested to occur in HF. Observations in this regard include a decrease in the ratio of SERCA2 to PLN and hypophosphorylation of PLN due to desensitization of the βadrenergic signaling pathway (42, 46). Both of 16
Kaye
·
Hoshijima
·
Chien
these changes in PLN would be expected to further impair SERCA2 function and hence contractility. In addition to changes in SERCA2 and PLN expression, changes in other related proteins may also contribute to altered EC coupling in HF. Some evidence points to a reduction in the expression of the L-type Ca2+ channel (47, 48), although its precise pathophysiological role in HF is controversial. More consistent observations implicate the SR Ca2+ release channel, RyR. Although
ANRV334-ME59-02
ARI
7 December 2007
12:18
Annu. Rev. Med. 2008.59:13-28. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
levels of RyR protein per se do not appear to be altered in HF (42), RyR appears to be hyperphosphorylated in the failing heart, as does an associated regulatory protein, FKBP12.6 or calstabin. Both of these proteins increase the release of Ca2+ and may contribute to the elevated diastolic Ca2+ that occurs in HF (49). Beyond changes in critical elements of the EC pathway, other changes in contractile and regulatory proteins themselves are well known in HF. These include alterations in the isoform type of actin, myosin, troponin T, and myofibrillar ATPase, among others (50–52).
ADRENERGIC NERVOUS SYSTEM, PROGRESSIVE HEART FAILURE, AND BETA BLOCKERS Heightened activity of the sympathetic nervous system is a hallmark pathophysiological feature in HF, as measured by a number of techniques (53–55). Although it is generally accepted that adrenergic stimulation of the failing heart is initially adaptive, the longer-term deleterious effects of prolonged adrenergic stimulation of the failing heart are equally evident (56, 57). In addition to the “toxic” effects of catecholamines on the myocardium, the adrenergic signaling pathway within cardiomyocytes is affected. One of the key changes in the failing heart is the downregulation of β-adrenoceptors, particularly the β1 -adrenoceptor (58), probably as a result of exposure to sustained high levels of noradrenaline. In contrast, the β2 adrenoceptor, located at both sympathetic presynaptic and postsynaptic neuroeffector junctions, is less prone to downregulation and may therefore assume a more prominent role in regulating myocardial function in the failing heart (59). The downregulation of β-adrenoceptors results from a combination of processes that include a reduction in β1 -adrenoceptor mRNA levels and an increase in the expression and activity of βadrenoceptor kinase (βARK), which desensitizes β-adrenoceptors and promotes their degradation. Transgenic animal studies have
confirmed the key role of the sympathetic nervous system in the progression of HF. For example, β-adrenoceptor overexpression models (60) clearly show that sustained overactivation of the sympathetic nervous system contributes to the pathophysiology of progressive HF. Ultimately, of course, clinical trials conducted in HF patients across a spectrum of clinical severity demonstrated the beneficial effects of adrenergic receptor antagonism using several different agents (61–63). The observations that adrenergic receptor antagonists improve the clinical outcome of HF, promote reverse remodeling, and improve contractility have prompted exploration of the molecular mechanisms that are responsible. Studies in both animal models and humans suggest that administration of beta blockers in the setting of chronic HF increases SERCA activity and improves myocardial function (64, 65). In a similar manner, it has also been observed that long-term mechanical support of the failing left ventricle may allow recovery of contractile function. This may in part be due to recovery of Ca2+ handling proteins, including SERCA2a (66, 67).
CALCIUM HANDLING: A TARGET FOR THERAPY IN HEART FAILURE? The recognition that abnormal Ca2+ handling is a pivotal component in the cellular biology of HF has attracted attention to this area as a potential therapeutic target (68). Interest is especially intense because there have been relatively few recent developments in the pharmacotherapy for HF (69). Moreover, for patients with end-stage HF, who have typically failed the routine armamentarium of pharmacotherapy and devices (biventricular pacemaker-defibrillators), the only therapeutic options are heart transplantation and possibly long-term mechanical circulatory support. For most patients, however, both of these interventions are inappropriate
www.annualreviews.org • Reversing Ca 2+ Defects in Heart Failure
17
ANRV334-ME59-02
ARI
7 December 2007
12:18
for many reasons, including age and comorbid diseases. Research into the possible effect of manipulating the myocardial Ca2+ handling mechanisms in the setting of HF has utilized
300
# ESP (mmHg)
200
*
150 100 50
*
30 EDP (mmHg)
Annu. Rev. Med. 2008.59:13-28. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
250
#
20
10
C
l tro n o
HF d +A
RC SE
A
Figure 2 Effect of restoration of SERCA levels on myocardial function in rats with heart failure induced by aortic banding. Top: End-systolic pressure. Bottom: End-diastolic pressure. ∗ p < 0.05 versus control, # p < 0.05 versus heart failure. Adapted with permission from Reference 74. 18
Kaye
·
Hoshijima
·
Chien
various tools including transgenic and knockout animal models and gene transfer methodology. One experimental strategy has been to “restore” the expression of SERCA2a in the setting of HF. In a transgenic animal model system, overexpression of the SERCA2a gene within the myocardium protected the heart against the adverse effects of pressure overload (70). Specifically, in this study aortic constriction caused a substantial reduction in dP/dt in wild-type animals, while the transgenic overexpression of SERCA significantly preserved left ventricular dP/dt under basal conditions, and this was accompanied by a hastening of the rate of relaxation. Several studies on the transfer of the SERCA2 gene have been conducted using virally mediated techniques after the onset of HF. Early studies showed that adenoviral transfer of SERCA2 to cardiomyocytes augmented contractility while also favorably affecting intracellular Ca2+ concentration (71). Subsequently, it was shown that adenovirally mediated transfer of SERCA to isolated cardiomyocytes from failing human heart samples significantly improved indices of contractile function (72). Since then, a number of in vivo gene transfer studies have confirmed the potential for augmenting SERCA2 expression to improve myocardial performance and also to restore the pattern of cardiac gene expression toward a more normal pattern. In a series of studies from Hajjar’s laboratory, gene transfer of SERCA2a attenuated ventricular remodeling in the aortic banding model of HF, preserved left ventricular contractility as assessed by pressure volume loop analysis (Figure 2), and improved survival (73, 74). The strong foundation of data regarding SERCA as a potential gene therapy target in human HF has recently provided the basis for a clinical trial that will explore the value of SERCA gene delivery in patients with HF (75). Considerable attention has also been directed toward the potential therapeutic value of manipulating PLN expression. Specifically, the intent is to inhibit the function
ARI
7 December 2007
12:18
delivery of S16E PLN was shown to increase cardiomyocyte contractility. Subsequently, in cardiomyopathic hamsters, we demonstrated that sustained overexpression of S16E PLN by adeno-associated virus (AAV) gene transfer blunted the progressive decline in left ventricular function (Figure 3). This study also showed that S16E PLN delivery abrogated
of PLN or to reduce its expression. Using a competitive approach, we engineered a PLN mutant, S16E PLN, in which the Ser16 amino acid residue was substituted for a glutamate. This substitution results in a conformational change that mimics the effect of phosphorylation of PLN at position 16 (76). Under basal conditions, the adenoviral
LVFS (%)
40
12 10
#
30
#
20 10
5-6 wks old + 5 weeks + 28-30 weeks
8
#
6 4 2
+ AAV S16E
+ AAV S16E
pre-GT 2 weeks post-GT
60 40
pre-GT 2 weeks post-GT
^
50 LVEDD (mm)
LVEF (%)
Annu. Rev. Med. 2008.59:13-28. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
50
5-6 wks old + 5 weeks + 28-30 weeks
LVEDD (mm)
ANRV334-ME59-02
#
20
^
40
#
30 20 10
+ Ad LacZ
+ Ad S16E
+ Ad LacZ
+ Ad S16E
Figure 3 Effect of inhibition of phospholamban (PLN) by a pseudophosphorylated PLN mutant (S16E) delivered via adeno-associated virus (AAV) gene therapy. Top: Effect of S16E PLN on LV ejection fraction and LV diastolic dimension in cardiomyopathic hamsters (from Reference 76 with permission). Bottom: Effect of S16E PLN on LV ejection fraction and LV diastolic dimension in sheep with pacing-induced cardiomyopathy (from Reference 78 with permission). # = p < 0.05, Λ = p < 0.01. www.annualreviews.org • Reversing Ca 2+ Defects in Heart Failure
19
ANRV334-ME59-02
ARI
7 December 2007
Annu. Rev. Med. 2008.59:13-28. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
AAV: adeno-associated virus S16E PLN: an engineered PLN mutant in which the Ser16 amino acid residue was substituted for a glutamate, mimicking phosphorylation of PLN at position 16
12:18
HF progression by reducing the extent of myocardial cell damage. A separate study examined the effect of AAV S16E PLN on HF progression after experimental myocardial infarction (77). In this series of experiments, S16E PLN gene delivery attenuated ventricular remodeling as determined by echocardiography, and this was accompanied by favorable effects on left ventricular contractility and diastolic function. Morphometric studies showed a beneficial effect of S16E PLN delivery on the extent of cardiac fibrosis. These findings have recently been further developed into a preclinical model of HF in large animals (78). By locally delivering the mutant PLN to the myocardium, it was also possible to show improved cardiac performance as well as evidence of reverse remodeling (Figure 3). Other approaches to the inhibition of PLN have also been employed and generally also demonstrate positive effects on cardiomyocyte and myocardial function. These include antisense strategies (79, 80), dominantnegative strategies (81), antibody methods (82), and RNA interference approaches (83, 84). In some studies, however, the effects of altered PLN expression or activity have not been consistent, possibly owing to the extent of PLN reduction. For example, in a study by Song and colleagues, PLN ablation (by knockout) in a transgenic model of HF augmented cardiomyocyte contractility and calcium handling, but this did not translate into a global improvement in cardiac performance (85).
APPROACHES TO CLINICAL TRANSLATION In attempting to translate laboratory observations regarding abnormalities of the EC coupling process in HF into clinical practice, it is important to take into account the selectivity of the approach for the myocardium and the potential for adverse effects. Although positive inotropic agents such as dobutamine or milrinone may improve myocardial con-
20
Kaye
·
Hoshijima
·
Chien
tractility in the short term, their longer-term use is associated with increased incidence of ventricular and atrial arrhythmias (86). These agents act on aspects of the adrenergic signaling pathway. More specific agents acting on aspects of the EC pathway have been developed and are considered below, followed by a discussion of gene therapy.
Pharmacotherapy Although it does not specifically affect Ca2+ handling per se, levosimendan is an agent that dose-dependently improves contractility by stabilizing the molecular conformation of troponin C when it binds calcium (87). Levosimendan is also a vasodilator, which works by activating ATP-sensitive potassium channels (88). Very few other smallmolecule agents have been developed to modulate myocardial Ca2+ handling. JTV519, a 1,4-benzothiazepine derivative, stabilizes the ryanodine receptor (RyR), thereby improving contractility and inhibiting diastolic calcium leakage (89).
Gene Therapy: Choice of Delivery Vector Cellular and experimental in vivo studies have utilized an extensive range of gene delivery approaches, including nonviral and viral-based techniques. Many of the critical issues (outlined below) that will face clinicians and regulatory bodies as gene therapy moves forward into clinical trials are now coming to the fore. For example, in the context of HF therapy, high long-term expression of a transgene might be desired, given the expected low biohazard profile. Early clinical studies particularly relied on gene transfer mediated by naked plasmid DNA because of its ease of production and safety profile (90, 91). However, it is an inefficient means of gene transfer, particularly when delivered intravascularly. The inclusion of various physicochemical agents to
Annu. Rev. Med. 2008.59:13-28. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-02
ARI
7 December 2007
12:18
enhance the efficacy of gene transfer may provide some clinical utility, but this has not been extensively explored. In the clinical setting, it is likely that unmodified DNA will be delivered only in very select and localized situations, if at all. The transfer of genes to cardiomyocytes and the myocardium in general is more difficult than gene transfer for many other cell types. Recognition of this difficulty has led to the widespread use of virally mediated transfer techniques for preclinical research and in clinical trials. Recombinant adenoviral vectors are widely used experimentally and in a variety of clinical trials. These vectors can be produced relatively easily, in large quantity, and have been approved for use in a wide range of clinical trials (http://www. clinicaltrials.gov). However, for applications such as HF the relatively short duration of expression, typically less than one month, limits their potential value. Furthermore, issues have been raised in regard to the potential for adenovirus to initiate an inflammatory response, although it is possible that restriction of the delivery of adenovirus to selected sites may prevent these adverse effects by limiting systemic exposure (78). The production of newer recombinant adenoviral vectors that elicit less marked immune responses may lead to renewed interest in their use, and the reduction in immunogenicity may also afford higher and more sustained levels of gene expression. More recently, AAVs have been developed for use as gene transfer vectors. In particular, the AAV2 serotype has already been employed in clinical trials (93). These vectors offer the potential for longer-term expression with less immunogenicity. However, several technical issues limit the clinical utility of AAVs for gene therapy. These difficulties include the size of the potential gene insert that can be carried by AAVs, difficulty with manufacture, and the presence of preformed antibodies. At present, intense interest is also focused on the characterization of a number
of serotypes, with particular emphasis on their relative tissue and cell-type selectivity (94). In experimental studies, lentiviral vectors show promise as vehicles for highly efficient gene transfer (95) with prolonged gene expression due to genomic integration.
Gene Therapy: Choice of Delivery Method The lessons learned from experimental studies using gene transfer in animal models of HF have proved invaluable in identifying potential therapeutic targets for clinical application. However, most of this work has been conducted in small animals. Therefore, the issue of scalability is important in determining the feasibility of gene delivery per se, as well as dosage. In broad terms, delivery of genes or possibly cells to the myocardium might be considered either as a localized therapy or more globally for a widespread myocardial process such as cardiomyopathy. For localized gene delivery, as might be exemplified by a region of myocardial ischemia or an electrical focus for arrhythmogenesis, injection via a needle-tip catheter under fluoroscopic control is well described. For example, this technique has been utilized in the delivery of proangiogenic factors in patients with refractory myocardial ischemia (96). Localized delivery via small coronary arterial branches may also possible in select cases. As mentioned above, in the context of a more widespread myocardial process, a technique that affords general delivery would be desirable. Gene therapy studies in large animals with experimental HF have been conducted using simple intracoronary delivery. For example, the intracoronary delivery of an adenovirus encoding adenylate cyclase was shown to result in increased myocardial expression of the enzyme and favorable hemodynamic effects (97, 98). However, in this study as in many others, the coinfusion of additional agents such as sodium nitroprusside was required to achieve significant viral
www.annualreviews.org • Reversing Ca 2+ Defects in Heart Failure
21
Annu. Rev. Med. 2008.59:13-28. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-02
ARI
7 December 2007
12:18
transfer. Other limitations of intracoronary delivery are that the single passage of the viral payload through the coronary circulation provides only a short time for gene transfer and exposes the systemic circulation to the possible adverse effects of gene expression or viral material in other organs. A variety of approaches have been proposed to improve uptake. Delivery of agents retrogradely via the coronary veins has also been tried with some success, although an epicardial predominance of delivery is typically noted (99). The high-pressure delivery of intracoronary perfusate with proximal balloon occlusion has been tested, but although it did augment gene
Coronary arterial catheter
Coronary sinus catheter
delivery, the procedure was complicated by significant tissue barotrauma (100). Another approach has been the simultaneous use of balloon occlusion of both the coronary artery and relevant coronary vein to localize and augment gene delivery to a particular vascular territory (101). Other potentially translatable approaches to myocardial gene delivery have been somewhat more complex. Cardiac gene transfer using surgical cardiopulmonary bypass techniques has been described in neonatal pigs (102), with evidence of efficient myocardial uptake and expression of the delivered transgene. In a somewhat analogous manner, we developed a percutaneous closed-loop system for myocardial gene delivery that could be applied to the failing heart in large animals and ultimately in man. We hypothesized that a closed-loop recirculation system for myocardial gene delivery might achieve several desirable features. First, by avoiding peripheral systemic delivery or even single-pass intracoronary infusion, this approach raises the concentration of vector reaching the myocardium. Furthermore, the required dose of viral vector may be reduced because dilution of loss is limited. This system has been safely deployed in large animals with severe HF (78, 103), as depicted in Figure 4.
CONCLUSION Coronary sinus recovery
Coronary artery infusion
Heart
Agent Pump
Oxygenator
Figure 4 Potential clinical means for gene delivery to the failing human heart. Upper panel shows the placement of catheters within the coronary arterial and coronary venous system, with gene recirculation mediated via the circuit depicted in the lower panel. 22
Kaye
·
Hoshijima
·
Chien
Despite remarkable pharmacological advances in the treatment of patients with HF, the rate of development of new therapies, particularly for patients with moderate to severe HF, appears to have slowed. This is somewhat surprising given the wealth of experimental data that have identified a number of very promising targets, particularly involving the Ca2+ cycling pathway, for selective manipulation using gene transfer approaches in the failing heart. There is now cautious optimism about a potential role for gene therapy in patients with HF. The results of several phase I studies soon to commence are eagerly awaited.
ANRV334-ME59-02
ARI
7 December 2007
12:18
DISCLOSURE STATEMENT Dr. Kaye is a cofounder of V-Kardia Inc., which is responsible for developing the closed-loop cardiac gene therapy platform.
Annu. Rev. Med. 2008.59:13-28. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
LITERATURE CITED 1. Hunt SA, Abraham WT, Chin MH, et al. 2005. ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult. Circulation 112:e154–235 2. Swedberg K, Cleland J, Dargie H, et al. 2005. Guidelines for the diagnosis and treatment of chronic heart failure. Eur. Heart J. 26:1115–40 3. Abhayaratna W, Smith W, Becker N, et al. 2006. Prevalence of heart failure and systolic ventricular dysfunction in older Australians: the Canberra Heart Study. Med. J. Aust. 184:151–54 4. Levy D, Kenchaiah S, Larson MG, et al. 2002. Long-term trends in the incidence of and survival with heart failure. N. Engl. J. Med. 347:1397–402 5. Roger VL, Weston SA, Redfield MM, et al. 2004. Trends in heart failure incidence and survival in a community-based population. JAMA 292:344–50 6. O’Connell J, Bristow M. 1994. Economic impact of heart failure in the United States: time for a different approach. J. Heart Lung Transpl. 13:S107–12 7. Mosterd A, Hoes AW, de Bruyne MC, et al. 1999. Prevalence of heart failure and left ventricular dysfunction in the general population; the Rotterdam Study. Eur. Heart J. 20:447–55 8. Cleland JG, Khand A, Clark A. 2001. The heart failure epidemic: Exactly how big is it? Eur. Heart J. 22:623–26 9. Rose EA, Gelijns AC, Moskowitz AJ, et al. 2001. Long-term mechanical left ventricular assistance for end-stage heart failure. N. Engl. J. Med. 345:1435–43 10. Kang PM, Yue P, Izumo S. 2002. New insights into the role of apoptosis in cardiovascular disease. Circ. J. 66:1–9 11. Olivetti G, Abbi R, Quaini F, et al. 1997. Apoptosis in the failing human heart. N. Engl. J. Med. 336:1131–41 12. Kajstura J, Liu Y, Baldini A, et al. 1998. Coronary artery constriction in rats: necrotic and apoptotic myocyte death. Am. J. Cardiol. 82:30K–41K 13. Iwai-Kanai E, Hasegawa K, Araki M, et al. 1999. Alpha- and beta-adrenergic pathways differentially regulate cell type–specific apoptosis in rat cardiac myocytes. Circulation 100:305–11 14. Leri A, Claudio PP, Li Q, et al. 1998. Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell. J. Clin. Invest. 101:1326–42 15. Pimentel DR, Amin JK, Xiao L, et al. 2001. Reactive oxygen species mediate amplitudedependent hypertrophic and apoptotic responses to mechanical stretch in cardiac myocytes. Circ. Res. 89:453–60 16. St John Sutton M, Lee D, Rouleau JL, et al. 2003. Left ventricular remodeling and ventricular arrhythmias after myocardial infarction. Circulation 107:2577–82 17. Anand IS, Liu D, Chugh SS, et al. 1997. Isolated myocyte contractile function is normal in postinfarct remodeled rat heart with systolic dysfunction. Circulation 96:3974–84 17a. Hunter JJ, Chien KR. 1999. Signaling pathways for cardiac hypertrophy and failure. N. Engl. J. Med. 341:1276–318 www.annualreviews.org • Reversing Ca 2+ Defects in Heart Failure
23
ARI
7 December 2007
12:18
18. Frey N, Olson EN. 2003. Cardiac hypertrophy: the good, the bad, and the ugly. Annu. Rev. Physiol. 65:45–79 19. Leinwand LA. 2001. Calcineurin inhibition and cardiac hypertrophy: a matter of balance. Proc. Natl. Acad. Sci. USA 98:2947–49 20. Taigen T, De Windt LJ, Lim HW, Molkentin JD. 2000. Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc. Natl. Acad. Sci. USA 97:1196– 201 21. Vega RB, Rothermel BA, Weinheimer CJ, et al. 2003. Dual roles of modulatory calcineurin-interacting protein 1 in cardiac hypertrophy. Proc. Natl. Acad. Sci. USA 100:669–74 22. Gao XM, Wong G, Wang B, et al. 2006. Inhibition of mTOR reduces chronic pressureoverload cardiac hypertrophy and fibrosis. J. Hypertens. 24:1663–70 23. Brown JH, Del Re DP, Sussman MA. 2006. The Rac and Rho hall of fame: a decade of hypertrophic signaling hits. Circ. Res. 98:730–42 24. Boluyt MO, O’Neill L, Meredith AL, et al. 1994. Alterations in cardiac gene expression during the transition from stable hypertrophy to heart failure. Marked upregulation of genes encoding extracellular matrix components. Circ. Res. 75:23–32 25. Chai W, Danser AH. 2006. Why are mineralocorticoid receptor antagonists cardioprotective? Naunyn Schmiedebergs Arch. Pharmacol. 374:153–62 26. Sundstrom J, Evans JC, Benjamin EJ, et al. 2004. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation 109:2850–56 27. Pitt B. 2004. Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. Mol. Cell Endocrinol. 217:53–58 28. Kobayashi M, Machida N, Mitsuishi M, Yamane Y. 2004. Beta-blocker improves survival, left ventricular function, and myocardial remodeling in hypertensive rats with diastolic heart failure. Am. J. Hypertens. 17:1112–19 29. See F, Kompa A, Martin J, et al. 2005. Fibrosis as a therapeutic target postmyocardial infarction. Curr. Pharm. Des. 11:477–87 30. Pfeffer JM, Pfeffer MA, Mirsky I, Braunwald E. 1982. Regression of left ventricular hypertrophy and prevention of left ventricular dysfunction by captopril in the spontaneously hypertensive rat. Proc. Natl. Acad. Sci. USA 79:3310–14 31. Pfeffer JM, Pfeffer MA, Braunwald E. 1987. Hemodynamic benefits and prolonged survival with long-term captopril therapy in rats with myocardial infarction and heart failure. Circulation 75:I149–55 32. Greenberg B, Quinones MA, Koilpillai C, et al. 1995. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation 91:2573–81 33. Zisman LS, Abraham WT, Meixell GE, et al. 1995. Angiotensin II formation in the intact human heart. Predominance of the angiotensin-converting enzyme pathway. J. Clin. Invest. 96:1490–98 34. Bers DM. 2002. Cardiac excitation-contraction coupling. Nature 415:198–205 35. Wier WG, Balke CW. 1999. Ca2+ release mechanisms, Ca2+ sparks, and local control of excitation-contraction coupling in normal heart muscle. Circ. Res. 85:770–76 36. MacLennan DH, Kranias EG. 2003. Phospholamban: a crucial regulator of cardiac contractility. Nat. Rev. Mol. Cell Biol. 4:566–77 37. Tada M, Toyofuku T. 1998. Molecular regulation of phospholamban function and expression. Trends Cardiovasc. Med. 8:330–40
Annu. Rev. Med. 2008.59:13-28. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-02
24
Kaye
·
Hoshijima
·
Chien
Annu. Rev. Med. 2008.59:13-28. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-02
ARI
7 December 2007
12:18
38. Gwathmey JK, Copelas L, MacKinnon R, et al. 1987. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ. Res. 61:70–76 39. Gwathmey JK, Hajjar RJ. 1990. Relation between steady-state force and intracellular [Ca2+ ] in intact human myocardium. Index of myofibrillar responsiveness to Ca2+ . Circulation 82:1266–78 40. Gwathmey JK, Bentivegna LA, Ransil BJ, et al. 1993. Relationship of abnormal intracellular calcium mobilisation to myocyte hypertrophy in human ventricular myocardium. Cardiovasc. Res. 27:199–203 41. Hasenfuss G. 1998. Alterations of calcium-regulatory proteins in heart failure. Cardiovasc. Res. 37:279–89 42. Hasenfuss G, Pieske B. 2002. Calcium cycling in congestive heart failure. J. Mol. Cell Cardiol. 34:951–69 42a. Minamisawa S, Hoshijima M, Chu G, et al. 1999. Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell 99:313–22 43. Arai M, Matsui H, Periasamy M. 1994. Sarcoplasmic reticulum gene expression in cardiac hypertrophy and heart failure. Circ. Res. 74:555–64 44. Beuckelmann DJ, Nabauer M, Erdmann E. 1992. Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation 85:1046– 55 45. DiPaola NR, Sweet WE, Stull LB, et al. 2001. Beta-adrenergic receptors and calcium cycling proteins in nonfailing, hypertrophied and failing human hearts: transition from hypertrophy to failure. J. Mol. Cell Cardiol. 33:1283–95 46. Tomaselli GF, Marban E. 1999. Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc. Res. 42:270–83 47. Chen X, Piacentino V 3rd, Furukawa S, et al. 2002. L-type Ca2+ channel density and regulation are altered in failing human ventricular myocytes and recover after support with mechanical assist devices. Circ. Res. 91:517–24 48. Yang Y, Chen X, Margulies K, et al. 2000. L-type Ca2+ channel alpha 1c subunit isoform switching in failing human ventricular myocardium. J. Mol. Cell Cardiol. 32:973–84 49. Marx SO, Reiken S, Hisamatsu Y, et al. 2000. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 101:365–76 50. Lowes BD, Minobe W, Abraham WT, et al. 1997. Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. J. Clin. Invest. 100:2315–24 51. Anderson PA, Malouf NN, Oakeley AE, et al. 1992. Troponin T isoform expression in the normal and failing human left ventricle: a correlation with myofibrillar ATPase activity. Basic Res. Cardiol. 87 Suppl 1:117–27 52. Solaro RJ, Rarick HM. 1998. Troponin and tropomyosin: proteins that switch on and tune in the activity of cardiac myofilaments. Circ. Res. 83:471–80 53. Cohn J, Levine T, Olivari M, et al. 1984. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. New Engl. J. Med. 311:819–23 54. Kaye DM, Lambert GW, Lefkovits J, et al. 1994. Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J. Am. Coll. Cardiol. 23:570–78 55. Leimbach WN Jr., Wallin BG, Victor RG, et al. 1986. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation 73:913–19 www.annualreviews.org • Reversing Ca 2+ Defects in Heart Failure
25
ARI
7 December 2007
12:18
56. Bristow MR, Ginsburg R, Minobe W, et al. 1982. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N. Engl. J. Med. 307:205–11 57. Kaye DM, Lefkovits J, Jennings GL, et al. 1995. Adverse consequences of high sympathetic nervous activity in the failing human heart. J. Am. Coll. Cardiol. 26:1257–63 58. Bristow MR, Ginsberg R, Umans V, et al. 1986. β1- and β2-Adrenergic receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective β1 receptor down-regulation in heart failure. Circ. Res. 59:297–309 59. Xiao RP, Cheng H, Zhou YY, et al. 1999. Recent advances in cardiac β2 -adrenergic signal transduction. Circ. Res. 85:1092–100 60. Du XJ, Autelitano DJ, Dilley RJ, et al. 2000. β2 -Adrenergic receptor overexpression exacerbates development of heart failure after aortic stenosis. Circulation 101:71–77 61. Packer M, Bristow MR, Cohn JN, et al. 1996. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N. Engl. J. Med. 334:1349–55 62. MERIT-HF Trial. 1999. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001–7 63. CIBIS-II Trial. 1999. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353:9–13 64. Lowes BD, Gilbert EM, Abraham WT, et al. 2002. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N. Engl. J. Med. 346:1357–65 65. Sun YL, Hu SJ, Wang LH, et al. 2005. Effect of beta-blockers on cardiac function and calcium handling protein in postinfarction heart failure rats. Chest 128:1812–21 66. Kogler H, Schott P, Toischer K, et al. 2006. Relevance of brain natriuretic peptide in preload-dependent regulation of cardiac sarcoplasmic reticulum Ca2+ -ATPase expression. Circulation 113:2724–32 67. Rodrigue-Way A, Burkhoff D, Geesaman BJ, et al. 2005. Sarcomeric genes involved in reverse remodeling of the heart during left ventricular assist device support. J. Heart Lung Transplant. 24:73–80 68. Chien KR, Ross J Jr., Hoshijima H. 2003. Calcium and heart failure: the cycle game. Nat. Med. 9:508–9 69. Kaye DM, Krum H. 2007. Drug discovery for heart failure: a new era or the end of the pipeline? Nat. Rev. Drug Discov. 6:127–39 70. Muller OJ, Lange M, Rattunde H, et al. 2003. Transgenic rat hearts overexpressing SERCA2a show improved contractility under baseline conditions and pressure overload. Cardiovasc. Res. 59:380–89 71. Hajjar RJ, Schmidt U, Kang JX, et al. 1997. Adenoviral gene transfer of phospholamban in isolated rat cardiomyocytes. Rescue effects by concomitant gene transfer of sarcoplasmic reticulum Ca2+ -ATPase. Circ. Res. 81:145–53 72. del Monte F, Harding SE, Schmidt U, et al. 1999. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation 100:2308–11 73. del Monte F, Williams E, Lebeche D, et al. 2001. Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca2+ ATPase in a rat model of heart failure. Circulation 104:1424–29 74. Sakata S, Lebeche D, Sakata N, et al. 2007. Restoration of mechanical and energetic function in failing aortic-banded rat hearts by gene transfer of calcium cycling proteins. J. Mol. Cell Cardiol. 42:852–61
Annu. Rev. Med. 2008.59:13-28. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-02
26
Kaye
·
Hoshijima
·
Chien
Annu. Rev. Med. 2008.59:13-28. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-02
ARI
7 December 2007
12:18
75. Ly H, Kawase Y, Yoneyama R, Hajjar RJ. 2007. Gene therapy in the treatment of heart failure. Physiology (Bethesda) 22:81–96 76. Hoshijima M, Ikeda Y, Iwanaga Y, et al. 2002. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat. Med. 8:864–71 77. Iwanaga Y, Hoshijima M, Gu Y, et al. 2004. Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. J. Clin. Invest. 113:727–36 78. Kaye D, Preovolos A, Marshall T, et al. 2007. Percutaneous cardiac recirculation mediated gene transfer of an inhibitory phospholamban peptide reverses advanced heart failure in large animals. J. Am. Coll. Cardiol. 50:253–60 79. Eizema K, Fechner H, Bezstarosti K, et al. 2000. Adenovirus-based phospholamban antisense expression as a novel approach to improve cardiac contractile dysfunction: comparison of a constitutive viral vs an endothelin-1-responsive cardiac promoter. Circulation 101:2193–99 80. del Monte F, Harding SE, Dec GW, et al. 2002. Targeting phospholamban by gene transfer in human heart failure. Circulation 105:904–7 81. Ziolo M, Martin J, Bossuyt J, et al. 2005. Adenoviral gene transfer of mutant phospholamban rescues contractile dysfunction in failing rabbit myocytes with relatively preserved SERCA function. Circ. Res. 96:815–17 82. Meyer M, Belke DD, Trost SU, et al. 2004. A recombinant antibody increases cardiac contractility by mimicking phospholamban phosphorylation. FASEB J. 18:1312–14 83. Watanabe A, Arai M, Yamazaki M, et al. 2004. Phospholamban ablation by RNA interference increases Ca2+ uptake into rat cardiac myocyte sarcoplasmic reticulum. J. Mol. Cell Cardiol. 37:691–98 84. Fechner H, Suckau L, Kurreck J, et al. 2007. Highly efficient and specific modulation of cardiac calcium homeostasis by adenovector-derived short hairpin RNA targeting phospholamban. Gene Ther. 14:211–18 85. Song Q, Schmidt AG, Hahn HS, et al. 2003. Rescue of cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in genetic hypertrophy. J. Clin. Invest. 111:859–67 86. Packer M, Carver JR, Rodeheffer RJ, et al. 1991. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N. Engl. J. Med. 325:1468–75 87. Sorsa T, Heikkinen S, Abbott MB, et al. 2001. Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. J. Biol. Chem. 276:9337–43 88. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N. 1997. The novel calcium sensitizer levosimendan activates the ATP-sensitive K+ channel in rat ventricular cells. J. Pharmacol. Exp. Ther. 283:375–83 89. Wehrens XH, Lehnart SE, Marks AR. 2005. Ryanodine receptor–targeted antiarrhythmic therapy. Ann. NY Acad. Sci. 1047:366–75 90. Nabel EG, 1995. Gene therapy for cardiovascular disease. Circulation 91:541–48 91. Nabel GJ. 2004. Genetic, cellular and immune approaches to disease therapy: past and future. Nat. Med. 10:135–41 92. Deleted in proof 93. Manno CS, Pierce GF, Arruda VR, et al. 2006. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12:342–47 www.annualreviews.org • Reversing Ca 2+ Defects in Heart Failure
27
ARI
7 December 2007
12:18
94. Palomeque J, Chemaly ER, Colosi P, et al. 2007. Efficiency of eight different AAV serotypes in transducing rat myocardium in vivo. Gene Ther. 14:989–97. 95. Bonci D, Cittadini A, Latronico MV, et al. 2003. ‘Advanced’ generation lentiviruses as efficient vectors for cardiomyocyte gene transduction in vitro and in vivo. Gene Ther. 10:630–36 96. Losordo DW, Vale PR, Hendel RC, et al. 2002. Phase 1/2 placebo-controlled, doubleblind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 105:2012–18 97. Lai NC, Roth DM, Gao MH, et al. 2000. Intracoronary delivery of adenovirus encoding adenylyl cyclase VI increases left ventricular function and cAMP-generating capacity. Circulation 102:2396–401 98. Roth DM, Lai NC, Gao MH, et al. 2004. Nitroprusside increases gene transfer associated with intracoronary delivery of adenovirus. Hum. Gene Ther. 15:989–94 99. Boekstegers P, von Degenfeld G, Giehrl W, et al. 2000. Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins. Gene Ther. 7:232–40 100. Emani SM, Shah AS, Bowman MK, et al. 2003. Catheter-based intracoronary myocardial adenoviral gene delivery: importance of intraluminal seal and infusion flow rate. Mol. Ther. 8:306–13 101. Hayase M, Del Monte F, Kawase Y, et al. 2005. Catheter-based antegrade intracoronary viral gene delivery with coronary venous blockade. Am. J. Physiol. Heart Circ. Physiol. 288:H2995–3000 102. Davidson MJ, Jones JM, Emani SM, et al. 2001. Cardiac gene delivery with cardiopulmonary bypass. Circulation 104:131–33 103. Preovolos AC, Mennen MT, Bilney A, et al. 2006. Development of a novel perfusion technique to allow targeted delivery of gene therapy—the V-Focus system. J. Extra Corpor. Technol. 38:51–52
Annu. Rev. Med. 2008.59:13-28. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-02
28
Kaye
·
Hoshijima
·
Chien
AR334-FM
ARI
18 December 2007
17:20
Annual Review of Medicine
Annu. Rev. Med. 2008.59:13-28. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Contents
Volume 59, 2008
The FDA Critical Path Initiative and Its Influence on New Drug Development Janet Woodcock and Raymond Woosley p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p1 Reversing Advanced Heart Failure by Targeting Ca2+ Cycling David M. Kaye, Masahiko Hoshijima, and Kenneth R. Chien p p p p p p p p p p p p p p p p p p p p p p p p 13 Tissue Factor and Factor VIIa as Therapeutic Targets in Disorders of Hemostasis Ulla Hedner and Mirella Ezban p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 29 Therapy of Marfan Syndrome Daniel P. Judge and Harry C. Dietz p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 43 Preeclampsia and Angiogenic Imbalance Sharon Maynard, Franklin H. Epstein, and S. Ananth Karumanchi p p p p p p p p p p p p p p p p p 61 Management of Lipids in the Prevention of Cardiovascular Events Helene Glassberg and Daniel J. Rader p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 79 Genetic Susceptibility to Type 2 Diabetes and Implications for Antidiabetic Therapy Allan F. Moore and Jose C. Florez p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 95 Array-Based DNA Diagnostics: Let the Revolution Begin Arthur L. Beaudet and John W. Belmont p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p113 Inherited Mitochondrial Diseases of DNA Replication William C. Copeland p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p131 Childhood Obesity: Adrift in the “Limbic Triangle” Michele L. Mietus-Snyder and Robert H. Lustig p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p147 Expanded Newborn Screening: Implications for Genomic Medicine Linda L. McCabe and Edward R.B. McCabe p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p163 Is Human Hibernation Possible? Cheng Chi Lee p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p177 Advance Directives Linda L. Emanuel p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p187 v
AR334-FM
ARI
18 December 2007
17:20
Genetic Determinants of Aggressive Breast Cancer Alejandra C. Ventura and Sofia D. Merajver p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p199 A Role for JAK2 Mutations in Myeloproliferative Diseases Kelly J. Morgan and D. Gary Gilliland p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p213 Appropriate Use of Cervical Cancer Vaccine Gregory D. Zimet, Marcia L. Shew, and Jessica A. Kahn p p p p p p p p p p p p p p p p p p p p p p p p p p p p p223 A Decade of Rituximab: Improving Survival Outcomes in Non-Hodgkin’s Lymphoma Arturo Molina p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p237
Annu. Rev. Med. 2008.59:13-28. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Nanotechnology and Cancer James R. Heath and Mark E. Davis p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p251 Cancer Epigenetics: Modifications, Screening, and Therapy Einav Nili Gal-Yam, Yoshimasa Saito, Gerda Egger, and Peter A. Jones p p p p p p p p p p p p267 T Cells and NKT Cells in the Pathogenesis of Asthma Everett H. Meyer, Rosemarie H. DeKruyff, and Dale T. Umetsu p p p p p p p p p p p p p p p p p p p p281 Complement Regulatory Genes and Hemolytic Uremic Syndromes David Kavanagh, Anna Richards, and John Atkinson p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p293 Mesenchymal Stem Cells in Acute Kidney Injury Benjamin D. Humphreys and Joseph V. Bonventre p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p311 Asthma Genetics: From Linear to Multifactorial Approaches Stefano Guerra and Fernando D. Martinez p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p327 The Effect of Toll-Like Receptors and Toll-Like Receptor Genetics in Human Disease Stavros Garantziotis, John W. Hollingsworth, Aimee K. Zaas, and David A. Schwartz p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p343 Advances in Antifungal Therapy Carole A. Sable, Kim M. Strohmaier, and Jeffrey A. Chodakewitz p p p p p p p p p p p p p p p p p p361 Herpes Simplex: Insights on Pathogenesis and Possible Vaccines David M. Koelle and Lawrence Corey p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p381 Medical Management of Influenza Infection Anne Moscona p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p397 Bacterial and Fungal Biofilm Infections A. Simon Lynch and Gregory T. Robertson p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p415 EGFR Tyrosine Kinase Inhibitors in Lung Cancer: An Evolving Story Lecia V. Sequist and Thomas J. Lynch p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p429 Adaptive Treatment Strategies in Chronic Disease Philip W. Lavori and Ree Dawson p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p443 vi
Contents
AR334-FM
ARI
18 December 2007
17:20
Antiretroviral Drug–Based Microbicides to Prevent HIV-1 Sexual Transmission Per Johan Klasse, Robin Shattock, and John P. Moore p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p455 The Challenge of Hepatitis C in the HIV-Infected Person David L. Thomas p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p473 Hide-and-Seek: The Challenge of Viral Persistence in HIV-1 Infection Luc Geeraert, Günter Kraus, and Roger J. Pomerantz p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p487
Annu. Rev. Med. 2008.59:13-28. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Advancements in the Treatment of Epilepsy B.A. Leeman and A.J. Cole p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p503 Indexes Cumulative Index of Contributing Authors, Volumes 55–59 p p p p p p p p p p p p p p p p p p p p p p p p525 Cumulative Index of Chapter Titles, Volumes 55–59 p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p529 Errata An online log of corrections to Annual Review of Medicine articles may be found at http://med.annualreviews.org/errata.shtml
Contents
vii
ANRV334-ME59-03
ARI
16 December 2007
14:39
Annu. Rev. Med. 2008.59:29-41. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Tissue Factor and Factor VIIa as Therapeutic Targets in Disorders of Hemostasis Ulla Hedner1,2 and Mirella Ezban2 1
Department of Medicine, University of Lund, Sweden; email:
[email protected]
2
Biopharmaceutical Research Unit, Novo Nordisk A/S, Maaloev, Denmark
Annu. Rev. Med. 2008. 59:29–41
Key Words
First published online as a Review in Advance on September 10, 2007
hemophilia, recombinant FVIIa, TF-FVII pathway inhibitors, TFPI, inactivated rFVIIa
The Annual Review of Medicine is online at http://med.annualreviews.org This article’s doi: 10.1146/annurev.med.59.061606.095605 c 2008 by Annual Reviews. Copyright All rights reserved 0066-4219/08/0218-0029$20.00
Abstract For hemophilia patients with inhibitors against FVIII or FIX, the development of recombinant factor VIIa (rFVIIa) raises the possibility of a therapeutic alternative whose availability and convenience of treatment are comparable to those of FVIII or FIX. In support of this new concept for the treatment of bleeding episodes, pharmacological doses of FVIIa have been shown to induce hemostasis. Pharmacological doses of rFVIIa enhance thrombin generation on thrombin-activated platelets, thereby facilitating the formation of strong, well-structured fibrin plugs resistant to premature proteolysis. Modified rFVIIa molecules with a stronger hemostatic potential have been produced. Inhibition of the FVII-TF-dependent pathway (TFPI and rFVIIai) has been tried in attempts to prevent thrombosis, with promising results in animal models so far not confirmed in clinical trials.
29
ANRV334-ME59-03
ARI
16 December 2007
14:39
INTRODUCTION rFVIIa: activated recombinant coagulation factor VII TF: tissue factor
Annu. Rev. Med. 2008.59:29-41. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
FV–FXIII: coagulation factor V–coagulation factor XIII; an “a” at the end indicates the active form of the protein TFPI: tissue factor pathway inhibitor AT: antithrombin OCS: open canicular system of platelets
30
The development of recombinant factor VIIa (rFVIIa) stimulated research into the tissue factor (TF)- and FVII-dependent pathway of hemostasis. As a result, investigators have begun to explore ways of interfering in this system to enhance hemostasis (as in the treatment of bleeding episodes) or to limit it (as in the prevention of thromboembolism). The finding that pharmacological doses of rFVIIa provided hemostasis in patients with severe hemophilia in the absence of FVIII or FIX was a breakthrough in the understanding of the importance of FVII and TF for hemostasis. In the 1960s, the hemostatic process was modeled as a waterfall or cascade (1) in which a number of clotting factors existed as coenzymes activating each other in the circulating blood. In the cascade model, FVII and TF were recognized as the extrinsic pathway. However, they received little attention until it was demonstrated in the 1970s that the complex between FVII and TF activated not only FX but also FIX, which was part of the so-called intrinsic system (2). The cascade model did not include cells and platelets and their role for the localization of the hemostatic process. Neither was it able to explain why patients with a FXII deficiency do not bleed excessively. A potential role of platelets in the hemostatic process was identified already in the late 1800s, and subsequently, it was demonstrated that the rate of clotting and generation of thrombin increased as a function of platelet number. It was later shown that the exposure of phospholipids, especially phosphatidylserine (PS), on the outer surface of thrombin-activated platelets was important. Phosphatidylserine is also needed to maintain the anticoagulant activity of endothelium, as it enhances thrombomodulin activity. Furthermore, it was shown that platelets have complex coagulant activities that are not completely mimicked by phospholipids (1). Also important for regulating the hemostatic process is the presence of potent inhibitors in the
Hedner
·
Ezban
circulation, such as the tissue factor pathway inhibitor (TFPI) and antithrombin (AT) (1, 3). It thus was recognized that the hemostatic process is strongly regulated by localization on cell surfaces and by plasma inhibitors. The so-called extrinsic and intrinsic pathways are much more complex than realized previously, and the idea of the two coagulation pathways—extrinsic and intrinsic—should be abandoned.
HEMOSTASIS According to the current concept, hemostasis occurs on cell surfaces, mainly involving the TF-bearing cells and the thrombinactivated platelets. A cell-based model system was used to study the hemostatic process, which allowed study of the TF-dependent and -independent processes together and apart (1). TF-expressing cells are present in the deeper layers of the vessel wall (4). When the vessel wall is injured, TF is exposed to circulating blood and forms complexes with FVIIa present in the circulation. Recently it was suggested that extravascular TF close to the vessels has bound FVII or FVIIa in the absence of an injury (5). TF may also originate from the circulating blood in the form of encrypted TF carried by cell elements such as white blood cells or microparticles (6). Furthermore, it was recently reported that washed platelets incubated with TF were able to take up TF in a process involving traffic of vesicles through channels of the open canicular system (OCS). TF was identified in the OCS and occasionally in the alpha-granulae of the platelets (7). Because TF is a receptor protein anchored to cells by a transmembrane domain, the TFFVII/FVIIa complex is localized by cells to the site of injury. Recently the activity of this complex was found to be markedly influenced by lipid bilayer composition. Using a novel experimental model to regulate the lipid bilayers, and allowing the incorporation of membrane-spanning proteins, investigators
Annu. Rev. Med. 2008.59:29-41. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-03
ARI
16 December 2007
14:39
demonstrated that full TF-FVIIa proteolytic activity required extremely high local concentrations of anionic phospholipids. The TFFVII/FVIIa complex activates FX into FXa as well as FIX into FIXa on the TF-bearing cells. Membrane microdomains with high phosphatidylserine (PS) content were shown to enhance the FX-activating capacity of the TFFVIIa complex (8). The importance of the membrane composition was also stressed by the finding that depletion of cholesterol from cell membranes impaired functional TF expression in fibroblasts. The FXa formed converts limited amounts of prothrombin into thrombin sufficient to activate FVIII and FV. This thrombin also activates FXI into FXIa, as well as platelets. The FXa activity is restricted to the TF-bearing cell surface. Any FXa that diffuses off the cell is immediately inhibited by the tissue factor pathway inhibitor (TFPI) and AT. As soon as FXa is formed, a complex including TF-FVIIa and FXa is formed, inhibited by TFPI, and internalized. TFPI-alpha contains an acidic N-terminal region followed by three tandem, Kunitz-type protease inhibitor domains and a basic C-terminal region (1). TFPI-beta is an alternatively spliced form of TFPI lacking the Kunitz domain 3 and the C-terminal part of TFPI-alpha. The C terminus of TFPI-alpha is presumably important for localizing the molecule to the cell surface through interactions with anionic phospholipids, glycosaminoglycans, or surface proteins. The majority of circulating TFPI is bound to plasma lipoproteins (9). Heparin releases the endothelial-cell-bound TFPI (3). Another pool of TFPI not released by heparin is bound to glycosylphosphatidylinositol (GPI), either directly (TFPI-beta) or indirectly (TFPI-alpha). Both forms of TFPI seem to be involved in the localization of TFPI to cell surfaces (9). TFPI has been found to enhance the TF-specific internalization and degradation of FVIIa, which requires the C-terminal domain of TFPI and FXa. Most of the internalized FVIIa is degraded, but a small fraction recycles back to the cell surface as an intact protein. In the
absence of TFPI, FVIIa bound to TF is internalized and degraded (10). The platelets activated by the initially formed thrombin will undergo the “flip-flop” reaction described by Bevers and coworkers (cited in Reference 1), which exposes negatively charged phospholipids on the surface (3). On this surface, the full thrombin burst necessary for effective hemostasis is generated (1). The binding of coagulation proteins on the platelet surface is facilitated by the combined stimulation of the platelet collagen receptor (GPVI) and thrombin receptor owing to the development of a subpopulation of platelets with an increased binding capacity (11; see also 12). Individual variations in such subpopulations may add to the variability of platelet procoagulant response. The binding of clotting factors to the platelet membrane depends on the PS content of the membrane (1). However, the binding of FIXa to the activated platelet surface is mediated not only by the membrane PS but also by specific sites promoting the formation of active FIXaFVIIIa complexes (“tenase complex”) (13). The tenase complex activates FX from the circulation into FXa on the platelet surface. FXa then associates with FVa on the surface and generates a burst of thrombin required to form a firm, well-structured fibrin hemostatic plug, which is resistant to premature proteolysis and capable of maintaining hemostasis until the wound healing process is established. Full thrombin generation is necessary for the formation of a tight fibrin structure and for the activation of FXIII, as well as the thrombinactivatable fibrinolytic inhibitor (TAFI). Also the fibrinogen concentration plays a key role in the formation of a dense and tight fibrin network (6). FXIa activated by thrombin also associates with the platelet surface, where it activates more FIX into FIXa, thereby enhancing thrombin generation. Hemostasis in hemophilia is characterized by the formation of loose, fragile hemostatic fibrin plugs, which may stop a bleeding initially but are easily dissolved by proteolytic enzymes bound to fibrin. As a result, the
www.annualreviews.org • TF-FVII Pathway and Therapeutic Opportunities
PS: phosphatidylserine GPI: glycosylphosphatidylinositol GPVI: platelet collagen receptor TAFI: thrombin activatable fibrinolytic inhibitor
31
ARI
16 December 2007
14:39
hemophilia patient rebleeds repeatedly and finally may succumb to extensive, profuse bleedings. In hemophilia the initial thrombin dependent on the TF-FVIIa complex is formed, but since FVIII or FIX is lacking, no tenase complex is formed on the platelet surface. Therefore, no full thrombin burst occurs in hemophilia patients, so the hemostatic plugs that form are loose and unstructured (6). In contrast, patients with FXI deficiency never have a bleeding disorder of the severity seen in hemophilia, since they do form basic tenase complexes on the activated platelet surface. However, because they miss the enhancement of thrombin generation on the platelet surface, their fibrin plugs may be less strong and less resistant to proteolysis. Furthermore, the thrombin generated may not be sufficient for full activation of the TAFI. As a result, patients with FXI deficiency often develop bleedings in association with surgery or major trauma, especially in areas of rich fibrinolytic activity (e.g., mouth, nose, gastrointestinal tract), although they do not develop spontaneous bleedings as seen in hemophilia (14).
Annu. Rev. Med. 2008.59:29-41. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-03
FVIIa AS A HEMOSTATIC AGENT Approximately 20% of hemophilia patients have developed inhibitors against FVIII or FIX. These patients do not benefit from concentrates of FVIII or FIX unless special measures are undertaken to overcome or remove the inhibitors. These procedures are not easy to perform and are not used to treat mild to moderate bleeding episodes. Prevention of joint bleedings diminishes the development of chronic disabling athropathy in hemophilia patients. In patients with inhibitors, “FVIII bypassing agents” (activated prothrombin complexes, APCCs) are used instead of concentrates of FVIII or FIX. The hemostatic effect of an APCC was found to vary between 50% and 65% in the only two controlled clinical studies performed (6). The APCCs, introduced in the 1970s, contain both zymogens and activated coagulation proteins and have been associated with thromboembolic events. 32
Hedner
·
Ezban
A dog model was used in an attempt to identify potential thrombogenic factors in the APCCs. Coinjection of antithrombin and heparin prevented the signs of a systemic activation of the coagulation system as evidenced by preventing decreased fibrinogen and thrombocytopenia. The conclusion drawn from these experiments was that FVIIa, which is not effectively inhibited by AT and heparin, should not be responsible for the thrombogenic effect of the APCCs. Furthermore, purified FVIIa did not induce any signs of a general activation of the coagulation system in the same dog model. However, FVIIa might well be a major contributor to the hemostatic effectiveness of APCCs. FVIIa occurs in the normal circulation in a concentration corresponding to ∼1% of the total FVII protein mass (6). In the 1970s, very little was known about the roles of FVII/FVIIa and TF in the hemostatic process, and FVIIa as a hemostatic agent was a new concept. FVIIa was purified from human plasma and infused into two hemophilia patients who had FVIII inhibitors. Hemostasis was achieved. No signs of a general activation of the coagulation system were observed (15). Development of rFVIIa required a design utilizing mammalian cells and recombinant technique. The need for a better treatment for hemophilia patients with inhibitors was obvious, and the observed hemostatic effect of plasma-derived purified FVIIa in severe hemophilia was encouraging in terms of the future usefulness of pharmacological doses of FVIIa. However, in the early 1980s, the risk of transmitting a pathogenic virus with blood products became evident. In addition, rFVIIa was tedious to prepare from plasma. Therefore, recombinant technology was chosen for preparing therapeutic rFVIIa with minimal risk of transmission of infectious agents (11). Between 1985 and 1988, rFVIIa was developed for treatment of hemophilia complicated by inhibitors against FVIII/FIX at Novo Nordisk A/S, Denmark. The vision at the time was to develop a therapy for hemophilia
Annu. Rev. Med. 2008.59:29-41. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-03
ARI
16 December 2007
14:39
patients with inhibitors that would be as easily available and convenient as existing treatments for hemophilia patients without inhibitors. This meant developing an effective hemostatic agent that worked in the absence of FVIII/FIX, which would not only make major surgery possible but also decrease the number of bleedings. If the new agent were successful, there would be no further need for complicated, inconvenient, and expensive therapies such as induced immune tolerance treatment. Recombinant FVII is produced in a baby hamster kidney (BHK) cell line, which is similar to human plasma-derived FVII in its amino acid sequence, gamma-carboxylation, and glycosylation. During the purification procedure, rFVII is autoactivated into rFVIIa. Preclinical development included an efficacy study in dogs with hemophilia A and B, which showed that rFVIIa shortened (normalized) the canine cuticle bleeding time without adverse reactions (6). In the past, elective surgery has been more or less contraindicated in hemophilia patients with inhibitors because of the risk of uncontrollable bleeding. However, rFVIIa was demonstrated to have an efficacy rate of 90%– 100% in major surgery, including major orthopedic surgery (6). Starting in 1988, rFVIIa was given to hemophilia patients with serious bleedings in the central nervous system, intraperitoneal and retroperitoneal bleedings, and severe intramuscular bleedings. The dosing schedule was essentially the same as that recommended in surgery, and the efficacy rate was 83%–95%. As part of the vision of providing a treatment for hemophilia patients with inhibitors that would make them similar to patients without inhibitors, the effect of rFVIIa in a home-treatment setting was explored. An efficacy rate of 92% was achieved; however, the average number of doses to achieve hemostasis was 2.3, which indicates that the dose used might not be optimal (14). The addition of pharmacological doses of rFVIIa, reaching plasma concentrations
of 25 nM or higher, induces hemostasis in the absence of FVIII or FIX, most probably by enhancing thrombin generation on the thrombin-activated platelet surface, which enables the formation of a tight, stable fibrin hemostatic plug. In the cell-based model, rFVIIa binds to the thrombin-activated platelet surface with a low affinity, requiring higher concentrations of rFVIIa than those found normally in circulating blood. The bound rFVIIa activates FX on the activated platelet surface independent of the presence of FVIII or FIX. The thrombin generation in the absence of FIX substantially improves following addition of rFVIIa in concentrations of 50 nM and up to 100 nM. Also, the clot lysis time in vitro in hemophilia plasma was found to be prolonged after addition of rFVIIa. Increased TAFI activation as a result of enhanced thrombin generation was suggested to contribute to the increased resistance to lysis. Furthermore, normalization of the fibrin permeability was achieved by the addition of rFVIIa to hemophilia plasma containing platelets, an effect that was reflected in a tighter fibrin structure. The hemostatic effect of exogenous rFVIIa in pharmacological doses thus seems to be mediated by an enhanced rate of thrombin generation on thrombin-activated platelet surfaces, resulting in an increased further activation of platelets at the site of injury, and increased platelet adhesion that may involve an enhanced platelet-platelet interaction initiated by thrombin binding to platelet glycoprotein Ib (GPIb) as well as other mechanisms. The enhanced thrombin generation ensures the formation of a tight fibrin structure of the hemostatic plug, as well as full activation of TAFI and FXIII necessary for maintaining hemostasis (6).
Dose Adjustment The substitution therapy with FVIII in hemophilia A and FIX in hemophilia B is monitored by following the plasma concentrations of FVIII or FIX and adjusted
www.annualreviews.org • TF-FVII Pathway and Therapeutic Opportunities
33
ANRV334-ME59-03
ARI
16 December 2007
14:39
by aiming at levels of >50% for hemostasis. The use of rFVIIa for treatment of bleeding in hemophilia is a new concept—a pharmacological instead of a substitution therapy. By increasing the physiological level of FVIIa, the nonspecific binding of rFVIIa to activated platelets is exploited. However, the exact relationship between the plasma concentration of FVII:C and the thrombin generation at the site of injury is not known. Furthermore, a perfect method for determining this localized effect does not exist. A number of assays for the measurement of thrombin generation have been described, but most of them measure thrombin formation in circulating blood rather than the localized thrombin. The recommended dose (90–120 μg/kg bolus i.v.) was based on test tube assays and dog experiments (16). Following the first observation that rFVIIa normalized the activated partial thromboplastin time in plasma from hemophilia patients with inhibitors if a concentration of 3.8 μg/ml was used, similar doses of human rFVIIa were found to normalize the cuticle bleeding time in dogs with hemophilia A and B (6). Taking into account a recovery (FVII:C at 10 min after injection) of 40%–50% (17; see also 14), this would approximately correspond to a concentration of 40 nM of rFVIIa in plasma. The concentration of rFVIIa required to start thrombin generation on preactivated platelets in the cellbased in vitro hemostasis model was 50 nM (6). Despite these results, the doses initially used in hemophilia patients were lower. Clearance rate, recovery at 10 min after injection, and the capacity to generate thrombin on the platelet surface vary widely among individuals (14), so the optimal dose might show great variation in a wider population. The clearance rate in children below 15 years of age may be as much as three times the normal rate for adults, which suggests that they may require higher doses of rFVIIa in order to ensure formation of the firm, tight initial hemostatic plug that is necessary for maintaining hemostasis (14). Recently, a dose of 270 μg/kg was approved in Europe on the basis of a study comparing
Annu. Rev. Med. 2008.59:29-41. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
FVII:C: FVII concentration in plasma
34
Hedner
·
Ezban
90 μg/kg three times per bleed with one single bolus of 270 μg/kg (11).
Effect of rFVIIa as Prophylaxis Several patients with severe hemophilia complicated by inhibitors against FVIII or FIX have been successfully treated with repeated daily doses of rFVIIa (18). These patients had all developed “target joints,” i.e., joints in which frequent bleeds had resulted in chronic swelling, inflammatory synovitis, and a tendency toward further bleeding. Bleedings in such a joint require a stable hemostatic plug for full hemostasis. Results in these patients supported the idea that rFVIIa could be used for prevention of chronic hemophilic arthropathy in hemophilia patients with inhibitors. In a recently published randomized prospective clinical trial (18a), rFVIIa was administered once daily in doses of 90 μg/kg or 270 μg/kg for three months. With oncedaily dosing of rFVIIa, the number of bleeds decreased, not only during the three-month treatment period but also during the observation period that followed (three months of no regular treatment). This outcome may mark another step toward the goal of making the treatment of hemophilia patients with inhibitors similar to that of noninhibitor patients. The decrease in bleeding during the treatment period was probably due to prevention of the repeated bleedings in target joints, resulting in amelioration of the inflammatory synovitis. However, it is not clear how this effect was achieved by once-daily administration of an agent with a plasma T/2 of 2–3 h. Another question related to this short halflife is why rFVIIa prophylaxis reduces the number of hemorrhagic events in the posttreatment period. Although this phenomenon may be due simply to a decrease in the inflammatory response, evidence related to the extravascular distribution of FVIIa suggests that extravascular coagulation may also play an important role in the prolonged reduction of bleeding episodes in hemophilia patients with
Annu. Rev. Med. 2008.59:29-41. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-03
ARI
16 December 2007
14:39
inhibitors treated repeatedly on a long-term basis with rFVIIa. Already in 1974 it was shown that fibrinopeptides are continuously cleaved from fibrinogen at low levels in normal individuals (3). Furthermore, activation peptides from FIX, FX, and prothrombin have been identified in the blood of normal individuals. There is also abundant evidence for the presence of many coagulation proteins in the extravascular space (18). Functional FVIIaTF complexes were also demonstrated in an umbilical vein model system (18) as well as around dermal vessels in mice (5). A hypothesis to account for a prophylactic effect of rFVIIa would be that some of the injected rFVIIa reaches the extravascular space and increases the local concentration in this compartment, which may then facilitate the formation of rFVIIa-TF complexes. In vitro studies have shown that FVIIa-TF complexes form on cell surfaces and that the bound FVIIa is internalized and partially degraded in the cell. However, some of it will reappear on the cell surface and bind to TF recruited from the Golgi to the cell surface. The amount of FVIIa internalized is directly proportional to the amount of FVIIa bound to cell surface TF, and the process may continue for a long time if there is plenty of FVIIa present in the extravascular compartment (18). Assuming that a similar process occurs in vivo, continuous formation of rFVIIa-TF complexes on extravascular cell surfaces may facilitate thrombin generation on platelets that plug the leak in small blood vessels. Another possibility is that rFVIIa administered in pharmacological doses may bind to some other protein or compound on the vessel walls and serve as a reservoir for complex formation at any exposure of TF, thereby facilitating the formation of a hemostatic plug by increasing thrombin generation on activated platelets.
Clinical Experience with rFVIIa Other Than in Hemophilia Patients The ability of rFVIIa to enhance thrombin generation on the surface of activated platelets
makes it a potential hemostatic agent in any situation that requires the formation of a tight hemostatic plug. In the cell-based model, rFVIIa was shown to cause a dose-dependent shortening of the lag phase of platelet activation in the presence of platelet counts down to at least 10,000 μl−1 . Also a tighter fibrin structure was observed in the presence of rFVIIa and low platelet counts. Furthermore, the addition of rFVIIa to whole blood made thrombocytopenic (<6000 μl−1 ) in a flow-chamber model increased the fibrin deposition. If the events observed in vitro also occur in vivo, these may contribute to the hemostatic effect of rFVIIa in many other conditions associated with uncontrolled hemorrhage (6). Anecdotal reports of a hemostatic effect in thrombocytopenic patients have been published, and following extensive reports on successful use of rFVIIa in patients with thrombasthenia, the use of rFVIIa (EU) in patients with Glanzmann’s thrombasthenia has been approved by the European Medicines Agency (EMEA). The dosage recommended is similar to the hemophilia dosage, 70–120 μg/kg every other hour in serious bleeding and surgery. The enhancement of thrombin generation on platelet surfaces by rFVIIa leads to a further activation of platelets (increased exposure of phospholipids) at the site of injury. It also increases platelet adhesion, suggested to involve an enhanced platelet-platelet interaction initiated by thrombin binding to GPIb as well as other mechanisms. Also, platelets from patients with Glanzmann’s thrombasthenia, deficient of GPIIb/IIIa, aggregated in the presence of rFVIIa under flow conditions using a collagen-coated surface; such aggregation may contribute to the effect of rFVIIa in Glanzmann’s thrombasthenia. A normalization of the fibrin structure following the addition of rFVIIa was also observed in plasma from a patient with Glanzmann’s thrombasthenia (6). Thrombin generation may be impaired in patients subjected to multiple transfusions, including plasma substitutes and other types of fluid that are used in patients sustaining
www.annualreviews.org • TF-FVII Pathway and Therapeutic Opportunities
35
ANRV334-ME59-03
ARI
16 December 2007
F1+2: prothrombin fragments split off during activation of prothrombin to thrombin
Annu. Rev. Med. 2008.59:29-41. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
D-dimer: fragments split off fibrin during proteolysis
14:39
major trauma, or extensive surgery with vast tissue and cell damage. In these patients a combination of dilution coagulopathy and local release of proteolytic enzymes that degrade coagulation proteins occurs. Owing to the dilution coagulopathy, loose, porous fibrin deposits may form, which will be easy targets for extensive degradation by released enzymes. The result is profuse, diffuse bleeding from surfaces of damaged tissue, a process that may be mainly localized without signs of generally increased fibrinolytic activity in the circulation. Successful use of rFVIIa in severely traumatized patients has been reported. rFVIIa has also been found effective in patients with uncontrollable hemorrhage unresponsive to conventional therapy (6, 14). Anecdotal reports of successful use of rFVIIa in patients with increased risk of bleeding due to treatment with anticoagulants have been published (19–22). Successful use of rFVIIa has also been reported in patients who did not have a preformed coagulation disorder but were subjected to a procedure expected to release an abundance of fibrinolytic enzymes (6). The rFVIIa may have helped to generate extra thrombin, resulting in the formation of tight fibrin plugs resistant to the fulminant fibrinolysis occurring locally. A single dose of rFVIIa was also reported to limit the growth of an intracerebral hematoma in patients with intracerebral hemorrhage. In this situation, the formation of a stable fibrin plug resistant to the fibrinolytic activity surrounding the primary hematoma may contribute to the effect.
Safety Injection of rFVIIa in normal individuals increased plasma concentrations of F1+2 and D-dimer, but these did not exceed the normal range. No side effects have been observed in healthy volunteers, and the incidence of thrombotic events has been extremely low. A recent article reported thrombotic events in 1.5% of 11,000 patients who had received rFVIIa. Almost all of these occurred 36
Hedner
·
Ezban
in nonhemophilia patients with an underlying condition predisposing them to thrombosis. Furthermore, not all thromboses could be attributed to rFVIIa, and all-cause mortality was 0.3%. The localized effect of rFVIIa through the binding to TF-expressing cells and activated platelets most probably makes the drug safe (11). No indication of the formation of antibodies against rFVIIa was seen in patients with hemophilia or in nonhemophilia patients treated with rFVIIa. However, FVII-deficient patients are at risk for development of antibodies against FVII (23).
Modified rFVIIa The hemostatic effect of pharmacological doses of rFVIIa seems to be mediated by enhancement of thrombin generation on thrombin-activated platelets independent of TF. Several rFVIIa variants have been prepared in the effort to optimize this reaction by mimicking the allosteric effect of TF on FVIIa activity and stabilization. The approach of “rational mutagenesis” was used to construct variants of FVIIa with increased intrinsic activity (24). Several variants of rFVIIa with different levels of increased thrombin generation on preactivated platelets (TF-independent activity) were constructed. The most dramatic effect on the activity of FVIIa was obtained by substituting the residues occupying positions 158, 296 and 298 in thrombin/FIXa for those of FVIIa. The catalytic effect of FVIIaDVQ(V158D/E296V/M298Q) on FX activation was enhanced about 40-fold, and the amidolytic activity was increased about eightfold (24). By combining these mutations (DVQ) with others, a further increased rate of FX activation catalyzed up to 100-fold more than wild-type FVIIa (approximately one third of wild-type FVIIa-TF). These superactive mutants activate FX independently of TF at a greater rate than either free or bound wildtype FVIIa (24, 25). Subsequent work has shown that the explanation for this might be a facilitated insertion of the N-terminus tail
Annu. Rev. Med. 2008.59:29-41. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-03
ARI
16 December 2007
14:39
of the protease domain into the FVII activation pocket and the formation of a stabilizing salt bridge (26) that is crucial for activity. The rFVIIa analogue with mutations DVQ (NN1731) has been further characterized in the cell-based reconstituted model system of coagulation (27). In this model, it was found that although rFVIIa and NN1731 resulted in similar rates of FX activation on TFbearing cells, NN1731 showed significantly greater activity on the platelet surface. However, NN1731 did not directly activate the platelets, whereas the increased generation of FXa, which caused an increase in thrombin generation (four- to tenfold higher than rFVIIa), resulted in a higher rate of platelet activation, shorter time to clot formation, and greater clot stability. Under conditions of hemophilia, NN1731 shortened the time to onset of clot formation even more than rFVIIa, and both NN1731 and rFVIIa increased the rate of clot formation. NN1731 may therefore induce more rapid clot formation than rFVIIa. As the generation of FXa is similar to that of rFVIIa on TF-bearing cells, the increase in thrombin generation rate by NN1731 is likely to depend on increased FX activation on the surface of activated platelets. Furthermore, a clot lysis assay (11) demonstrated that rFVIIa has not only a procoagulant effect but also an antifibrinolytic effect in plasma from hemophilia patients, which is at least partly due to enhanced TAFI activation. In these assays, the FVIIa analogues also had an enhanced effect. Overall, the data so far indicate that the modified rFVIIa, NN1731, employs a similar, albeit amplified, mechanism to promote clot formation and clot stabilization as rFVIIa. Because both procoagulant and antifibrinolytic potentials are significantly enhanced compared with rFVIIa, NN1731 may provide more prompt cessation of bleeding episodes and may reduce the risk of rebleeding. The FVIIa analogues, such as NN1731, show an increased rate of inhibition by AT (24). More extensive studies of the inhibition showed that free NN1731 was more readily
inhibited by TFPI and AT-heparin than was rFVIIa in the absence of TF. As for inhibition, no difference between rFVIIa and NN1731 was found in the presence of TF. AT inhibition of both rFVIIa and NN1731 is dependent on the presence of heparin, which probably means glucoseaminoglycans in vivo. Furthermore, only trace amounts of FXa were generated on the surface of unperturbed endothelium by rFVIIa, whereas significantly higher amounts of FXa were generated by NN1731. The reaction was not TF-dependent and was inhibited by Annexin 5, indicating that anionic phospholipids were involved. Although higher amounts of activated FXa were generated by NN1731, no difference was observed between rFVIIa and NN1731 in thrombin generation on unperturbed endothelial cells in the presence of plasma. These results indicate that native endothelium does not support thrombin generation actively and that, although NN1731 may generate FXa on native endothelium, this does not enhance thrombin generation (28). Some of the modified rFVIIa molecules have been shown to reduce tail bleeding time and blood loss in a mouse hemophilia model (29).
NN1731: mutated FVIIa (V158D/E296V/ M298Q8)
INHIBITION OF FVII-TF-DEPENDENT HEMOSTASIS As knowledge of the TF-FVII-dependent pathway increased, the importance of regulating the initiation phase of coagulation in hemophilia was recognized (3). Inhibiting TFPI by adding a TFPI antibody was found to normalize the prolonged clotting time in plasma from hemophilia A and B patients, using a dilute prothrombin time assay (30). When TFPI is prevented from inhibiting the TF-FVIIa-FXa complex, thrombin generation in the absence of the prothrombinase complex is facilitated. This was further verified in an in vivo model (31) in which the cuticle bleeding time of rabbits made hemophilic was significantly reduced after
www.annualreviews.org • TF-FVII Pathway and Therapeutic Opportunities
37
ANRV334-ME59-03
Table 1
ARI
16 December 2007
14:39
Summary of studies using FVIIai (32)
Model system
Results
Annu. Rev. Med. 2008.59:29-41. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Immediate antithrombotic effect of rFVIIai Surgical carotid endarterectomy or femoral angioplasty in a baboon. Dosage: 1 mg/kg i.v. bolus
Decreased platelet and fibrin deposition. Decrease in intimal thickening 30 days after surgery. Modest effect on bleeding
Femoral angioplasty in atherosclerotic rabbits. Dosage: 1 mg/kg i.v. bolus+ of 50 μg/kg/h for 3 days
Reduced angiographic restenosis and neointima hyperplasia 21 days after angioplasty
Recurrent arterial thrombosis in rabbits (Folts model). Dosage: i.v. 0.1 mg/kg/min for 10 min
Abolished cyclic flow variations for up to 20 h
An ex vivo flow system using a severely damaged porcine vessel in an extracorporeal shunt. Dosage: i.v. 0.5 mg and 1.0
Decreased platelet and fibrin deposition
Micro-arterial thrombosis induced by deep vessel denudation in rabbits. Dosage: topical 0.5 mg
Increased patency rates after 30 min and 120 min
Venous thrombosis model (rabbit) induced by chemical destruction and restricted blood flow. Dosage topical: application on the injured vessel
Increased patency and reduced thrombus weight
Effect of rFVIIai on postischemic reperfusion injury Temporary occlusion of the circumflex coronary artery (rabbit). Dosage: 1 mg/kg prior to reperfusion
Infarct size and no-flow area decreased. Reduction in platelets and fibrinogen
Isogenic rat aorta transplantation model. Dosage: i.v. bolus 1 mg/kg injected at surgery of the transplant
Reduction of chronic vascular changes such as intimal hyperplasia
Antiinflammatory effects of rFVIIai E. coli induced DIC and inflammation (baboon). Dosage: 280 μg/kg at 10 min, + 2, 4, 6, and 8 h after E. coli
Attenuation of inflammatory response, increased survival, and prevention of fibrinogen consumption
ARDS-induced lung injury by E. coli (baboon). Dosage: i.v. bolus 1 mg/kg rFVIIai pulmonary
Reduction of pulmonary fibrin and development of ARDS (38)
Abbreviations: DIC, disseminated intravascular coagulation; ARDS, adult respiratory distress syndrome.
the administration of an anti-TFPI antibody. Thus, enhancing the TF pathway either by adding pharmacological concentrations of rFVIIa or by blocking TFPI seems to induce hemostasis independent of the presence of FVIII or FIX. However, inhibition of TF-FVII-induced hemostasis may have a beneficial effect on pathological situations characterized by fibrin deposition in various organs. Recombinant TFPI (rTFPI) was produced in order to test this hypothesis. In several models, rTFPI was shown to inhibit or mitigate the development of disseminated intravascular coagulation. It reduced mortality in a baboon model of E. coli sepsis, prevented thrombosis in vascular trauma, and prevented arterial reocclusion after thrombolysis (32). However, a randomized controlled study including 1754 patients 38
Hedner
·
Ezban
with severe sepsis and high international normal ratio (INR) found no effect on all-cause mortality (33).
TF Inhibition Apart from its role in the initiation of coagulation, TF-FVIIa also induces cell signaling that plays a role in several other biological processes, such as the inflammatory response and the pathophysiology of septicemia and cancer (34). Antibodies against TF were found to attenuate the coagulopathy induced by E. coli sepsis in baboons when given as a pretreatment (35; see also 36). A chimeric monoclonal antibody to TF blocking the binding of FX to the TF-FVIIa complex was tested in an open-label dose-escalation study including 26 patients with stable coronary
Annu. Rev. Med. 2008.59:29-41. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-03
ARI
16 December 2007
14:39
artery disease who were taking aspirin. Spontaneous dose-dependent minor bleeding occurred in 14 patients, but no serious adverse events were seen (37). Despite dedicated work, no small-molecule inhibitors of TF are currently known. Such a discovery seems, in fact, unlikely given the high-energy contacts between TF and FVIIa. Active-site-inhibited rFVIIa (rFVIIai) would be a third possibility to achieve inhibition of the TF-FVII-dependent pathway. rFVIIai is prepared from rFVIIa by reaction with FFR (D-Phe-L-Phe-L-Argchloromethylketone). The tripeptide is covalently incorporated into the active site of rFVIIa, thereby blocking the reactive center. rFVIIai competes efficiently with endogenous FVIIa for binding to TF and thereby limits the formation of functional TF-FVIIa complexes (38).
The effects of rFVIIai have been studied in animal models of thrombus formation induced by mechanical injury, induced ischemia, and endotoxin infection. These studies are summarized in Table 1 (32). Recombinant nematode anticoagulant protein c2 (rNAPc2) is an 85-amino-acid serine protease inhibitor that directly inhibits the catalytic complex of TF-FVIIa. A potential anticoagulant effect was investigated in an open-label sequential dose-ranging study that included 293 patients undergoing total knee replacement. This study reported an overall rate of deep vein thrombosis of 12.2% and a proximal deep vein thrombosis rate of 1%–3%. Major bleedings occurred in 2%– 3% of patients. The efficacy and safety profile demonstrated for rNAPc2 was comparable to results reported with low-molecular-weight heparin prophylaxis (39).
DISCLOSURE STATEMENT Both authors are employees of Novo Nordisk A/S, the manufacturer of rFVIIa (NovoSeven).
LITERATURE CITED 1. Monroe DM, Hoffman M, Roberts HR. 2002. Platelets and thrombin generation. Art. Thromb. Vasc. Biol. 22:1381–89 2. Østerud B, Rapaport SI. 1977. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc. Natl. Acad. Sci. USA 74:5260–64 3. Roberts HR, Monroe DM, Hoffman M. 2001. Molecular biology and biochemistry of the coagulation factors and pathways of hemostasis. In Williams Hematology, ed. E Beutler, MA Lichtman, BS Coller, TJ Kipps, U Seligsohn, pp. 1409–34. McGraw-Hill. 6th ed. 4. Rapaport SI, Rao LVM. 1995. The tissue factor pathway: how it has become a “prima ballerina.” Thromb. Haemost. 74:7–17 5. Hoffman M, Colina CM, McDonald AG, et al. 2007. Tissue factor around dermal vessels has bound factor VII in the absence of injury. J. Thromb. Haemost. 5:1403–8 6. Hedner U. 2006. Mechanism of action, development and clinical experience of recombinant FVIIa. J. Biotechnol. 124:747–57 7. Lopez-Vilchez I, Escolar G, Diaz-Ricart M, et al. 2007. Tissue factor enriched vesicles are taken up by platelets and induce platelet aggregation in the presence of factor VII. Thromb. Haemost. 97:202–11 8. Shaw AW, Pureza VS, Sligar SG, et al. 2007. The local phospholipid environment modulates the activation of blood clotting. J. Biol. Chem. 282:6556–63 9. Zhang J, Piro O, Lu L, Broze GJ Jr. 2003. Glycosyl phosphatidylinositol anchorage of tissue factor pathway inhibitor. Circulation 108:623–627 www.annualreviews.org • TF-FVII Pathway and Therapeutic Opportunities
1. Contains many references.
6. One of the most recent extensive reviews; includes many references.
39
Annu. Rev. Med. 2008.59:29-41. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-03
ARI
16 December 2007
15. First demonstration of a hemostatic effect of pharmacological doses of FVIIa.
24. Describes the basis for modified FVII molecules.
40
14:39
10. Ghosh S, Pendurthi UR, Steinoe A, et al. 2007. Endothelial cell protein C receptor acts as a cellular receptor for factor VII on endothelium. J. Biol. Chem. 282:11849–57 11. Hedner U. 2007. Recombinant factor VIIa: its background, development and clinical use. Curr. Opin. Hemat. 14:225–29 12. Kjalke M, Kjellev S, Røjkjær R. 2007. Preferential localization of recombinant factor VIIa to platelets activated with a combination of thrombin and a glycoprotein VI receptor agonist. J. Thromb. Haemost. 5:774–80 13. Melton LG, Li T, Stafford DW, et al. 2001. Location of the platelet binding site in zymogen coagulation factor IX. Blood Coag. Fibrinolysis 12:237–43 14. Hedner U, Erhardtsen E. 2003. Potential role of recombinant factor VIIa as a hemostatic agent. Clin. Adv. Hematol. Oncol. 1:112–19 15. Hedner U, Kisiel W. 2003. The use of human factor VIIa in the treatment of two hemophilia patients with high-titer inhibitors. J. Clin. Invest. 71:1836–41 16. Hedner U. 2004. Dosing with recombinant factor VIIa based on current evidence. Semin. Hemat. 41(Suppl. 1):35–39 17. Fridberg MJ, Hedner U, Roberts HR, et al. 2005. A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese. Blood Coag. Fibrinolysis 16:259–66 18. Hedner U. 2006. Potential role of recombinant factor FVIIa in prophylaxis in severe hemophilia patients with inhibitors. J. Thromb. Haemost. 4:2498–500 18a. Konkle BA, Ebbesen LS, Erhardtsen E, et al. 2007. Randomized prospective clinical trial of rFVIIa for secondary prophylaxis in hemophilia patients with inhibitors. J. Thromb. Haemost. In press. doi: 12.1111/j.1538-7836.2007.02663.x 19. Bijsterveld NR, Moons AH, Boekholdt SM, et al. 2002. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 106:2550–54 20. Deveras RAE, Kessler CM. 2002. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann. Int. Med. 137:884–88 21. Firozvi K, Acs P, Baidas S, et al. 2004. Efficacious and safe use of recombinant activated factor VII (rFVIIa) in patients with enoxaparin (ENOX)-induced bleeding in patients with pre-existing hypercoagulable states. Blood 104(11, Pt 1):300A 22. Carnazzo SA, Saitta R, Laurentini GM, et al. 2005. Use of recombinant activated factor VII in an elderly female undergoing acenocoumarol thromboprophylaxis requiring an emergency laparotomy. J. Thromb. Thrombolysis 19:213–14 23. Nicolaisen EM. 1998. Antigenicity of activated recombinant factor VII followed through nine years of clinical experience. Blood Coag. Fibrinolysis 9(Suppl. 1):S119–23 24. Persson E, Kjalke M, Olsen OH. 2001. Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity. Proc. Natl. Acad. Sci. USA 98:13583–88 25. Persson E, Bak H, Ostergaard A, et al. 2004. Augmented intrinsic activity of factor VIIa by replacement of residues 305, 314, 337 and 374; evidence of two unique mutational mechanisms of activity enhancement. Biochem. J. 379:497–503 26. Rand KD, Jorgensen TJ, Olsen OH, et al. 2006. The allosteric activation of coagulation factor VIIa visualized by hydrogen exchange. J. Biol. Chem. 281:23018–24 27. Allen AG, Persson E, Campbell RA, et al. 2007. A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia. Arterioscler. Thromb. Vasc. Biol. 27:683–89 28. Ghosh S, Ezban M, Persson E, et al. 2007. Activity and regulation of factor VIIa analogs with increased potency at the endothelial cell surface. J. Thromb. Haemost. 5:336–46 Hedner
·
Ezban
Annu. Rev. Med. 2008.59:29-41. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-03
ARI
16 December 2007
14:39
29. Tranholm M, Kristensen K, Kristensen AT, et al. 2003. Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A. Blood 102:3615–20 30. Nordfang O, Valentin S, Beck T, et al. 1991. Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and of hemophilia plasma. Thromb. Hemost. 66:464–67 31. Erhardtsen E, Ezban M, Madsen MT, et al. 1995. Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A. Blood Coag. Fibrinol. 6:388–94 32. Hedner U, Erhardtsen E. 2000. Future possibilities in the regulation of the extrinsic pathway: rFVIIa and TFPI. Ann. Med. 32(Suppl. 1):68–72 33. Abraham E, Reinhart K, Opal S, et al. 2003. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis. JAMA 290:238–47 34. Rao LVM, Pendurthi UR. 2005. Tissue factor–factor VIIa signaling. Arterioscler. Thromb. Vasc. Biol. 25(1):47–56 35. Huang H, Norledge BV, Liu C, et al. 2003. Selective attenuation of the extrinsic limb of the tissue factor-driven coagulation protease cascade by occupancy of a novel peptidyl docking site on tissue factor. Biochemistry 42:10619–26 36. Taylor FB Jr, Chang ACK, Peer G, et al. 1998. Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD100 Escherichia coli. Blood 91:1609–15 37. Morrow DA, Murphy SA, McCabe CH, et al. 2005. Potent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36): results of the PROXIMATETIMI 27 trial. Eur. Heart J. 26:682–88 38. Rao LVM, Ezban M. 2000. Active site-inactivated factor VIIa as an effective antithrombotic agent: mechanism of action (review). Blood Coag. Fibrinol. 11(Suppl. 1):135–43 ¨ 39. Lee A, Agnelli G, Buller H, et al. 2001. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation 104:74–78
www.annualreviews.org • TF-FVII Pathway and Therapeutic Opportunities
30. First experiments suggesting a hemostatic effect of decreased or absent TFPI.
41
AR334-FM
ARI
18 December 2007
17:20
Annual Review of Medicine
Annu. Rev. Med. 2008.59:29-41. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Contents
Volume 59, 2008
The FDA Critical Path Initiative and Its Influence on New Drug Development Janet Woodcock and Raymond Woosley p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p1 Reversing Advanced Heart Failure by Targeting Ca2+ Cycling David M. Kaye, Masahiko Hoshijima, and Kenneth R. Chien p p p p p p p p p p p p p p p p p p p p p p p p 13 Tissue Factor and Factor VIIa as Therapeutic Targets in Disorders of Hemostasis Ulla Hedner and Mirella Ezban p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 29 Therapy of Marfan Syndrome Daniel P. Judge and Harry C. Dietz p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 43 Preeclampsia and Angiogenic Imbalance Sharon Maynard, Franklin H. Epstein, and S. Ananth Karumanchi p p p p p p p p p p p p p p p p p 61 Management of Lipids in the Prevention of Cardiovascular Events Helene Glassberg and Daniel J. Rader p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 79 Genetic Susceptibility to Type 2 Diabetes and Implications for Antidiabetic Therapy Allan F. Moore and Jose C. Florez p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 95 Array-Based DNA Diagnostics: Let the Revolution Begin Arthur L. Beaudet and John W. Belmont p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p113 Inherited Mitochondrial Diseases of DNA Replication William C. Copeland p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p131 Childhood Obesity: Adrift in the “Limbic Triangle” Michele L. Mietus-Snyder and Robert H. Lustig p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p147 Expanded Newborn Screening: Implications for Genomic Medicine Linda L. McCabe and Edward R.B. McCabe p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p163 Is Human Hibernation Possible? Cheng Chi Lee p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p177 Advance Directives Linda L. Emanuel p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p187 v
AR334-FM
ARI
18 December 2007
17:20
Genetic Determinants of Aggressive Breast Cancer Alejandra C. Ventura and Sofia D. Merajver p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p199 A Role for JAK2 Mutations in Myeloproliferative Diseases Kelly J. Morgan and D. Gary Gilliland p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p213 Appropriate Use of Cervical Cancer Vaccine Gregory D. Zimet, Marcia L. Shew, and Jessica A. Kahn p p p p p p p p p p p p p p p p p p p p p p p p p p p p p223 A Decade of Rituximab: Improving Survival Outcomes in Non-Hodgkin’s Lymphoma Arturo Molina p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p237
Annu. Rev. Med. 2008.59:29-41. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Nanotechnology and Cancer James R. Heath and Mark E. Davis p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p251 Cancer Epigenetics: Modifications, Screening, and Therapy Einav Nili Gal-Yam, Yoshimasa Saito, Gerda Egger, and Peter A. Jones p p p p p p p p p p p p267 T Cells and NKT Cells in the Pathogenesis of Asthma Everett H. Meyer, Rosemarie H. DeKruyff, and Dale T. Umetsu p p p p p p p p p p p p p p p p p p p p281 Complement Regulatory Genes and Hemolytic Uremic Syndromes David Kavanagh, Anna Richards, and John Atkinson p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p293 Mesenchymal Stem Cells in Acute Kidney Injury Benjamin D. Humphreys and Joseph V. Bonventre p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p311 Asthma Genetics: From Linear to Multifactorial Approaches Stefano Guerra and Fernando D. Martinez p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p327 The Effect of Toll-Like Receptors and Toll-Like Receptor Genetics in Human Disease Stavros Garantziotis, John W. Hollingsworth, Aimee K. Zaas, and David A. Schwartz p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p343 Advances in Antifungal Therapy Carole A. Sable, Kim M. Strohmaier, and Jeffrey A. Chodakewitz p p p p p p p p p p p p p p p p p p361 Herpes Simplex: Insights on Pathogenesis and Possible Vaccines David M. Koelle and Lawrence Corey p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p381 Medical Management of Influenza Infection Anne Moscona p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p397 Bacterial and Fungal Biofilm Infections A. Simon Lynch and Gregory T. Robertson p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p415 EGFR Tyrosine Kinase Inhibitors in Lung Cancer: An Evolving Story Lecia V. Sequist and Thomas J. Lynch p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p429 Adaptive Treatment Strategies in Chronic Disease Philip W. Lavori and Ree Dawson p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p443 vi
Contents
AR334-FM
ARI
18 December 2007
17:20
Antiretroviral Drug–Based Microbicides to Prevent HIV-1 Sexual Transmission Per Johan Klasse, Robin Shattock, and John P. Moore p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p455 The Challenge of Hepatitis C in the HIV-Infected Person David L. Thomas p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p473 Hide-and-Seek: The Challenge of Viral Persistence in HIV-1 Infection Luc Geeraert, Günter Kraus, and Roger J. Pomerantz p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p487
Annu. Rev. Med. 2008.59:29-41. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Advancements in the Treatment of Epilepsy B.A. Leeman and A.J. Cole p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p503 Indexes Cumulative Index of Contributing Authors, Volumes 55–59 p p p p p p p p p p p p p p p p p p p p p p p p525 Cumulative Index of Chapter Titles, Volumes 55–59 p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p529 Errata An online log of corrections to Annual Review of Medicine articles may be found at http://med.annualreviews.org/errata.shtml
Contents
vii
ANRV334-ME59-04
ARI
16 December 2007
14:42
Therapy of Marfan Syndrome Annu. Rev. Med. 2008.59:43-59. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Daniel P. Judge1 and Harry C. Dietz2 1
Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine; 2 McKusick-Nathans Institute of Genetic Medicine and Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205; email:
[email protected]
Annu. Rev. Med. 2008. 59:43–59
Key Words
First published online as a Review in Advance on September 10, 2007
aortic aneurysm, fibrillin-1, Loeys-Dietz syndrome, transforming growth factor beta
The Annual Review of Medicine is online at http://med.annualreviews.org This article’s doi: 10.1146/annurev.med.59.103106.103801 c 2008 by Annual Reviews. Copyright All rights reserved 0066-4219/08/0218-0043$20.00
Abstract Marfan syndrome is a common inherited disorder of connective tissue caused by deficiency of the matrix protein fibrillin-1. Effective surgical therapy for the most life-threatening manifestation, aortic root aneurysm, has led to a nearly normal lifespan for affected individuals who are appropriately recognized and treated. Traditional medical therapies, such as beta-adrenergic receptor blockade, are used to slow pathologic aortic growth and decrease the risk of aortic dissection by decreasing hemodynamic stress. New insights regarding the pathogenesis of Marfan syndrome have developed from investigation of murine models of this disorder. Fibrillin-1 deficiency is associated with excess signaling by transforming growth factor beta (TGFβ). TGFβ antagonists have shown great success in improving or preventing several manifestations of Marfan syndrome in these mice, including aortic aneurysm. These results highlight the potential for development of targeted therapies based on discovery of disease genes and interrogation of pathogenesis in murine models.
43
ANRV334-ME59-04
ARI
16 December 2007
14:42
INTRODUCTION Dolichocephaly: disproportionately long, narrow head Dolichostenomelia: long bone overgrowth
Annu. Rev. Med. 2008.59:43-59. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Ectopia lentis: ocular lens dislocation MASS phenotype: mitral valve prolapse, myopia, borderline and nonprogressive aortic root enlargement, nonspecific skin and skeletal findings LDS: Loeys-Dietz syndrome TGFβ: transforming growth factor beta
44
Marfan syndrome (MFS) is a systemic disorder of connective tissue with cardinal manifestations involving the ocular, skeletal, and cardiovascular systems. Conventional therapies have relied largely on hypothetical approaches to prevent life-threatening features such as aortic aneurysm and dissection. As our knowledge of the pathophysiology grows, emerging therapeutic strategies are predicted to surpass the traditional treatments for this condition. Before describing both traditional and emerging therapies, this review outlines the clinical features of MFS, as well as our current knowledge of the mechanisms of pathogenesis.
CLINICAL DIAGNOSIS In 1896, French pediatrician AntoineBernard Marfan first described the skeletal features of Gabrielle P., a five-year-old girl with slender digits, dolichocephaly, and tall stature (1). Over the subsequent four decades, he compiled reports on >150 similar cases, recognizing Mendelian inheritance with cosegregation of dolichostenomelia, ectopia lentis, and mitral valve disease (2). The cardiac manifestations were described by Victor A. McKusick in 1955, who reported dilatation and dissection of the aorta and aortic valve regurgitation in MFS, which he classified among the heritable disorders of connective tissue (3). Despite these reports, the diagnosis of MFS was somewhat variable until the mid1980s. At the 1986 International Congress of Human Genetics in Berlin, consensus opinions were compiled regarding the clinical diagnosis (4). This conference led to a series of diagnostic criteria that attempted to draw distinctions within a broad spectrum of connective tissue disorders that showed overlap with the phenotypes seen in MFS. Accurate phenotypic assignment was important in subsequent linkage analyses and the eventual recognition that MFS is caused by mutations Judge
·
Dietz
in FBN1, the gene encoding the extracellular matrix protein fibrillin-1 (5, 6). However, the Berlin Nosology for the diagnosis of MFS was later recognized to be inappropriately inclusive of individuals with mild features within families segregating MFS (7). In 1996, revised diagnostic criteria for MFS were proposed, with continued reliance on a series of major and minor clinical manifestations in different organ systems (8). These criteria were more stringent (Table 1); they required at least four of eight skeletal features for assignment of the skeletal system as a major criterion, potentially included molecular testing, and increased requirements for family members of an unequivocally affected individual. Although it is currently estimated that >90% of people with classic MFS will have a definable FBN1 mutation, the large size of this gene and the extreme allelic heterogeneity characteristic of MFS have frustrated efficient molecular diagnosis for this disorder (9). More importantly, many other conditions, such as mitral valve prolapse syndrome, MASS phenotype, familial ectopia lentis, Weill-Marchesani syndrome, and Shprintzen-Goldberg syndrome, have also been associated with mutations in FBN1 (10–14). It is often difficult or impossible to predict the phenotype from the character or location of a mutation. Mutation analysis is best used to determine if a presymptomatic individual has inherited the predisposition for a defined phenotype seen in the extended family. Although mutation testing can serve as an adjunct, diagnosis of MFS in a proband is currently made on clinical grounds. An important consideration in the differential diagnosis of MFS is a recently described condition known as Loeys-Dietz syndrome (LDS) (15). LDS is caused by heterozygous mutations in the genes encoding the transforming growth factor (TGFβ) receptors 1 and 2 (TGFBR1 or TGFBR2) (15). These mutations result in increased TGFβ signaling in both cells and involved tissues from affected patients (15). This disorder shares
ANRV334-ME59-04
Table 1
ARI
16 December 2007
14:42
Diagnostic criteria for Marfan syndrome
Index case: • If the family/genetic history is not contributory, major criteria in ≥2 different organ systems and involvement of a third organ system. • If a mutation known to cause Marfan syndrome in others is detected, 1 major criterion in an organ system and involvement of a second organ system. Relative of an index case: • Presence of a major criterion in the family history, 1 major criterion in an organ system, and involvement of a second organ system.
Annu. Rev. Med. 2008.59:43-59. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Organ systems: Skeletal: Major criteria: The presence of at least 4 of the following constitutes a major criterion in the skeletal system. • Pectus carinatum (protrusion of sternum) • Pectus excavatum (depression of sternum) requiring surgery • Reduced upper- to lower-segment ratio or arm span–to–height ratio >1.05 • Wrist and thumb signs • Scoliosis of >20◦ or spondylolisthesis (displacement of vertebra, usually in lumbar spine) • Reduced extension at the elbows (<170◦ ) • Medial displacement of the medial malleolus causing pes planus (flat feet) • Protrusio acetabulae (protrusion of the femoral head into the pelvis) of any degree (ascertained on radiographs) Minor criteria: • Pectus excavatum of moderate severity • Joint hypermobility • Highly arched palate with crowding of teeth • Facial appearance [dolichocephaly, malar hypoplasia, enophthalmos (deeply set eyes), retrognathia (receding chin), down-slanting palpebral fissures) For involvement of the skeletal system, at least 2 features contributing to major criteria, or 1 feature from the list contributing to the major criterion and 2 of the minor criteria must be present. Ocular system: Major criterion: • Ectopia lentis Minor criteria: • Abnormally flat cornea • Increased axial length of globe • Hypoplastic iris or hypoplastic ciliary muscle causing decreased miosis For involvement of the ocular system, at least 2 of the minor criteria must be present. Cardiovascular system: Major criteria: • Dilation of the ascending aorta, with or without aortic regurgitation, and involving at least the sinuses of Valsalva • Dissection of the ascending aorta Minor criteria: • Mitral valve prolapse with or without mitral valve regurgitation • Dilatation of the main pulmonary artery, in the absence of valvular or peripheral pulmonic stenosis or any other obvious cause, younger than age 40 • Calcification of the mitral annulus younger than age 40 • Dilatation or dissection of the descending thoracic or abdominal aorta younger than age 50 For involvement of the cardiovascular system, only 1 of the minor criteria must be present. (Continued )
www.annualreviews.org • Therapy of Marfan Syndrome
45
ANRV334-ME59-04
Table 1
ARI
16 December 2007
14:42
(Continued )
Annu. Rev. Med. 2008.59:43-59. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Pulmonary system: Major criteria: none Minor criteria: • Spontaneous pneumothorax • Apical blebs For involvement of the pulmonary system, only 1 of the minor criteria must be present Skin and integument: Major criteria: none Minor criteria: • Striae atrophicae (stretch marks) without marked weight gain, pregnancy, or repetitive stress • Recurrent or incisional herniae For involvement of the skin and integument, only 1 of the minor criteria must be present Dura: Major criterion: • Lumbosacral dural ectasia (widening of the dural sac) Minor criteria: none Family/genetic history: Major criteria: • Having a parent, child, or sibling who meets these diagnostic criteria independently • Presence of a mutation in FBN1 that is known to cause MFS • Presence of a haplotype around FBN1, inherited by descent, known to be associated with unequivocally diagnosed MFS in the family Minor criteria: none
selected features with MFS (pectus deformity, scoliosis, and aortic root aneurysm) but can be distinguished on the basis of characteristic features, including hypertelorism, cleft palate, bifid or broad-based uvula, and the absence of ectopia lentis. Additional features that help to differentiate LDS from MFS are listed in Table 2. The arterial disease in LDS is notable for arterial tortuosity in large and medium-sized vessels (prominently of neck vessels) and the high risk of aneurysms and dissection throughout the arterial tree (16). Furthermore, aortic root aneurysms tend to dissect at younger ages and smaller dimensions than those seen in MFS. One series of 52 families reported an average age at death of 26 years among affected individuals (16). Because of the increased risk of aortic dissection at smaller aortic sizes in LDS, we advise affected adults to undergo prophylactic surgery when the aortic root diameter approaches 4.0 cm. Earlier intervention is con-
Hypertelorism: widely spaced eyes
46
Judge
·
Dietz
sidered depending on family history or an individual’s personal assessment of risk versus benefit. Surgery in severely affected children is considered once the aortic annulus exceeds 1.8 cm, allowing placement of a graft of sufficient size to accommodate growth. This approach differs substantially from our approach to MFS.
PATHOGENESIS MFS was traditionally considered to reflect a simple structural deficiency in connective tissues. Early hypotheses suggested that this condition might be due to a primary problem of the elastic fiber (3). Studies of both skin and aorta from affected individuals have shown decreased elastin with elastic fiber fragmentation (17, 18). Linkage analyses identified an associated locus on chromosome 15, excluding the elastin gene as the site of mutations causing this condition (5, 19). Upon recognition of FBN1 mutations resulting in MFS,
ANRV334-ME59-04
Table 2
ARI
16 December 2007
14:42
Features differentiating Marfan and Loeys-Dietz syndromesa
Annu. Rev. Med. 2008.59:43-59. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Marfan syndrome
Loeys-Dietz syndrome
Gene:
FBN1
TGFBR1 or TGFBR2
Ocular features: ectopia lentis myopia
typical typical
not associated observed
Skeletal features: arachnodactyly cervical spine instability club foot dolichostenomelia joint laxity pectus deformity scoliosis
typical not associated not associated typical typical typical typical
common common common observed (but subtle) typical and severe common common
Cardiovascular features: aortic root aneurysm arterial tortuosity childhood death/dissection congenital heart defectsb other aneurysms
typical not associated exceedingly rare not associated exceedingly rare
typical typical common common common
Craniofacial features: broad-based or bifid uvula cleft palate craniosynostosis hypertelorism
not associated not associated not associated not associated
typical common common typical
Neurodevelopmental features: Chiari I malformation developmental delay
not associated not associated
common observed
Skin/integument features: easy bruising dystrophic scars soft skin texture striae atrophicae (stretch marks) translucent skin
not associated not associated not associated typical not associated
typical common typical typical typical
a This table compares frequencies of clinical manifestations of Marfan syndrome and Loeys-Dietz syndrome, organized by organ systems. “Typical” indicates a majority of affected individuals, “common” indicates 20%–50% of affected individuals, “observed” indicates 1%–20% of affected individuals, and “not associated” indicates that affected individuals have a risk of this manifestation equal to the risk in an unaffected population. “Exceedingly rare” indicates that this feature occurs in <1% of affected individuals, but at a rate higher than in an unaffected population. b Includes patent ductus arteriosus, atrial septal defect, and bicuspid aortic valve.
this structural impairment was attributed to loss of fibrillin-1 in the extracellular matrix. Consequently, in response to stress, such as hemodynamic forces in the proximal aorta, affected organ systems were thought to manifest this structural insufficiency with accelerated degeneration. In this traditional view, the
opportunity for effective treatments for MFS was greatly limited, as the bulk of elastic fiber formation occurs during embryogenesis. A dominant negative effect of mutant fibrillin-1 was inferred from the dominant pattern of inheritance, the requirement for multimerization of fibrillin-1 monomers to www.annualreviews.org • Therapy of Marfan Syndrome
47
ANRV334-ME59-04
ARI
16 December 2007
Annu. Rev. Med. 2008.59:43-59. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
LTBP: latent transforming growth factor beta binding protein
48
14:42
form microfibrils, and the dramatic paucity of fibrillin-1 in immunostained samples derived from affected individuals (20, 21). This deficiency of fibrillin-1 was thought to lead to a primary derangement of elastic fiber deposition, with ultimate failure of the connective tissues inevitable in affected tissues (22). Supporting this hypothesis is the observation that some (though not all) people with a premature termination codon in FBN1 have mild clinical manifestations of MFS (23, 24). This may be attributable to rapid and efficient destruction of these transcripts by the nonsense-mediated mRNA decay pathway, and insufficient mutant protein present to exert a dominant negative effect (25). Accordingly, one putative strategy for MFS therapy was to target the mutant allele with hammerhead ribozyme antisense technology (26). The role of haploinsufficiency in the pathogenesis of MFS was emphasized by investigation of murine models of this disorder (27). If dominant negative interference by the mutant allele is solely responsible for pathogenesis, then overexpression of a mutant FBN1 transgene on a wild-type background should result in similar manifestations. However, several strains of mice with robust expression of a transgene containing a cysteinesubstitution FBN1 mutation known to cause MFS, in addition to the normal two murine Fbn1 alleles, have no discernible aortic disease (27). In contrast, strains of mice with comparable targeted mutations in one endogenous murine Fbn1 allele have classic features of MFS, including progressive aortic root dilatation (27, 28). Finally, characterization of mice harboring both an endogenous Fbn1 mutation and a mutant FBN1 transgene revealed improvement in features of MFS (27). These data suggest that a threshold reduction in fibrillin-1 function is needed for disease expression, that mutant fibrillin-1 retains some of its function, and that dominant negative interference alone is insufficient to trigger the pathogenetic sequence that culminates in MFS. From these experiments, it appears that strategies for therapy that promote producJudge
·
Dietz
tion of fibrillin-1 (mutant and/or wild-type) may mitigate this disorder. These conclusions are strengthened by observations within families segregating hypomorphic FBN1 alleles and MFS. The level of expression of the normal allele in some of these families appears to correlate inversely with the severity of disease (29). Recent research has identified a regulatory role for fibrillin-1 that appears to have important implications for the therapy of MFS. This extracellular matrix protein shares significant homology with the latent transforming growth factor beta binding proteins (LTBPs), and binding studies have demonstrated their interaction (30, 31). TGFβ is secreted from the cell in the context of a large latent complex (LLC) that includes the mature cytokine, a dimer of its processed amino-terminal propetide called latency associated peptide (LAP), and one of three LTBP molecules. The possibility that failed matrix sequestration of the LLC by fibrillin-1 leads to altered TGFβ signaling was first analyzed in mice with reduced expression of fibrillin-1 (32). These mice have defective alveolar septation, which causes enlarged airspaces. Immunostaining with an antibody specific for the free and active form of TGFβ identified increased amounts of this cytokine; reduced staining was seen for LAP suggesting increased activation (rather than production) of TGFβ in the fibrillin-1 deficient state (32). A transgenic strain was developed to produce green fluorescent protein (GFP) in response to TGFβ stimulation. Production of GFP was progressively increased in developing lungs of mice with one or two mutant Fbn1 alleles. Further supporting the hypothesis that fibrillin-1 deficiency leads to localized increase in TGFβ activity, treatment of these mice with a neutralizing antibody to this cytokine led to normalization of alveolar septation (32). Many manifestations of MFS are not logically explained by a structural deficiency resulting from FBN1 mutations. For instance,
Annu. Rev. Med. 2008.59:43-59. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-04
ARI
16 December 2007
14:42
myxomatous atrioventricular valve leaflets are difficult to reconcile with a pathogenetic model that singularly invokes tissue weakness. Mitral valves in mice homozygous for a Fbn1 mutation are longer and thicker than those in heterozygous mice, and both are longer and thicker than those in wild-type mice (33). These findings correlate with increased TGFβ activation and signaling, as well as augmented proliferation of cells within these valves, diminished apoptosis, and increased production of various targets of TGFβ activation (33). Once again, treatment of these mice with a neutralizing antibody to TGFβ improved atrioventricular valve length and thickness. The major life-threatening manifestation of MFS is aortic aneurysm with eventual dissection. Traditionally, aortic aneurysm has been attributed to a putative structural deficiency resulting from fibrillin-1 mutation. Recently, a regulatory role for fibrillin-1 has also been recognized as relevant in the aorta (34). Increased staining for markers of TGFβ signaling is present in heterozygous mutant mice with aortic aneurysm, as well as aortic wall from individuals with MFS (15). Neutralizing antibodies to TGFβ reduce aortic size and improve aortic wall architecture (34). However, therapeutic delivery of TGFβ neutralizing antibody is not currently available for people with MFS. Extensive evidence links angiotensin II signaling to TGFβ activation and signaling. Upon stimulation of the TGFβ receptors, a family of transcription factors called Smads is activated by sequential phosphorylation (35). Direct activation of the Smad pathway by angiotensin II, independent of TGFβ ligands, was reported in vascular smooth muscle cells (36). In addition, reports on therapy with angiotensin-converting enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blockers (ARBs) in renal disorders mediated by excessive TGFβ further support the likelihood that either of these medications would ameliorate other disorders associated with excessive TGFβ (37, 38).
The two distinct receptors for angiotensin II, type 1 (AT1) and type 2 (AT2), appear to have opposing effects. For instance, Daugherty and colleagues reported that infusion of angiotensin II in apoE−/− mice results in abdominal aortic aneurysm (39). Subsequently, they assessed the relative contribution of AT1 and AT2 stimulation with use of selective antagonists (40). Aortic aneurysm was prevented in these mice with simultaneous infusion of angiotensin II and losartan, an AT1 antagonist, but worsened in both frequency and severity in mice that received angiotensin II and PD123319, a selective AT2 antagonist (40). Because losartan is specific for blocking the AT1 receptor, its use would not prevent stimulation of the AT2 receptor by angiotensin II, which appears to be beneficial in aortic aneurysms. On the other hand, treatment with an ACE inhibitor should decrease angiotensin II stimulation of both the culprit AT1 and the potentially protective AT2 receptors. We tested the ability of losartan to delay or prevent ascending aortic aneurysm in a murine model of MFS (34). Treatment was initiated after moderate proximal aortic enlargement and compared with propranolol, a beta-adrenergic receptor antagonist (beta blocker), in doses that had similar hemodynamic effects. Mice treated with propranolol showed a relative reduction in aortic root growth rate compared to those receiving no treatment, but pathologic aortic root growth was completely prevented in these mice by treatment with losartan (34). Furthermore, losartan normalized aortic wall thickness and architecture, findings not observed in the propranolol-treated group. At the end of six months of treatment, the aortic wall of losartan-treated fibrillin-1-deficient mice could not be distinguished from that of wildtype mice, even though the mice already had established aortic enlargement when therapy was initiated (34) (Figure 1). These data suggest the potential for productive aortic wall remodeling after TGFβ inhibition. Remarkably, improvements in pulmonary and www.annualreviews.org • Therapy of Marfan Syndrome
ACE: angiotensinconverting enzyme ARB: angiotensin II receptor blocker AT1: angiotensin II, type 1 receptor AT2: angiotensin II, type 2 receptor
49
ARI
16 December 2007
Annu. Rev. Med. 2008.59:43-59. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-04
14:42
Figure 1 Losartan prevents aortic aneurysm in mice. Representative mouse ascending aortas (arrowheads) are shown after latex injection. (A) Wild-type mouse. (B–F ) Mice heterozygous for Fbn1 mutation (C1039G), treated with placebo (B ), propranolol (C ), or losartan (D–F ). Scale bars: 4 mm. From Science (34), with permission.
skeletal muscle pathology also occurred with losartan treatment, further supporting the conclusion that this treatment works by decreasing TGFβ signaling rather than by reducing hemodynamic stress on structurally predisposed tissues (34, 41).
tions, (b) current pharmacologic approaches, (c) surgeries, (d ) endocarditis prophylaxis, and (e) emerging or experimental strategies. Most therapies that are currently available or under investigation seek to diminish aortic complications, such as aneurysm and dissection.
CURRENT AND FUTURE THERAPIES
Activity Restrictions
For the purpose of this review, therapies are categorized as follows: (a) activity restric50
Judge
·
Dietz
Because of the tall stature associated with dolichostenomelia (long bone overgrowth) in MFS, many affected individuals are drawn to
ANRV334-ME59-04
ARI
16 December 2007
14:42
Annu. Rev. Med. 2008.59:43-59. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
athletic activities such as volleyball and basketball. However, strenuous physical exertion, competitive athletics, and particularly isometric activities are associated with increased risk of aortic dissection, ocular problems, and skeletal complications for those with MFS. Consensus guidelines have been developed for activity limitations (42). It is our practice to advise against isometric exercise such as weight lifting, and to recommend moderation in aerobic exertion. A more detailed review on exercise and MFS is available (43).
Current Pharmacologic Approaches Despite the limitations of the data supporting their use, beta blockers are widely considered the standard of care to slow the rate of enlargement of aortic aneurysm in people with MFS. This treatment was first proposed in 1971 (44). Its rationale relies on the putative role of hemodynamic stress in the progressive enlargement of the proximal aorta. Beta blockers are probably beneficial through both negative inotropic and chronotropic effects. Several small or retrospective studies have demonstrated the benefit of beta blockers in slowing aortic root growth in MFS (45–48). Only one prospectively randomized trial has been reported to date assessing the efficacy of beta blockers in MFS (47). Subjects included 70 individuals with a clinical diagnosis of MFS based on the Berlin criteria, which was the standard in 1994 when the study was published (4). In an open-label fashion, enrolled individuals were prospectively randomized to receive either no pharmacologic treatment (control) or propranolol (47). Importantly, the dose of propranolol was individualized for each treated case by targeting for a heart rate below 100 beats per minute during exercise or resulting in a 30% increase in the systolic time interval (corrected for the heart rate). This led to an average propranolol dose of 212 ± 68 mg per day. Fewer people who were treated with propranolol reached the primary clinical endpoints of aortic regurgita-
tion, aortic dissection, cardiovascular surgery, congestive heart failure, and death (five in treatment group, nine in control group). The rate of aortic enlargement was lower in the propanolol group than in the control group (47). Variation in the method of prescribing beta blockers for MFS is associated with disparate results. A recent meta-analysis reviewed 17 clinical trials and excluded 11 of these from the analysis because of incomplete or redundant information or absence of a control group (49). Of the remaining six trials, heart rate response to exercise was tested in only two, and only one was prospective (45, 47). The authors conclude that there is insufficient evidence from these trials to support routine use of beta blockers in MFS. New studies are needed to prospectively address the utility of beta blockers (49). Side effects of beta blockers are common and are typically more evident at higher doses (50, 51). Use of cardiac-specific beta blockers may improve their tolerability, but some individuals do not tolerate any medications with this class of action. For such patients, limited clinical evidence supports use of verapamil, a calcium channel blocker, in an attempt to reduce cardiac inotropy and chronotropy and thereby reduce proximal aortic shear stress. One report describes 26 individuals with MFS who received pharmacologic treatment for aortic aneurysm (46). Of these, five were using verapamil. The rate of aortic growth was greater among 18 people who did not receive pharmacologic treatment than in the 26 who did (46). The subgroup receiving verapamil was too small to definitively establish that this therapy provided benefit, and no prospectively randomized assessment of this strategy has been reported. Another strategy to delay pathologic aortic root growth involves use of ACE inhibitors. One trial compared 58 individuals with MFS who received either an ACE inhibitor (enalapril) or a beta blocker (propranolol or atenolol), reporting that those treated with enalapril had improved aortic www.annualreviews.org • Therapy of Marfan Syndrome
51
ARI
16 December 2007
14:42
distensibility, reduced aortic stiffness, and smaller aortic root diameter (52). It remains unknown whether increased aortic stiffness contributes to the pathogenesis of aneurysm and dissection. An important limitation of this nonrandomized trial was that beta blocker dosage was not titrated to physiologic response but rather was capped at 2 mg/kg once daily of atenolol or 1 mg/kg twice daily of propranolol (52). Moreover, the vast majority of patients who had previously been diagnosed with Marfan syndrome and were on beta blockers remained on beta blockers, whereas the bulk of “new patients,” presumably with a less well-defined natural history of disease, chose to receive enalapril (52). Forty percent of new patients who originally chose to receive beta blockers subsequently switched to the enalapril group owing to subjective measures of intolerance (52). This practice might impose bias, as patients with a greater perception of risk may have greater motivation to continue standard therapy. At this point, the use of ACE inhibitors to slow pathologic aortic growth in MFS shares many of the uncertainties of other more established therapies. As discussed above, experimental evidence regarding other forms of aortic aneurysm suggests that signaling through the AT2 receptor is protective whereas signaling through the AT1 receptor contributes to pathogenesis. If relevant to MFS, these data suggest that reducing the production of angiotensin II, as achieved with ACE inhibitors, would not be optimal because the protective (AT2) pathway would also be blocked. Furthermore, ACE inhibitors would not address alternative tissue pathways for the production of angiotensin II, such as through the activity of chymase (53). Selective AT1 blockade would seem to be a better choice. (This concept is developed more completely in the subsection on emerging therapies for MFS.) Finally, it should be noted that many patients with MFS have been treated with ACE inhibitors for valve dysfunction. This usage has not been systematically assessed, but no pronounced effect on aortic root growth has been apparent.
Annu. Rev. Med. 2008.59:43-59. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-04
52
Judge
·
Dietz
Surgery for Aortic Aneurysm Successful surgical repair of aortic root aneurysms may be the single most important cause of the improvement in life expectancy for individuals with MFS. Although the prognosis is highly variable, a 1972 publication stated that life expectancy for affected individuals was about two thirds that of unaffected people, with life-table mortality curves deviating in infancy (54). In that analysis, most of the deaths had a cardiovascular cause, including aortic dissection, heart failure, or cardiac valve disease. More recently, the average life expectancy for people with MFS was reported to be nearly normal, with a significant increase in survival for those who underwent aortic root surgery after 1980 (55). In 1968, the surgical approach to aortic root aneurysm was revolutionized by publication of the first description of replacement of the aortic root with a composite valve graft and direct coronary reanastomosis (56). Over the past 20 years, several modifications of this technique have been described. Some alternative methods have addressed different ways to construct the anastomosis of the coronary arteries (57, 58). A strategy to replace the aortic root with a pulmonary root autograft (Ross procedure) is not recommended owing to the possibility of progressive enlargement of the pulmonary root when it is exposed to systemic pressure, and eventual autograft failure, particularly in patients with a systemic connective tissue disorder (59, 60). Consistent with this concern, many patients with MFS show pulmonary artery dilation, although pulmonary pressures are lower than systemic pressures. It is now well established that aortic root surgery should be recommended for individuals with an aortic root diameter 5.0 cm or greater (61). Additional factors that may influence an earlier recommendation for aortic root surgery are a rapid rate of enlargement (>0.5–1.0 cm/y) or a family history of early aortic dissection. Gott and colleagues have demonstrated marked reduction in mortality
Annu. Rev. Med. 2008.59:43-59. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-04
ARI
16 December 2007
14:42
for aortic root surgery if it is undertaken on an elective basis, rather than on an urgent or emergent basis (61). Preserving the native aortic valve at the time of aortic root repair is naturally very desirable because the need for lifelong anticoagulation with warfarin may be avoided (62, 63). The long-term durability of the native aortic valve in the setting of MFS remains somewhat uncertain. Several promising series have been reported (64–66). However, concerns include valvular insufficiency, late annular dilatation, and the possible need for reoperation to replace the valve (67). An ongoing registry by the National Marfan Foundation is currently enrolling individuals with MFS who receive aortic root surgery, comparing outcomes between those with “classic” aortic root and valve replacement to those with valve-sparing aortic root replacement. Until longer-term results of this operation are known, short- and medium-term results guide the clinical decision between composite graft and valve-sparing aortic root surgeries.
Endocarditis Prophylaxis Individuals with MFS often have multiple abnormal cardiac valves. Abnormalities include myxomatous thickening with prolapse and regurgitation of the mitral and tricuspid valves, as well as dilatation of the aortic and pulmonic roots, with insufficiency of these valve leaflets. Accordingly, these individuals are at greater risk of bacterial endocarditis than those without structural heart disease. Antibiotic prophylaxis was recommended to diminish the likelihood of infective endocarditis (IE) in this setting (68). Recently, the American Heart Association modified its recommendations for the use of prophylactic antibiotics during procedures that are associated with bacteremia, such as dental, gastrointestinal, or genitourinary interventions (69). In the absence of large randomized prospective placebo-controlled trials demonstrating efficacy of antibiotic prophylaxis to prevent IE, these revised guidelines
recommend antibiotics only in patients considered to be at highest risk, such as those with prosthetic cardiac valves or with a history of IE, certain forms of congenital heart disease, or cardiac transplantation with subsequent cardiac valve disease (69). These conditions also pose the highest risk for adverse outcomes in the setting of IE. The pathogenesis of bacterial endocarditis is thought to rely on bloodstream infection, intracardiac turbulence, and abnormal endocardial surface of the affected valve (70). We consider individuals with MFS and myxomatous mitral or tricuspid valve disease with audible regurgitation not only to be at high risk of developing IE with dental, gastrointestinal, and genitourinary procedures, but also to be among those at highest risk for adverse outcome if they were to develop IE. In the absence of clinical trials performed specifically to address this question in this cohort of patients, we advise continued use of prophylactic antibiotics among individuals with MFS who have prosthetic cardiac valves, valve-sparing aortic root surgery, or myxomatous valve disease.
Emerging Therapies Several important insights have arisen from murine models of MFS, leading to therapies that are either currently being tested or are anticipated in the near future. Foremost among these is the strategy to modulate TGFβ activity with ARBs such as losartan that selectively block AT1 (34). ARBs have been shown to reduce the level of expression of TGFβ ligands and their receptors and to limit the production of activators of TGFβ such as thrombospondin-1 (TSP-1) (71). Increased TSP-1 expression has been identified in diseased tissues in mouse models of MFS, and this is attenuated or eliminated after treatment with losartan (41). Interestingly, TSP-1 appears to be a minor physiologic activator of TGFβ, as evidenced by the subtlety of phenotypes suggestive of TGFβ deficiency in Tsp1 knockout mice (72). In contrast, TSP-1 may www.annualreviews.org • Therapy of Marfan Syndrome
53
ARI
16 December 2007
14:42
be a major pathologic activator of TGFβ in MFS. If so, TSP-1 may prove to be an ideal therapeutic target because antagonists would have a high therapeutic index. Both TSP-1 antagonists and AT2 agonists are currently being tested in mouse models of MFS. Enthusiasm regarding the possibility of completely halting pathologic aortic root growth in affected individuals, as occurred in treated mice with a similar genetic predisposition to aortic aneurysm, is tempered by the lack of clinical trial data. In a clinical trial coordinated by the Pediatric Heart Network of the National Heart, Lung and Blood Institute of the National Institutes of Health, 19 sites within the United States, Canada, and Belgium are enrolling individuals with MFS, aged six months to 25 years, with aortic root Z-score >3.0. Enrolled subjects will receive either a beta blocker (atenolol) or ARB (losartan) for a period of three years. The primary outcome will be the rate of change in normalized aortic root size. Secondary outcomes will include size and rate of change in other segments of aorta; time to aortic dissection, surgery, or death; and measures of cardiac size and aortic stiffness. Several studies have shown the ability of antibodies that antagonize TGFβ to modulate manifestations of MFS in mice, including defective pulmonary alveolar septation, myxomatous atrioventricular valves, skeletal muscle myopathy, and aortic root aneurysms (32–34, 41). A humanized anti-TGFβ1 monoclonal antibody (CAT-192) has been produced and is currently under investigation for treatment of other disorders in which this cytokine has been determined to play a pathogenetic
Annu. Rev. Med. 2008.59:43-59. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-04
role (73). Direct inhibition of TGFβ with neutralizing antibodies remains a promising strategy to ameliorate many manifestations of MFS. Insights derived from the study of MFS may prove relevant to other conditions. The finding that other inherited arteriopathies (LDS, arterial tortuosity syndrome, and autosomal recessive cutis laxa) also relate to excessive TGFβ signaling (15, 74, 75) suggests that this may be a common final pathway for aneurysm formation, and that ARBs may prove effective regardless of the underlying reason for aneurysm. There is already evidence derived from a mouse model of Duchenne muscular dystrophy that losartanmediated restoration of muscle regeneration, architecture, and function (as initially observed in MFS) may develop into a productive treatment strategy (41).
CONCLUSIONS Successful treatment of MFS relies on several important steps: first, recognition of the disorder with anticipation of potential complications; second, early intervention with activity restrictions and pharmacologic therapies; and third, surgical intervention when appropriate. Investigation of the pathophysiologic basis for many aspects of MFS in murine models has led to remarkable insights. We anticipate that translation of these research discoveries to clinical trials will demonstrate effectiveness of a pharmacologic approach in which target selection is based on our improved understanding of the molecular basis for pathologic features of this condition.
SUMMARY POINTS 1. The diagnosis of Marfan syndrome is made through clinical criteria (Table 1). It is important to exclude the diagnosis of Loeys-Dietz syndrome (Table 2). 2. Many manifestations of Marfan syndrome, including aortic aneurysm, are caused by increased activation of and signaling by transforming growth factor beta (TGFβ).
54
Judge
·
Dietz
ANRV334-ME59-04
ARI
16 December 2007
14:42
3. For individuals with Marfan syndrome, we advise moderation in aerobic activity and avoidance of isometric exercise. 4. Beta-adrenergic receptor blockers appear to slow pathologic aortic root growth, but the data supporting their use is limited.
Annu. Rev. Med. 2008.59:43-59. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
5. Elective repair of aortic root aneurysm is recommended with aortic root diameter of 5 cm or greater in adults with Marfan syndrome. Guidelines for surgery in children are less precise and require a more individualized approach. 6. Because of high lifetime risk of infective endocarditis, as well as high risk for adverse outcomes in the setting of endocarditis, we continue to advise patients with Marfan syndrome and other connective tissue disorders who have myxomatous valves or valvesparing aortic root surgery to use antibiotic prophylaxis for dental, gastrointestinal, and genitourinary procedures. 7. Angiotensin II type 1 (AT1) receptor blockers such as losartan prevent pathologic aortic root growth, normalize aortic wall architecture and thickness, and improve noncardiovascular manifestations such as pulmonary and skeletal muscle pathology in a murine model of Marfan syndrome. Clinical trials are under way to test the efficacy of this treatment in people with Marfan syndrome.
DISCLOSURE STATEMENT The authors are not aware of any biases that might be perceived as affecting the objectivity of this review.
ACKNOWLEDGMENTS The authors acknowledge the William S. Smilow Center for Marfan Syndrome Research, the Dana and Albert “Cubby” Broccoli Center for Aortic Diseases, and the National Marfan Foundation.
LITERATURE CITED 1. Marfan A-B. 1896. Un cas de deformation congenitale des quarte membres plus prononc´ee aux extremit´es caracteris´ee par l’allongement des os avec un certain degr`e d’amincissement. Bull. Mem. Soc. Med. Hop. Paris 13:220–26 2. Marfan A-B. 1938. La dolichost´enom´elie [dolichom´elie arachnodactylie]. Ann. Med. 44:5– 29 3. McKusick VA. 1955. The cardiovascular aspects of Marfan’s syndrome. Circulation 11:321 4. Beighton P, de Paepe A, Danks D, et al. 1988. International Nosology of Heritable Disorders of Connective Tissue, Berlin, 1986. Am. J. Med. Genet. 29:581–94 5. Dietz HC, Pyeritz RE, Hall BD, et al. 1991. The Marfan syndrome locus: confirmation of assignment to chromosome 15 and identification of tightly linked markers at 15q15–q21.3. Genomics 9:355–61 6. Dietz HC, Cutting GR, Pyeritz RE, et al. 1991. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 352:337–39 www.annualreviews.org • Therapy of Marfan Syndrome
55
ARI
16 December 2007
14:42
7. Pereira L, Levran O, Ramirez F, et al. 1994. A molecular approach to the stratification of cardiovascular risk in families with Marfan’s syndrome. N. Engl. J. Med. 331:148–53 8. De Paepe A, Devereux RB, Dietz HC, et al. 1996. Revised diagnostic criteria for the Marfan syndrome. Am. J. Med. Genet. 62:417–26 9. Loeys B, De Backer J, Van Acker P, et al. 2004. Comprehensive molecular screening of the FBN1 gene favors locus homogeneity of classical Marfan syndrome. Hum. Mutat. 24:140–46 10. Glesby MJ, Pyeritz RE. 1989. Association of mitral valve prolapse and systemic abnormalities of connective tissue. A phenotypic continuum. JAMA 262:523–28 11. Montgomery RA, Geraghty MT, Bull E, et al. 1998. Multiple molecular mechanisms underlying subdiagnostic variants of Marfan syndrome. Am. J. Hum. Genet. 63:1703–11 12. Kainulainen K, Karttunen L, Puhakka L, et al. 1994. Mutations in the fibrillin gene responsible for dominant ectopia lentis and neonatal Marfan syndrome. Nat. Genet. 6:64–69 13. Faivre L, Gorlin RJ, Wirtz MK, et al. 2003. In frame fibrillin-1 gene deletion in autosomal dominant Weill-Marchesani syndrome. J. Med. Genet. 40:34–36 14. Sood S, Eldadah ZA, Krause WL, et al. 1996. Mutation in fibrillin-1 and the Marfanoidcraniosynostosis (Shprintzen-Goldberg) syndrome. Nat. Genet. 12:209–11 15. Loeys BL, Chen J, Neptune ER, et al. 2005. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat. Genet. 37:275–81 16. Loeys BL, Schwarze U, Holm T, et al. 2006. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N. Engl. J. Med. 355:788–98 17. Halme T, Savunen T, Aho H, et al. 1985. Elastin and collagen in the aortic wall: changes in the Marfan syndrome and annuloaortic ectasia. Exp. Mol. Pathol. 43:1–12 18. Tsuji T. 1986. Marfan syndrome: demonstration of abnormal elastic fibers in skin. J. Cutan. Pathol. 13:144–53 19. Kainulainen K, Pulkkinen L, Savolainen A, et al. 1990. Location on chromosome 15 of the gene defect causing Marfan syndrome. N. Engl. J. Med. 323:935–39 20. Sakai LY, Keene DR, Engvall E. 1986. Fibrillin, a new 350-kD glycoprotein, is a component of extracellular microfibrils. J. Cell. Biol. 103:2499–509 21. Hollister DW, Godfrey M, Sakai LY, et al. 1990. Immunohistologic abnormalities of the microfibrillar-fiber system in the Marfan syndrome. N. Engl. J. Med. 323:152–59 22. Kielty CM, Shuttleworth CA. 1995. Fibrillin-containing microfibrils: structure and function in health and disease. Int. J. Biochem. Cell Biol. 27:747–60 23. Dietz HC, McIntosh I, Sakai LY, et al. 1993. Four novel FBN1 mutations: significance for mutant transcript level and EGF-like domain calcium binding in the pathogenesis of Marfan syndrome. Genomics 17:468–75 24. Schrijver I, Liu W, Odom R, et al. 2002. Premature termination mutations in FBN1: distinct effects on differential allelic expression and on protein and clinical phenotypes. Am. J. Hum. Genet. 71:223–37 25. Frischmeyer PA, Dietz HC. 1999. Nonsense-mediated mRNA decay in health and disease. Hum. Mol. Genet. 8:1893–900 26. Montgomery RA, Dietz HC. 1997. Inhibition of fibrillin 1 expression using U1 snRNA as a vehicle for the presentation of antisense targeting sequence. Hum. Mol. Genet. 6:519–25 27. Judge DP, Biery NJ, Keene DR, et al. 2004. Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome. J. Clin. Invest. 114:172–81 28. Pereira L, Andrikopoulos K, Tian J, et al. 1997. Targeting of the gene encoding fibrillin-1 recapitulates the vascular aspect of Marfan syndrome. Nat. Genet. 17:218–22
Annu. Rev. Med. 2008.59:43-59. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-04
56
Judge
·
Dietz
Annu. Rev. Med. 2008.59:43-59. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-04
ARI
16 December 2007
14:42
29. Hutchinson S, Furger A, Halliday D, et al. 2003. Allelic variation in normal human FBN1 expression in a family with Marfan syndrome: a potential modifier of phenotype? Hum. Mol. Genet. 12:2269–76 30. Sinha S, Nevett C, Shuttleworth CA, et al. 1998. Cellular and extracellular biology of the latent transforming growth factor-beta binding proteins. Matrix Biol. 17:529–45 31. Isogai Z, Ono RN, Ushiro S, et al. 2003. Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. J. Biol. Chem. 278:2750–57 32. Neptune ER, Frischmeyer PA, Arking DE, et al. 2003. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat. Genet. 33:407–11 33. Ng CM, Cheng A, Myers LA, et al. 2004. TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J. Clin. Invest. 114:1586–92 34. Habashi JP, Judge DP, Holm TM, et al. 2006. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312:117–21 35. Massague J, Seoane J, Wotton D. 2005. Smad transcription factors. Genes. Dev. 19:2783– 810 36. Rodriguez-Vita J, Sanchez-Lopez E, Esteban V, et al. 2005. Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-betaindependent mechanism. Circulation 111:2509–17 37. Lavoie P, Robitaille G, Agharazii M, et al. 2005. Neutralization of transforming growth factor-beta attenuates hypertension and prevents renal injury in uremic rats. J. Hypertens. 23:1895–903 38. Houlihan CA, Akdeniz A, Tsalamandris C, et al. 2002. Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diab. Care 25:1072–77 39. Daugherty A, Manning MW, Cassis LA. 2000. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J. Clin. Invest. 105:1605–12 40. Daugherty A, Manning MW, Cassis LA. 2001. Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis. Br. J. Pharmacol. 134:865–70 41. Cohn RD, van Erp C, Habashi JP, et al. 2007. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat. Med. 13:204–10 42. Maron BJ, Chaitman BR, Ackerman MJ, et al. 2004. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 109:2807–16 43. Braverman AC. 1998. Exercise and the Marfan syndrome. Med. Sci. Sports Exerc. 30:S387– 95 44. Halpern BL, Char F, Murdoch JL, et al. 1971. A prospectus on the prevention of aortic rupture in the Marfan syndrome with data on survivorship without treatment. Johns Hopkins Med. J. 129:123–29 45. Salim MA, Alpert BS, Ward JC, et al. 1994. Effect of beta-adrenergic blockade on aortic root rate of dilation in the Marfan syndrome. Am. J. Cardiol. 74:629–33 46. Rossi-Foulkes R, Roman MJ, Rosen SE, et al. 1999. Phenotypic features and impact of beta blocker or calcium antagonist therapy on aortic lumen size in the Marfan syndrome. Am. J. Cardiol. 83:1364–68 www.annualreviews.org • Therapy of Marfan Syndrome
57
ARI
16 December 2007
14:42
47. Shores J, Berger KR, Murphy EA, et al. 1994. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan’s syndrome. N. Engl. J. Med. 330:1335–41 48. Ladouceur M, Fermanian C, Lupoglazoff J-M, et al. 2007. Effect of beta-blockade on ascending aortic dilatation in children with the Marfan syndrome. Am. J. Cardiol. 99:406– 9 49. Gersony DR, McClaughlin MA, Jin Z, et al. 2007. The effect of beta-blocker therapy on clinical outcome in patients with Marfan’s syndrome: a meta-analysis. Int. J. Cardiol. 114:303–8 50. Dahlof C, Dimenas E, Kendall M, et al. 1991. Quality of life in cardiovascular diseases. Emphasis on beta-blocker treatment. Circulation 84:VI108–18 51. Gleiter CH, Deckert J. 1996. Adverse CNS-effects of beta-adrenoceptor blockers. Pharmacopsychiatry 29:201–11 52. Yetman AT, Bornemeier RA, McCrindle BW. 2005. Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome. Am. J. Cardiol. 95:1125–27 53. Takai S, Jin D, Sakaguchi M, et al. 1999. Chymase-dependent angiotensin II formation in human vascular tissue. Circulation 100:654–58 54. Murdoch JL, Walker BA, Halpern BL, et al. 1972. Life expectancy and causes of death in the Marfan syndrome. N. Engl. J. Med. 286:804–8 55. Silverman DI, Burton KJ, Gray J, et al. 1995. Life expectancy in the Marfan syndrome. Am. J. Cardiol. 75:157–60 56. Bentall H, De Bono A. 1968. A technique for complete replacement of the ascending aorta. Thorax 23:338–39 57. Cabrol C, Pavie A, Gandjbakhch I, et al. 1981. Complete replacement of the ascending aorta with reimplantation of the coronary arteries: new surgical approach. J. Thorac. Cardiovasc. Surg. 81:309–15 58. Svensson LG, Crawford ES, Hess KR, et al. 1992. Composite valve graft replacement of the proximal aorta: comparison of techniques in 348 patients. Ann. Thorac. Surg. 54:427–37; discussion 438–39 59. Ross DN. 1967. Replacement of aortic and mitral valves with a pulmonary autograft. Lancet 290:956–58 60. Luciani GB, Casali G, Favaro A, et al. 2003. Fate of the aortic root late after Ross operation. Circulation 108:II-61–67 61. Gott VL, Greene PS, Alejo DE, et al. 1999. Replacement of the aortic root in patients with Marfan’s syndrome. N. Engl. J. Med. 340:1307–13 62. Sarsam MA, Yacoub M. 1993. Remodeling of the aortic valve anulus. J. Thorac. Cardiovasc. Surg. 105:435–38 63. David TE, Feindel CM. 1992. An aortic valve-sparing operation for patients with aortic incompetence and aneurysm of the ascending aorta. J. Thorac. Cardiovasc. Surg. 103:617– 21; discussion 22 64. Miller DC. 2007. Valve-sparing aortic root replacement: current state of the art and where are we headed? Ann. Thorac. Surg. 83:S736–39; discussion S85–90 65. Patel ND, Williams JA, Barreiro CJ, et al. 2006. Valve-sparing aortic root replacement: early experience with the De Paulis Valsalva graft in 51 patients. Ann. Thorac. Surg. 82:548– 53 66. David TE, Feindel CM, Webb GD, et al. 2006. Long-term results of aortic valve-sparing operations for aortic root aneurysm. J. Thorac. Cardiovasc. Surg. 132:347–54
Annu. Rev. Med. 2008.59:43-59. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-04
58
Judge
·
Dietz
Annu. Rev. Med. 2008.59:43-59. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-04
ARI
16 December 2007
14:42
67. Bethea BT, Fitton TP, Alejo DE, et al. 2004. Results of aortic valve-sparing operations: experience with remodeling and reimplantation procedures in 65 patients. Ann. Thorac. Surg. 78:767–72 68. Dajani AS, Taubert KA, Wilson W, et al. 1997. Prevention of bacterial endocarditis. Recommendations by the American Heart Association. JAMA 277:1794–801 69. Wilson W, Taubert KA, Gewitz M, et al. 2007. Prevention of infective endocarditis. Guidelines from the American Heart Association. Circulation. Epub ahead of print 70. Thiene G, Basso C. 2006. Pathology and pathogenesis of infective endocarditis in native heart valves. Cardiovasc. Pathol. 15:256–63 71. Naito T, Masaki T, Nikolic-Paterson DJ, et al. 2004. Angiotensin II induces thrombospondin-1 production in human mesangial cells via p38 MAPK and JNK: a mechanism for activation of latent TGF-beta1. Am. J. Physiol. Renal Physiol. 286:F278–87 72. Lawler J, Sunday M, Thibert V, et al. 1998. Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J. Clin. Invest. 101:982– 92 73. Denton CP, Merkel PA, Furst DE, et al. 2007. Recombinant human antitransforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum. 56:323–33 74. Coucke PJ, Willaert A, Wessels MW, et al. 2006. Mutations in the facilitative glucose transporter GLUT10 alter angiogenesis and cause arterial tortuosity syndrome. Nat. Genet. 38:452–57 75. Hanada K, Vermeij M, Garinis GA, et al. 2007. Perturbations of vascular homeostasis and aortic valve abnormalities in fibulin-4 deficient mice. Circ. Res. 100:738–46
RELATED RESOURCES National Marfan Foundation, http://www.marfan.org, 22 Manhasset Avenue, Port Washington, NY 11050; 1-800-862-7326
www.annualreviews.org • Therapy of Marfan Syndrome
59
AR334-FM
ARI
18 December 2007
17:20
Annual Review of Medicine
Annu. Rev. Med. 2008.59:43-59. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Contents
Volume 59, 2008
The FDA Critical Path Initiative and Its Influence on New Drug Development Janet Woodcock and Raymond Woosley p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p1 Reversing Advanced Heart Failure by Targeting Ca2+ Cycling David M. Kaye, Masahiko Hoshijima, and Kenneth R. Chien p p p p p p p p p p p p p p p p p p p p p p p p 13 Tissue Factor and Factor VIIa as Therapeutic Targets in Disorders of Hemostasis Ulla Hedner and Mirella Ezban p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 29 Therapy of Marfan Syndrome Daniel P. Judge and Harry C. Dietz p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 43 Preeclampsia and Angiogenic Imbalance Sharon Maynard, Franklin H. Epstein, and S. Ananth Karumanchi p p p p p p p p p p p p p p p p p 61 Management of Lipids in the Prevention of Cardiovascular Events Helene Glassberg and Daniel J. Rader p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 79 Genetic Susceptibility to Type 2 Diabetes and Implications for Antidiabetic Therapy Allan F. Moore and Jose C. Florez p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 95 Array-Based DNA Diagnostics: Let the Revolution Begin Arthur L. Beaudet and John W. Belmont p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p113 Inherited Mitochondrial Diseases of DNA Replication William C. Copeland p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p131 Childhood Obesity: Adrift in the “Limbic Triangle” Michele L. Mietus-Snyder and Robert H. Lustig p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p147 Expanded Newborn Screening: Implications for Genomic Medicine Linda L. McCabe and Edward R.B. McCabe p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p163 Is Human Hibernation Possible? Cheng Chi Lee p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p177 Advance Directives Linda L. Emanuel p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p187 v
AR334-FM
ARI
18 December 2007
17:20
Genetic Determinants of Aggressive Breast Cancer Alejandra C. Ventura and Sofia D. Merajver p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p199 A Role for JAK2 Mutations in Myeloproliferative Diseases Kelly J. Morgan and D. Gary Gilliland p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p213 Appropriate Use of Cervical Cancer Vaccine Gregory D. Zimet, Marcia L. Shew, and Jessica A. Kahn p p p p p p p p p p p p p p p p p p p p p p p p p p p p p223 A Decade of Rituximab: Improving Survival Outcomes in Non-Hodgkin’s Lymphoma Arturo Molina p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p237
Annu. Rev. Med. 2008.59:43-59. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Nanotechnology and Cancer James R. Heath and Mark E. Davis p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p251 Cancer Epigenetics: Modifications, Screening, and Therapy Einav Nili Gal-Yam, Yoshimasa Saito, Gerda Egger, and Peter A. Jones p p p p p p p p p p p p267 T Cells and NKT Cells in the Pathogenesis of Asthma Everett H. Meyer, Rosemarie H. DeKruyff, and Dale T. Umetsu p p p p p p p p p p p p p p p p p p p p281 Complement Regulatory Genes and Hemolytic Uremic Syndromes David Kavanagh, Anna Richards, and John Atkinson p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p293 Mesenchymal Stem Cells in Acute Kidney Injury Benjamin D. Humphreys and Joseph V. Bonventre p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p311 Asthma Genetics: From Linear to Multifactorial Approaches Stefano Guerra and Fernando D. Martinez p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p327 The Effect of Toll-Like Receptors and Toll-Like Receptor Genetics in Human Disease Stavros Garantziotis, John W. Hollingsworth, Aimee K. Zaas, and David A. Schwartz p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p343 Advances in Antifungal Therapy Carole A. Sable, Kim M. Strohmaier, and Jeffrey A. Chodakewitz p p p p p p p p p p p p p p p p p p361 Herpes Simplex: Insights on Pathogenesis and Possible Vaccines David M. Koelle and Lawrence Corey p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p381 Medical Management of Influenza Infection Anne Moscona p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p397 Bacterial and Fungal Biofilm Infections A. Simon Lynch and Gregory T. Robertson p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p415 EGFR Tyrosine Kinase Inhibitors in Lung Cancer: An Evolving Story Lecia V. Sequist and Thomas J. Lynch p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p429 Adaptive Treatment Strategies in Chronic Disease Philip W. Lavori and Ree Dawson p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p443 vi
Contents
AR334-FM
ARI
18 December 2007
17:20
Antiretroviral Drug–Based Microbicides to Prevent HIV-1 Sexual Transmission Per Johan Klasse, Robin Shattock, and John P. Moore p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p455 The Challenge of Hepatitis C in the HIV-Infected Person David L. Thomas p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p473 Hide-and-Seek: The Challenge of Viral Persistence in HIV-1 Infection Luc Geeraert, Günter Kraus, and Roger J. Pomerantz p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p487
Annu. Rev. Med. 2008.59:43-59. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Advancements in the Treatment of Epilepsy B.A. Leeman and A.J. Cole p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p503 Indexes Cumulative Index of Contributing Authors, Volumes 55–59 p p p p p p p p p p p p p p p p p p p p p p p p525 Cumulative Index of Chapter Titles, Volumes 55–59 p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p529 Errata An online log of corrections to Annual Review of Medicine articles may be found at http://med.annualreviews.org/errata.shtml
Contents
vii
ANRV334-ME59-05
ARI
7 December 2007
12:25
Annu. Rev. Med. 2008.59:61-78. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Preeclampsia and Angiogenic Imbalance Sharon Maynard,1 Franklin H. Epstein,2 and S. Ananth Karumanchi2 1
Renal Division, Department of Medicine, George Washington University School of Medicine; 2 Departments of Medicine, Obstetrics and Gynecology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215; email:
[email protected]
Annu. Rev. Med. 2008. 59:61–78
Key Words
First published online as a Review in Advance on October 15, 2007
hypertension in pregnancy, VEGF, sFlt1, endothelial dysfunction
The Annual Review of Medicine is online at http://med.annualreviews.org This article’s doi: 10.1146/annurev.med.59.110106.214058 c 2008 by Annual Reviews. Copyright All rights reserved 0066-4219/08/0218-0061$20.00
Abstract Preeclampsia is a systemic syndrome of pregnancy that originates in the placenta and is characterized by widespread maternal endothelial dysfunction. Until recently, the molecular pathogenesis of preeclampsia was largely unknown, but recent work suggests a key role for altered expression of placental antiangiogenic factors. Soluble Flt1 and soluble endoglin, secreted by the placenta, are increased in the maternal circulation weeks before the onset of preeclampsia. These antiangiogenic factors produce systemic endothelial dysfunction, resulting in hypertension, proteinuria, and the other systemic manifestations of preeclampsia. The molecular basis for placental dysregulation of these pathogenic factors remains unknown, and the role of angiogenic proteins in early placental vascular development is just beginning to be explored. These discoveries have exciting clinical implications and are likely to transform the detection and treatment of preeclampsia in the future.
61
ANRV334-ME59-05
ARI
7 December 2007
12:25
INTRODUCTION
Annu. Rev. Med. 2008.59:61-78. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Preeclampsia is a systemic syndrome that occurs in pregnant women. It is characterized by the new onset of hypertension and proteinuria usually after 20 weeks gestation. Preeclampsia affects ∼3%–5% of pregnancies worldwide (1). Despite many advances in our understanding of the pathophysiology of preeclampsia, delivery of the placenta remains the only definitive treatment. Preeclampsia is a leading cause of preterm birth and consequent neonatal morbidity and mortality in the developed world. In developing countries, where access to safe, emergent delivery is less readily available, preeclampsia claims the lives of >60,000 mothers every year (1). This article describes recent discoveries concerning the pathogenesis of preeclampsia, with emphasis on the emerging role of angiogenic factors as potential mediators of the clinical signs and symptoms of preeclampsia. This work clarifies the pathogenesis of this enigmatic disease and holds promise for the prediction, prevention, and treatment of preeclampsia.
centa is a product of both mother and father (5). Several large genome-wide scans seeking a specific linkage to preeclampsia have been fairly discordant and disappointing, with significant LOD scores in isolated Finnish (2p25, 9p13) (6) and Icelandic (2p12) (7) populations. Specific genetic mutations consistent with these loci have not been identified. Several medical conditions are associated with increased preeclampsia risk, including chronic hypertension, diabetes mellitus, renal disease, obesity, and hypercoagulable states. Women with preeclampsia in a prior pregnancy have a high risk of preeclampsia in subsequent pregnancies. Conditions associated with increased placental mass, such as multifetal gestations and hyatidiform mole, also are associated with increased preeclampsia risk. Interestingly, smoking during pregnancy is thought to reduce the risk of preeclampsia (8). Although none of these risk factors is fully understood, they have provided insights into pathogenesis.
CLINICAL FEATURES EPIDEMIOLOGY AND RISK FACTORS Most cases of preeclampsia occur in healthy, nulliparous women, in whom the incidence of preeclampsia may be as high as 7.5%. Although it is classically a disorder of first pregnancies, multiparous women who are pregnant with a new partner are said to have an elevated preeclampsia risk similar to that of nulliparous women (2). This effect may be due to increased interpregnancy interval rather than the change in paternity per se (3). Although most cases of preeclampsia occur in the absence of a family history, the presence of preeclampsia in a first-degree relative increases a woman’s risk of severe preeclampsia two- to fourfold (4), suggesting a genetic contribution to the disease. A history of preeclampsia in the father’s mother also confers an increased risk, recalling that the pla62
Maynard
·
Epstein
·
Karumanchi
The new onset of hypertension and proteinuria are the cardinal features of preeclampsia. The severity of hypertension in preeclampsia can vary widely, from mild blood pressure elevations easily managed with bed rest, to severe hypertension resistant to multiple medications, often associated with headache and visual changes. The degree of proteinuria in preeclampsia also varies, from minimal to nephrotic range. Occasionally, gestational hypertension without proteinuria is associated with features of severe preeclampsia, such as alterations in liver function, hemolysis, or seizures (9). Although edema was historically part of the diagnostic triad for preeclampsia, it is also a common feature of normal pregnancy, diminishing its usefulness as a specific pathological sign. Still, the sudden onset of severe edema–especially edema of the hands and face–can be an important symptom in this
Annu. Rev. Med. 2008.59:61-78. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-05
ARI
7 December 2007
12:25
otherwise insidious disease and is often the only change detectable by the patient. Serum uric acid is elevated in preeclampsia primarily as a result of enhanced tubular urate reabsorption. Hyperuricemia may contribute to the pathogenesis of preeclampsia by inducing endothelial dysfunction (10). Serum uric acid levels are correlated with the presence and severity of preeclampsia and with adverse pregnancy outcomes (11), even in gestational hypertension without proteinuria (12). Nevertheless, uric acid is of limited clinical utility in either distinguishing preeclampsia from other hypertensive disorders of pregnancy or predicting adverse outcomes (13). Uncommon but serious complications of preeclampsia include acute renal failure, seizures, pulmonary edema, acute liver injury, hemolysis, and/or thrombocytopenia. The latter three signs frequently occur together as part of the HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome. The HELLP syndrome is considered a severe variant of preeclampsia and is associated with a higher risk of maternal and neonatal adverse outcomes than preeclampsia alone. Seizures (eclampsia) complicate ∼2% of preeclampsia cases in the United States. Although eclampsia most often occurs in the setting of hypertension and proteinuria, it can occur without these warning signs. Up to one third of eclampsia cases occur postpartum, sometimes days to weeks after delivery (14). Complications affecting the developing fetus and the neonate include iatrogenic prematurity (and its associated sequelae), fetal growth restriction, oligohydramnios, and placental abruption. Although the exact pathogenesis of these complications is unknown, impaired uteroplacental blood flow or placental infarction are likely to contribute.
Maternal and Neonatal Mortality Approximately 500,000 women die in childbirth each year worldwide, and preeclampsia/eclampsia is estimated to account for 10%–15% of these deaths. Maternal death is
most often due to eclampsia, cerebral hemorrhage, renal failure, hepatic failure, or the HELLP syndrome. Adverse maternal outcomes can often be avoided with timely delivery; hence, in the developed world, the burden of morbidity and mortality falls on the neonate.Worldwide, preeclampsia is associated with a perinatal and neonatal mortality rate of 10% (15). Neonatal death is most commonly due to iatrogenic premature delivery undertaken to preserve the health of the mother, but it can also result from placental abruption or intrauterine fetal death.
HELLP: hemolysis, elevated liver enzymes, and low platelets
Long-Term Cardiovascular Complications Traditionally, women with preeclampsia have been reassured that the syndrome remits completely after delivery, with no long-term consequences aside from increased preeclampsia risk in future pregnancies. Epidemiologic studies have tempered this claim. Approximately 20% of women with preeclampsia develop hypertension or microalbuminuria within seven years of a pregnancy complicated by preeclampisa, compared with only 2% among women with uncomplicated pregnancies (16). The long-term risk of cardiovascular and cerebrovascular disease is doubled in women with preeclampsia and gestational hypertension compared with age-matched controls (17, 18). This increase in subsequent cardiovascular disease is observed for both preeclampsia and gestational hypertension (17), suggesting either common risk factors or a common pathophysiology in these two syndromes. Severe preeclampsia, recurrent preeclampsia, preeclampsia with preterm birth, and preeclampsia with intrauterine growth restriction (IUGR) are most strongly associated with adverse cardiovascular outcomes. Preeclampsia, especially in association with low birthweight, also carries an increased risk of later maternal kidney disease requiring a kidney biopsy (19). Preeclampsia and cardiovascular disease share many common risk factors, such as
www.annualreviews.org • Preeclampsia and Angiogenic Imbalance
63
ANRV334-ME59-05
ARI
7 December 2007
12:25
chronic hypertension, diabetes, obesity, renal disease, and the metabolic syndrome. Still, the increase in long-term cardiovascular mortality holds even for women who develop preeclampsia in the absence of any overt vascular risk factors. Whether the increase in long-term cardiovascular events results from vascular damage or persistent endothelial dysfunction caused by preeclampsia, or instead reflects the common risk factors shared by preeclampsia and cardiovascular disease, remains speculative.
Annu. Rev. Med. 2008.59:61-78. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
HIF: hypoxia-inducible factor
PLACENTAL VASCULAR DEVELOPMENT The Role of the Placenta Observational evidence suggests the placenta has a central role in preeclampsia. Preeclampsia only occurs in the presence of a placenta— though not necessarily a fetus, as in the case of hyatidiform mole—and almost always remits after its delivery. In a case of preeclampsia with extrauterine pregnancy, removal of the fetus alone was not sufficient; symptoms persisted until the placenta was delivered (20). Cases of postpartum eclampsia have been associated with retained placental fragments, with rapid improvement after uterine curettage (21). Severe preeclampsia is associated with pathologic evidence of placental hypoperfusion and ischemia. Findings include acute atherosis, a lesion of diffuse vascular obstruction that includes fibrin deposition, intimal thickening, necrosis, atherosclerosis, and endothelial damage. Placental infarcts, probably due to occlusion of maternal spiral arteries, are also common. Although these findings are not universal, they appear to be correlated with severity of clinical disease (22). Abnormal uterine artery Doppler ultrasound, consistent with decreased uteroplacental perfusion, is observed before the clinical onset of preeclampsia. Unfortunately, this finding is nonspecific, so it is not diagnostically useful if used alone (23). In women residing at high altitude (24), there are alterations 64
Maynard
·
Epstein
·
Karumanchi
in placental hypoxia-inducible factor (HIF) and its targets similar to those seen in women with preeclampsia (25, 26) (see below). This observation suggests that hypoxia may be a contributing factor in preeclampsia pathogenesis. Hypertension and proteinuria can be induced by constriction of uterine blood flow in pregnant primates and other mammals (27, 28). These observations suggest that placental ischemia may be an early event in preeclampsia, at least in some patients. However, evidence that placental ischemia causes preeclampsia remains circumstantial, and several observations call the hypothesis into question. For example, the animal models based on uterine hypoperfusion fail to induce several of the multiorgan features of preeclampsia, including seizures and the HELLP syndrome. In most cases of preeclampsia, there is no evidence of growth restriction or fetal intolerance of labor, expected consequences of placental ischemia. Conversely, cases of fetal growth restriction, where placental insufficiency is the rule, often occur without preeclampsia. Hence, overt placental ischemia may be neither universal nor specific for preeclampsia but instead may be an important secondary event observed in severe cases.
Placental Vascular Remodeling Early in normal placental development, extravillous cytotrophoblasts invade the uterine spiral arteries of the decidua and myometrium. These invasive fetal cells replace the endothelial layer of the uterine vessels, transforming them from small resistance vessels to flaccid, high-caliber capacitance vessels (Figure 1). This vascular transformation allows the increase in uterine blood flow needed to sustain the fetus through the pregnancy. In preeclampsia, this transformation is incomplete. Cytotrophoblast invasion of the arteries is limited to the superficial decidua, and the myometrial segments remain narrow (29). Fisher et al. have shown that in normal placental development, invasive
ANRV334-ME59-05
ARI
7 December 2007
12:25
Figure 1
Annu. Rev. Med. 2008.59:61-78. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Placentation abnormalities in preeclampsia (from Reference 97 with permission). In normal placental development (top), invasive cytotrophoblasts of fetal origin invade the maternal spiral arteries, transforming them into high-caliber capacitance vessels capable of providing adequate placental perfusion to sustain the growing fetus. During this process, the cytotrophoblasts take on an endothelial phenotype (pseudovasculogenesis). In preeclampsia (bottom), cytotrophoblasts fail to adopt an invasive endothelial phenotype. Instead, invasion of the spiral arteries is shallow and they remain small-caliber resistance vessels.
cytotrophoblasts downregulate the expression of adhesion molecules characteristic of their epithelial cell origin and adopt an endothelial cell-surface adhesion phenotype, a process dubbed pseudovasculogenesis (30) or vascular mimicry. In preeclampsia, cytotrophoblasts do not undergo this switching of cell-surface integrins and adhesion molecules, and they fail to adequately invade the myometrial spiral arteries (31).
The factors that regulate this process are just beginning to be elucidated. Angiogenic factors, including Flt1 (VEGFR-1), VEGFR-2, Tie-1, and Tie-2, are essential for normal placental vascular development; mice deficient in these receptors have defective placental vasculogenesis and die in utero (32). HIF-1, which modulates expression of these angiogenic proteins, is increased in preeclampsia. Invasive cytotrophoblasts
www.annualreviews.org • Preeclampsia and Angiogenic Imbalance
65
ANRV334-ME59-05
ARI
7 December 2007
12:25
express several other angiogenic factors, also regulated by HIF, including vascular endothelial growth factor (VEGF), placental growth factor (PlGF), and VEGFR-1 (Flt1); expression of these proteins by immunolocalization is altered in preeclampsia (33). Another HIF target, transforming growth factor beta3 (TGF-β3), may block cytotrophoblast invasion (34). A genetic study recently identified polymorphisms in STOX1, a paternally imprinted gene and member of the winged helix gene family, in a Dutch preeclampsia cohort (35). The authors hypothesized that loss-of-function mutations in this gene could result in defective polyploidization of extravillous trophoblast, leading to loss of cytotrophoblast invasion. More work is needed to uncover the molecular signals governing cytotrophoblast invasion early in placentation, defects in which may underlie the early stages of preeclampsia. The lack of a naturally occurring animal model for preeclampsia and lack of access to human placental samples from early gestation have greatly limited research in this area.
VEGF: vascular endothelial growth factor
Annu. Rev. Med. 2008.59:61-78. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
PlGF: placental growth factor
MATERNAL ENDOTHELIAL DYSFUNCTION Although preeclampsia appears to begin in the placenta, the target organ is the maternal endothelium. The clinical manifestations of preeclampsia reflect widespread endothelial dysfunction, resulting in vasoconstriction and end-organ ischemia. Incubation of endothelial cells with serum from women with preeclampsia results in endothelial dysfunction; hence, it has been hypothesized that circulating factors, probably originating in the placenta, are responsible for the manifestations of the disease (36). Dozens of serum markers of endothelial activation and endothelial dysfunction are deranged in women with preeclampsia, including von Willebrand antigen, cellular fibronectin, soluble tissue factor, soluble Eselectin, platelet-derived growth factor, and endothelin. There is evidence of oxidative 66
Maynard
·
Epstein
·
Karumanchi
stress and platelet activation (37). Inflammation is often present; for example, neutrophil infiltration is observed in the vascular smooth muscle of subcutaneous fat, with increased vascular smooth muscle expression of IL-8 and intercellular adhesion molecule1 (ICAM-1) (38). Several of these aberrations occur well before the onset of symptoms, supporting the central role of endothelial dysfunction in the pathogenesis of preeclampsia.
Hemodynamic Changes The decreases in peripheral vascular resistance and arterial blood pressure that occur during normal pregnancy are absent or reversed in preeclampsia. Systemic vascular resistance is high and cardiac output is low owing to widespread vasoconstriction. Interestingly, some have suggested that patients destined to develop preeclampsia start out with a hyperdynamic circulation during the preclinical stage and cross over to the vasoconstricted stage during the hypertensive phase (39). There is exaggerated sensitivity to vasopressors such as angiotensin II and norepinephrine (36). Women who go on to develop preeclampsia have impaired endothelium-dependent vasorelaxation (40) and subtle increases in blood pressure and pulse pressure (41) prior to onset of overt hypertension and proteinuria, suggesting that changes in endothelial function are present early in the course of the disease.
Renal Pathology The most characteristic pathologic changes in preeclampsia are seen in the kidney. In 1959, Spargo et al. coined the term glomerular endotheliosis to describe ultrastructural changes in renal glomeruli, including generalized swelling and vacuolization of the endothelial cells and loss of the capillary space (Figure 2a–c). There are deposits of fibrin within and under the endothelial cells, and electron microscopy shows loss of glomerular endothelial fenestrae. The primary injury appears to be to the endothelial cells; the
Annu. Rev. Med. 2008.59:61-78. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-05
ARI
7 December 2007
12:25
a
b
c
d
e
f
Figure 2 Glomerular endotheliosis (from Reference 98 with permission). All light micrographs taken at identical original magnification of 40×. (a) Normal human glomerulus, H & E. (b) Human preeclamptic glomerulus, H & E. Patient is a 33-year-old woman with twin gestation and severe preeclampsia at 26 weeks gestation with urine protein/creatinine ratio of 26 at the time of biopsy. (c) Electron microscopy of glomerulus of same patient. Note occlusion of capillary lumen with cytoplasm and expansion of subendothelial space with electron-dense material (asterisks). Podocyte cytoplasm shows protein resorption droplets (arrow) and relatively intact foot processes (arrow). Original magnification 1500×. (d ) Control rat glomerulus, H & E. Note normal cellularity and open capillary loops. (e) Glomerulus of rat treated with soluble fms-like tyrosine kinase-1 (sFlt-1), H & E. Note occlusion of capillary loops with minimal increase in cellularity. ( f ) Electron microscopy of sFlt-1 treated rat. Note occlusion of capillary loops by cytoplasm (asterisk) with relative preservation of podocyte foot processes (arrows). Original magnification 2500×.
podocyte foot processes are relatively intact early in disease, a finding atypical of other nephrotic diseases. Although glomerular endotheliosis was once considered pathognomonic for preeclampsia, recent studies have shown that mild glomerular endotheliosis also occurs in pregnancy without preeclampsia, especially in gestational hypertension (42). This suggests the endothelial dysfunction of preeclampsia may be an exaggeration of a process present near term in many normal pregnancies.
Cerebral Edema Cerebral edema and intracerebral parenchymal hemorrhage are common autopsy findings in women who died from eclampsia. The
presence of cerebral edema in eclampsia correlates with markers of endothelial damage but not the severity of hypertension (43), suggesting the edema is secondary to endothelial dysfunction rather than a direct result of blood pressure elevation. Findings on head CT and MRI are similar to those seen in hypertensive encephalopathy, with vasogenic cerebral edema and infarctions in the subcortical white matter and adjacent gray matter, predominantly in the parietal and occipital lobes (14). A syndrome that includes these characteristic MRI changes, along with headache, seizures, altered mental status, and hypertension, has been described in patients with acute hypertensive encephalopathy in the setting of renal disease, eclampsia, or immunosuppression (44). This syndrome, termed reversible
www.annualreviews.org • Preeclampsia and Angiogenic Imbalance
67
ANRV334-ME59-05
ARI
7 December 2007
12:25
posterior leukoencephalopathy, has subsequently been associated with the use of antiangiogenic agents for cancer therapy (45). This association supports the involvement of innate antiangiogenic factors in the pathophysiology of preeclampsia/eclampsia, as detailed in the next section.
sFlt1: soluble fms-like tyrosine kinase-1
ALTERATIONS IN ANGIOGENIC FACTORS
Annu. Rev. Med. 2008.59:61-78. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Recent work suggests that changes in circulating angiogenic factors play a key role in the pathogenesis of preeclampsia. Increased expression of soluble fms-like tyrosine kinase-1 (sFlt1), associated with decreased PlGF and VEGF signaling, were the first abnormalities described (46, 47). sFlt1 is a truncated splice variant of the membrane-bound VEGF receptor Flt1, also called VEGFR1. sFlt1 consists of the extracellular ligand-binding domain without the transmembrane and
intracellular signaling domains. Hence, sFlt1 is secreted rather than bound to the cell surface, and it has biological activity as an antagonist to both VEGF and PlGF, binding them in the circulation and preventing interaction with their endogenous receptors (48) (Figure 3). Placental expression of soluble Flt1 is increased in preeclampsia and is associated with a marked increase in maternal circulating sFlt1 (46). Several investigators have confirmed that the increase in maternal circulating sFlt1 precedes the onset of clinical disease (49–52) and is correlated with disease severity (51, 53). In vitro effects of sFlt1 include vasoconstriction and endothelial dysfunction. Exogenous sFlt1 administered to pregnant rats produces a syndrome resembling preeclampsia, including hypertension, proteinuria, and glomerular endotheliosis (46) (Figure 2d–f ). Thus, sFlt1 may be a key part of the mechanism linking the placenta with maternal endothelial dysfunction.
Figure 3 sFlt1 and soluble endoglin (sEng) cause endothelial dysfunction by antagonizing VEGF and TGF-β1 signaling (from Reference 99 with permission). There is mounting evidence that VEGF and TGF-β1 are required to maintain endothelial health in several tissues, including the kidney and perhaps the placenta. During normal pregnancy, vascular homeostasis is maintained by physiological levels of VEGF and TGF-β1 signaling in the vasculature. In preeclampsia, excess placental secretion of sFlt1 and sEng (two endogenous circulating antiangiogenic proteins) inhibits VEGF and TGF-β1 signaling, respectively, in the vasculature. This results in endothelial cell dysfunction, including decreased prostacyclin and nitric oxide production, and release of procoagulant proteins. 68
Maynard
·
Epstein
·
Karumanchi
Annu. Rev. Med. 2008.59:61-78. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-05
ARI
7 December 2007
12:25
Derangements in other angiogenic molecules have also been observed. Maternal serum levels of endostatin, an inhibitor of angiogenesis, are elevated in preeclampsia (54). Soluble endoglin (sEng) is upregulated in preeclampsia in a pattern similar to that of sFlt1. sEng is a truncated form of endoglin (CD105), a cell surface receptor for TGF-β, which binds and antagonizes TGF-β. sEng amplifies the vascular damage mediated by sFlt1 in pregnant rats, inducing a severe preeclampsia-like syndrome with features of the HELLP syndrome (55). This effect may be mediated by interference with nitric oxide–mediated vasodilation (Figure 3). As with sFlt1, circulating sEng levels are elevated weeks prior to preeclampsia onset (56). The precise role of sEng in preeclampsia and its relationship with sFlt1 is currently being explored.
(62). This suggests that VEGF deficiency— induced by excess sFlt1—can produce the characteristic renal manifestations of preeclampsia. It is also interesting to note that women with a history of preeclampsia have a decreased risk of malignancy (18, 63), suggesting that the antiangiogenic milieu of preeclampsia may extend beyond pregnancy. The physiologic role of PlGF is less well understood than that of VEGF, but PlGF appears to stimulate angiogenesis under conditions of ischemia, inflammation, and wound healing (64) and may contribute to atherosclerosis (65). Blockade of both VEGF and PlGF is required to produce preeclampsialike changes in pregnant rats (46), signifying that PlGF blockade may be important in the pathogenesis of sFlt1-induced endothelial dysfunction.
VEGF Signaling and Endothelial Cell Health
Angiogenic Signals in Placental Vascular Development
Circumstantial evidence supports the hypothesis that interference with VEGF/PlGF signaling could mediate endothelial dysfunction in preeclampsia. VEGF is important in the stabilization of endothelial cells in mature blood vessels. VEGF is particularly important in the health of the fenestrated and sinusoidal endothelium found in the renal glomerulus, brain, and liver (57)—organs severely affected in preeclampsia. VEGF is highly expressed by glomerular podocytes, and VEGF receptors are present on glomerular endothelial cells (58). Anti-VEGF therapies given to adult animals cause glomerular endothelial damage with proteinuria (59, 60). In a podocytespecific VEGF knockout mouse, heterozygosity for VEGF-A resulted in renal disease characterized by proteinuria and glomerular endotheliosis (61). The most striking experimental illustration of the effect of VEGF antagonism in humans comes from antiangiogenesis cancer trials, where anti-VEGF antibodies produce proteinuria, hypertension, and loss of glomerular endothelial fenestrae
Angiogenic factors are likely to be important in the regulation of placental vasculogenesis. VEGF ligands and receptors are highly expressed by placental tissue in the first trimester. sFlt1 decreases cytotrophoblast invasiveness in vitro (33). Circulating sFlt1 levels are relatively low early in pregnancy and begin to rise in the third trimester. This may reflect a physiologic antiangiogenic shift in the placental milieu toward the end of pregnancy, corresponding to completion of the vasculogenic phase of placental growth. It is intuitive to hypothesize that placental vascular development might be regulated by a local balance between pro- and antiangiogenic factors and that alterations in these pathways in early gestation could contribute to inadequate cytotrophoblast invasion in preeclampsia. By the third trimester, excess placental sFlt1 is detectable in the maternal circulation, producing end-organ effects. In this case, placental ischemia may not be causative but rather reflective of this derangement of angiogenic balance.
www.annualreviews.org • Preeclampsia and Angiogenic Imbalance
sEng: soluble endoglin
69
ANRV334-ME59-05
ARI
7 December 2007
12:25
Mechanistic Insights into Clinical Risk Factors
Annu. Rev. Med. 2008.59:61-78. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
The discovery of the importance of sFlt1 has provided insight into certain preeclampsia risk factors. Higher sFlt1 levels have been noted in first versus second pregnancies (66), twin versus singleton pregnancies (67), and pregnancies with fetuses having trisomy 13 (68)— all established risk factors for preeclampsia. Conversely, decreased levels of sFlt1 in smokers (69) may explain the protective effect of smoking in preeclampsia. This effect may be mediated by carbon monoxide, a byproduct of cigarette smoking, which diminishes VEGFinduced sFlt1 and sEng release from cultured endothelial cells (70).
Preeclampsia and IUGR: Shared Clinical and Pathophysiologic Features It has long been recognized that preeclampsia and intrauterine growth restriction (IUGR) share many common clinical and pathologic features. IUGR is a common complication of preeclampsia, and abnormal uterine blood flow by Doppler ultrasound in early pregnancy is associated with an increased risk for both disorders. Why some women with placental insufficiency manifest the systemic syndrome of preeclampsia, while others have small-for-gestational-age babies without these maternal symptoms, is unknown. With regard to angiogenic factors, there appears to be some overlap between the two syndromes. Some (71–73) but not all (49, 74) studies report that women with IUGR but without preeclampsia have increased circulating sFlt1 and sEng and decreased PlGF. Alterations in angiogenic factors in IUGR without preeclampsia, when detected, are less pronounced than in preeclampsia. Given the pathologic and clinical overlap between IUGR and preeclampsia, it is our belief that the two conditions probably share common pathophysiologic underpinnings, at least at the level of insufficient placental vascular de70
Maynard
·
Epstein
·
Karumanchi
velopment. Variability in clinical phenotype is probably attributable to individual environmental and genetic differences that alter the maternal response to the placental disease.
OTHER PIECES OF THE PREECLAMPSIA PUZZLE The Renin-Angiotensin-Aldosterone System Women with preeclampsia have increased vascular responsiveness to angiotensin II and other vasoconstrictive agents. However, plasma renin levels are suppressed relative to normal pregnancy as a secondary response to systemic vasoconstriction and hypertension. Wallukat et al. (75) identified agonistic angiotensin II type 1 (AT1) receptor autoantibodies in women with preeclampsia. They hypothesized that these antibodies, which activate the AT1 receptor, may account for the increased angiotensin II sensitivity of preeclampsia. The same investigators later showed that these AT1 receptor autoantibodies, like angiotensin II itself, stimulate endothelial cells to produce tissue factor, an early marker of endothelial dysfunction. Xia et al. (76) found that AT1 receptor autoantibodies decreased invasiveness of immortalized human trophoblasts in an in vitro invasion assay, suggesting that these autoantibodies might contribute to defective placental pseudovasculogenesis as well. AT1 receptor autoantibodies are not limited to pregnancy; they also appear to be increased in malignant renovascular hypertension and vascular rejection in nonpregnancy (77). Work by Abdalla et al. (78) has suggested that heterodimerization of AT1 receptors with bradykinin 2 receptors may contribute to angiotensin II hypersensitivity in preeclampsia. This work remains to be validated in other studies.
Oxidative Stress and Inflammation Oxidative stress—i.e., the presence of reactive oxygen species in excess of antioxidant
Annu. Rev. Med. 2008.59:61-78. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-05
ARI
7 December 2007
12:25
buffering capacity—is a prominent feature of preeclampsia. It has been hypothesized that in preeclampsia, placental oxidative stress is transferred to the systemic circulation, resulting in oxidative damage to the maternal vascular endothelium. However, the absence of any clinical benefit of antioxidant supplementation for the prevention of preeclampsia suggests that oxidative stress is probably a secondary phenomenon in preeclampsia and not a promising therapeutic target (79). Circulating placental cytotrophoblast debris and the accompanying inflammation have also been proposed as a pathogenic mechanism to explain the maternal endothelial dysfunction, but causal evidence for this hypothesis is still lacking (80).
important role in immune tolerance required for normal placental development, have been recently noted to induce angiogenic factors and vascular remodeling (84). Moreover, genetic studies suggest that the susceptibility to preeclampsia may be influenced by polymorphic human leukocyte antigen C (HLA-C) ligands and the killer immunoglobulin receptors (KIRs) present on NK cells (85). These data suggest that decidual NK cells secrete cytokines and angiogenic factors that play an important role during normal placental vascular remodeling and differentiation, and that alterations in NK cell signaling may mediate abnormal placentation noted in preeclampsia.
CLINICAL IMPLICATIONS OF RECENT ADVANCES
Immunologic Intolerance Immune maladaption remains an intriguing but unproven theory of the pathogenesis of preeclampsia. Normal placentation requires the development of immune tolerance between the fetus and the mother. Preeclampsia occurs more often in first pregnancies, after a change in paternity (81), or with long interpregnancy interval (3). Prolonged maternal exposure to paternal ejaculate appears to be associated with a decreased risk of preeclampsia. For example, women using contraceptive methods that reduce exposure to sperm have increased preeclampsia incidence (82). Women impregnated by intracytoplasmic sperm injection (ICSI) in which sperm were surgically obtained (i.e., the woman was never exposed to partner’s sperm in intercourse) had a threefold increased risk of preeclampsia compared to ICSI cases where sperm were obtained by ejaculation (i.e., the woman was likely to have prior exposure to paternal ejaculate via intercourse) (83). These observations suggest preeclampsia may involve an abnormal maternal immune response to novel paternally derived fetal antigens. Natural killer (NK) cells at the maternal/ fetal interface, which are thought to play an
Screening and Prediction Although there is not yet any definitive therapeutic or preventive strategy for preeclampsia, clinical experience suggests that early detection, monitoring, and supportive care are beneficial to the patient and the fetus. Reliable prediction of preeclampsia would allow closer prenatal monitoring, early diagnosis, and timely intervention with steroids to enhance fetal lung maturity, magnesium for seizure prophylaxis, antihypertensive medications, bed rest, and—when indicated— expeditious delivery. Furthermore, a robust biomarker for preeclampsia would enable targeted studies of therapies and preventive strategies for preeclampsia, including existing (e.g., antiplatelet agents), controversial (calcium, antioxidants), and novel approaches. However, no screening test has yet proven accurate enough for widespread clinical use (86). Alterations in circulating levels of angiogenic factors occur weeks prior to the onset of preeclampsia and are promising biomarkers for screening and/or diagnosis. Significant elevations in maternal sFlt1 and sEng are observed from mid-gestation onward
www.annualreviews.org • Preeclampsia and Angiogenic Imbalance
71
ARI
7 December 2007
12:25
(49, 87) and appear to rise 5–8 weeks prior to preeclampsia onset (51, 56). Maternal sFlt1 levels are particularly elevated in severe preeclampsia, early-onset preeclampsia, and preeclampsia complicated by a small-forgestational-age baby (51, 88). Serum levels of PlGF are lower in women who go on to develop preeclampsia from the first (89) or early second (51, 90, 91) trimester. The ratio of sFlt1 to PlGF has been proposed as an index of antiangiogenic activity that reflects alterations in both biomarkers (92) and is a better predictor of preeclampsia than either measure alone (56). Because PlGF is small enough to pass into the urine, changes in urinary PlGF may be a potential marker for preeclampsia. Urinary levels of PlGF are significantly lower in women who develop preeclampsia from the late second trimester (92) and may prove useful in screening and diagnosis of preeclampsia, especially in early-onset and severe disease (93). SEng is also elevated in the maternal circulation prior to preeclampsia onset, with gestational patterns similar to those of sFlt1. From the late second and early third trimester, elevations in both sEng and the sFlt1:PlGF ratio (but not either biomarker alone) are associated with very high risk (odds ratio >30) for the development of preterm preeclampsia (56). The timing, source (i.e., serum versus urinary), and combination of biomarkers and other tests that will prove most predictive of preeclampsia and its sequelae are now being explored in prospective studies. For example, a recent cohort study found that the combination of abnormal uterine artery Doppler and low serum PlGF in the second trimester was strongly associated with both early-onset and severe preeclampsia, with odds ratios of 35–45 (94). Other work suggests that rapid changes in angiogenic factor levels with advancing gestation may be more predictive of preeclampsia than levels at any single point in gestation (95, 96). It is likely that these discoveries will enhance our ability to identify women at high risk much earlier in gestation, which
Annu. Rev. Med. 2008.59:61-78. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-05
72
Maynard
·
Epstein
·
Karumanchi
would improve clinical management and open up possibilities for early intervention.
Novel Treatment Strategies Currently, the only definitive treatment for preeclampsia is delivery of the fetus and placenta. In the late second and early third trimester, preeclampsia requiring delivery to preserve the health of the mother can result in significant neonatal morbidity and mortality due to prematurity. The identification of sFlt1 and sEng as a key pathogenic link between placental pathology and maternal endothelial damage provides hope that these biomarkers may also be effective therapeutic targets. Potential therapies may be directed at restoring normal angiogenic balance in the maternal circulation—that is, the relative biologic activity of proangiogenic factors such as VEGF and PlGF relative to antiangiogenic factors such as sFlt1 and sEng. For example, VEGF121 was recently shown to diminish hypertension and proteinuria in a rat model of sFlt1induced preeclampsia, without apparent harm to the fetus (96a). Such therapies may transform the way preeclampsia is treated; an intervention that allows clinicians to safely postpone delivery for even a few weeks could have a tremendous impact on neonatal morbidity and mortality in select cases. Although much more work is needed, we soon may see real improvements in the management of this ancient syndrome.
SUMMARY AND FUTURE DIRECTIONS The past five years have provided exciting advances in our understanding of the pathogenesis of preeclampsia. Although the initiating events in preeclampsia are still not known, recent work suggests that excess circulating antiangiogenic factors (sFlt1 and sEng) may be a pathophysiologic link between the placental disease and the systemic maternal manifestations. The implications for the management of preeclampsia may be profound. More
ANRV334-ME59-05
ARI
7 December 2007
12:25
work is needed to further define the regulation of placental vascular development and expression of these factors in normal pregnancy
and in preeclampsia, and the mechanisms responsible for variability in the maternal response.
DISCLOSURE STATEMENT S.E.M. and S.A.K are listed as coinventors on provisional patents filed by the Beth Israel Deaconess Medical Center for the diagnosis and therapy of preeclampsia. S.A.K is a consultant to Beckman Coulter, Johnson & Johnson, and Abbott Diagnostics.
Annu. Rev. Med. 2008.59:61-78. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ACKNOWLEDGMENTS S.A.K. is supported by NIH grants (DK065997 and HL079594). S.E.M. is supported by the Partnership for Cures, Charles E. Culpeper Scholarship in Medical Sciences.
LITERATURE CITED 1. WHO. 2005. World Health Report: Make Every Mother and Child Count. Geneva: World Health Org. 2. Tuffnell DJ, Jankowicz D, Lindow SW, et al. 2005. Outcomes of severe preeclampsia/eclampsia in Yorkshire. 1999/2003. Br. J. Obstet. Gynaecol. 112:875–80 3. Skjaerven R, Wilcox AJ, Lie RT. 2002. The interval between pregnancies and the risk of preeclampsia. N. Engl. J. Med. 346:33–38 4. Carr DB, Epplein M, Johnson CO, et al. 2005. A sister’s risk: family history as a predictor of preeclampsia. Am. J. Obstet. Gynecol. 193:965–72 5. Esplin MS, Fausett MB, Fraser A, et al. 2001. Paternal and maternal components of the predisposition to preeclampsia. N. Engl. J. Med. 344:867–72 6. Laivuori H, Lahermo P, Ollikainen V, et al. 2003. Susceptibility loci for preeclampsia on chromosomes 2p25 and 9p13 in Finnish families. Am. J. Hum. Genet. 72:168–77 7. Arngrimsson R, Sigurardottir S, Frigge ML, et al. 1999. A genome-wide scan reveals a maternal susceptibility locus for pre-eclampsia on chromosome 2p13. Hum. Mol. Genet. 8:1799–805 8. England LJ, Levine RJ, Qian C, et al. 2002. Smoking before pregnancy and risk of gestational hypertension and preeclampsia. Am. J. Obstet. Gynecol. 186:1035–40 9. Buchbinder A, Sibai BM, Caritis S, et al. 2002. Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild preeclampsia. Am. J. Obstet. Gynecol. 186:66–71 10. Khosla UM, Zharikov S, Finch JL, et al. 2005. Hyperuricemia induces endothelial dysfunction. Kidney Int. 67:1739–42 11. Thadhani RI, Johnson RJ, Karumanchi SA. 2005. Hypertension during pregnancy: a disorder begging for pathophysiological support. Hypertension 46:1250–51 12. Roberts JM, Bodnar LM, Lain KY, et al. 2005. Uric acid is as important as proteinuria in identifying fetal risk in women with gestational hypertension. Hypertension 46:1263–69 13. Thangaratinam S, Ismail K, Sharp S, et al. 2006. Accuracy of serum uric acid in predicting complications of pre-eclampsia: a systematic review. Br. J. Obstet. Gynaecol. 113:369–78 14. Sibai BM. 2005. Diagnosis, prevention, and management of eclampsia. Obstet. Gynecol. 105:402–10 www.annualreviews.org • Preeclampsia and Angiogenic Imbalance
73
ARI
7 December 2007
12:25
15. Altman D, Carroli G, Duley L, et al. 2002. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebocontrolled trial. Lancet 359:1877–90 16. Nisell H, Lintu H, Lunell NO, et al. 1995. Blood pressure and renal function seven years after pregnancy complicated by hypertension. Br. J. Obstet. Gynaecol. 102:876–81 17. Ray JG, Vermeulen MJ, Schull MJ, et al. 2005. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet 366:1797–803 18. Irgens HU, Reisaeter L, Irgens LM, et al. 2001. Long-term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ 323:1213–17 19. Vikse BE, Irgens LM, Bostad L, et al. 2006. Adverse perinatal outcome and later kidney biopsy in the mother. J. Am. Soc. Nephrol. 17:837–45 20. Shembrey MA, Noble AD. 1995. An instructive case of abdominal pregnancy. Aust. N. Z. J. Obstet. Gynaecol. 35:220–21 21. Matsuo K, Kooshesh S, Dinc M, et al. 2007. Late postpartum eclampsia: report of two cases managed by uterine curettage and review of the literature. Am. J. Perinatol. 24(4):257–66 22. Salafia CM, Pezzullo JC, Ghidini A, et al. 1998. Clinical correlations of patterns of placental pathology in preterm pre-eclampsia. Placenta 19:67–72 23. North RA, Ferrier C, Long D, et al. 1994. Uterine artery Doppler flow velocity waveforms in the second trimester for the prediction of preeclampsia and fetal growth retardation. Obstet. Gynecol. 83:378–86 24. Palmer SK, Moore LG, Young D, et al. 1999. Altered blood pressure course during normal pregnancy and increased preeclampsia at high altitude (3100 meters) in Colorado. Am. J. Obstet. Gynecol. 180:1161–68 25. Zamudio S, Wu Y, Ietta F, et al. 2007. Human placental hypoxia-inducible factor-1α expression correlates with clinical outcomes in chronic hypoxia in vivo. Am. J. Pathol. 170:2171–79 26. Soleymanlou N, Jurisica I, Nevo O, et al. 2005. Molecular evidence of placental hypoxia in preeclampsia. J. Clin. Endocrinol. Metab. 90:4299–308 27. Makris A, Thornton C, Thompson J, et al. 2007. Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int. 71(10):997–84 28. Granger JP, LaMarca BB, Cockrell K, et al. 2006. Reduced uterine perfusion pressure (RUPP) model for studying cardiovascular-renal dysfunction in response to placental ischemia. Methods Mol. Med. 122:383–92 29. Meekins JW, Pijnenborg R, Hanssens M, et al. 1994. A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. Br. J. Obstet. Gynaecol. 101:669–74 30. Zhou Y, Fisher SJ, Janatpour M, et al. 1997. Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion? J. Clin. Invest. 99:2139–51 31. Zhou Y, Damsky CH, Fisher SJ. 1997. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? J. Clin. Invest. 99:2152–64 32. Calesson-Welsh L. 1999. Vascular Endothelial Growth Factors, p. 123. Berlin: Springer 33. Zhou Y, McMaster M, Woo K, et al. 2002. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am. J. Pathol. 160:1405–23
Annu. Rev. Med. 2008.59:61-78. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-05
74
Maynard
·
Epstein
·
Karumanchi
Annu. Rev. Med. 2008.59:61-78. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-05
ARI
7 December 2007
12:25
34. Caniggia I, Mostachfi H, Winter J, et al. 2000. Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFbeta(3). J. Clin. Invest. 105:577–87 35. van Dijk M, Mulders J, Poutsma A, et al. 2005. Maternal segregation of the Dutch preeclampsia locus at 10q22 with a new member of the winged helix gene family. Nat. Genet. 37:514–19 36. Roberts JM, Taylor RN, Musci TJ, et al. 1989. Preeclampsia: an endothelial cell disorder. Am. J. Obstet. Gynecol. 161:1200–4 37. Roberts JM, Gammill HS. 2005. Preeclampsia: recent insights. Hypertension 46:1243–49 38. Leik CE, Walsh SW. 2004. Neutrophils infiltrate resistance-sized vessels of subcutaneous fat in women with preeclampsia. Hypertension 44:72–77 39. Easterling TR. 1992. The maternal hemodynamics of preeclampsia. Clin. Obstet. Gynecol. 35:375–86 40. Khan F, Belch JJ, MacLeod M, et al. 2005. Changes in endothelial function precede the clinical disease in women in whom preeclampsia develops. Hypertension 46:1123–28 41. Duckitt K, Harrington D. 2005. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 330:565 42. Strevens H, Wide-Swensson D, Hansen A, et al. 2003. Glomerular endotheliosis in normal pregnancy and pre-eclampsia. Br. J. Obstet. Gynaecol. 110:831–36 43. Schwartz RB, Feske SK, Polak JF, et al. 2000. Preeclampsia-eclampsia: clinical and neuroradiographic correlates and insights into the pathogenesis of hypertensive encephalopathy. Radiology 217:371–76 44. Hinchey J, Chaves C, Appignani B, et al. 1996. A reversible posterior leukoencephalopathy syndrome. N. Engl. J. Med. 334:494–500 45. Ozcan C, Wong SJ, Hari P. 2006. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N. Engl. J. Med. 354:980–82 46. Maynard SE, Min JY, Merchan J, et al. 2003. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111:649–58 47. Ahmad S, Ahmed A. 2004. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ. Res. 95:884–91 48. Kendall RL, Thomas KA. 1993. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. USA 90:10705– 9 49. Wathen KA, Tuutti E, Stenman UH, et al. 2006. Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation. J. Clin. Endocrinol. Metab. 91:180–84 50. McKeeman GC, Ardill JE, Caldwell CM, et al. 2004. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am. J. Obstet. Gynecol. 191:1240–46 51. Levine RJ, Maynard SE, Qian C, et al. 2004. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350:672–83 52. Hertig A, Berkane N, Lefevre G, et al. 2004. Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. Clin. Chem. 50:1702–3 53. Chaiworapongsa T, Romero R, Espinoza J, et al. 2004. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am. J. Obstet. Gynecol. 190:1541–47 www.annualreviews.org • Preeclampsia and Angiogenic Imbalance
75
ARI
7 December 2007
12:25
54. Hirtenlehner K, Pollheimer J, Lichtenberger C, et al. 2003. Elevated serum concentrations of the angiogenesis inhibitor endostatin in preeclamptic women. J. Soc. Gynecol. Invest. 10:412–17 55. Venkatesha S, Toporsian M, Lam C, et al. 2006. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat. Med. 12:642–49 56. Levine RJ, Lam C, Qian C, et al. 2006. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N. Engl. J. Med. 355:992–1005 57. Esser S, Wolburg K, Wolburg H, et al. 1998. Vascular endothelial growth factor induces endothelial fenestrations in vitro. J. Cell Biol. 140:947–59 58. Maharaj ASR, Saint-Geniez M, Maldonado AE, et al. 2006. Vascular endothelial growth factor localization in the adult. Am. J. Pathol. 168:639–48 59. Sugimoto H, Hamano Y, Charytan D, et al. 2003. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J. Biol. Chem. 278:12605–8 60. Kitamoto Y, Takeya M, Tokunaga H, et al. 2001. Glomerular endothelial cells are maintained by vascular endothelial growth factor in the adult kidney. Tohoku. J. Exp. Med. 195:43–54 61. Eremina V, Sood M, Haigh J, et al. 2003. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J. Clin. Invest. 111:707– 16 62. Zhu X, Wu S, Dahut WL, et al. 2007. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am. J. Kidney Dis. 49:186–93 63. Aagaard-Tillery KM, Stoddard GJ, Holmgren C, et al. 2006. Preeclampsia and subsequent risk of cancer in Utah. Am. J. Obstet. Gynecol. 195:691–99 64. Carmeliet P, Moons L, Luttun A, et al. 2001. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 7:575–83 65. Luttun A, Tjwa M, Moons L, et al. 2002. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat. Med. 8:831–40 66. Wolf M, Shah A, Lam C, et al. 2005. Circulating levels of the antiangiogenic marker sFLT-1 are increased in first vs second pregnancies. Am. J. Obstet. Gynecol. 193:16–22 67. Maynard SE, Moore-Simas T, Solitro M, et al. 2007. Circulating angiogenic factors in singleton vs. multiple gestation pregnancies. Am. J. Obstet. Gyencol. 197:244.e1–8 68. Bdolah Y, Palomaki GE, Yaron Y, et al. 2006. Circulating angiogenic proteins in trisomy 13. Am. J. Obstet. Gynecol. 194:239–45 69. Belgore FM, Lip GY, Blann AD. 2000. Vascular endothelial growth factor and its receptor, Flt-1, in smokers and nonsmokers. Br. J. Biomed. Sci. 57:207–13 70. Cudmore M, Ahmad S, Al-Ani B, et al. 2007. Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation 115:1789–97 71. Tsatsaris V, Goffin F, Munaut C, et al. 2003. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J. Clin. Endocrinol. Metab. 88:5555–63 72. Stepan H, Kramer T, Faber R. 2007. Maternal plasma concentrations of soluble endoglin in pregnancies with intrauterine growth restriction. J. Clin. Endocrinol. Metab. 92(7):2831– 34
Annu. Rev. Med. 2008.59:61-78. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-05
76
Maynard
·
Epstein
·
Karumanchi
Annu. Rev. Med. 2008.59:61-78. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-05
ARI
7 December 2007
12:25
73. Crispi F, Dominguez C, Llurba E, et al. 2006. Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. Am. J. Obstet. Gynecol. 195:201–7 74. Shibata E, Rajakumar A, Powers RW, et al. 2005. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestationalage neonates: relationship to circulating placental growth factor. J. Clin. Endocrinol. Metab. 90:4895–903 75. Wallukat G, Homuth V, Fischer T, et al. 1999. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J. Clin. Invest. 103:945–52 76. Xia Y, Wen H, Bobst S, et al. 2003. Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells. J. Soc. Gynecol. Invest. 10:82–93 77. Fu ML, Herlitz H, Schulze W, et al. 2000. Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension. J. Hypertens. 18:945–53 78. Abdalla S, Lother H, el Massiery A, et al. 2001. Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat. Med. 7:1003–9 79. Poston L, Briley AL, Seed PT, et al. 2006. Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP Trial): randomised placebo-controlled trial. Lancet 367:1145– 54 80. Redman CW, Sargent IL. 2005. Latest advances in understanding preeclampsia. Science 308:1592–94 81. Tubbergen P, Lachmeijer AMA, Althuisius SM, et al. 1999. Change in paternity: a risk factor for preeclampsia in multiparous women? J. Reprod. Immunol. 45:81–88 82. Klonoff-Cohen HS, Savitz DA, Cefalo RC, et al. 1989. An epidemiologic study of contraception and preeclampsia. JAMA 262:3143–47 83. Wang JX, Knottnerus A-M, Schuit G, et al. 2002. Surgically obtained sperm, and risk of gestational hypertension and pre-eclampsia. Lancet 359:673–74 84. Hanna J, Goldman-Wohl D, Hamani Y, et al. 2006. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat. Med. 12:1065–74 85. Hiby SE, Walker JJ, O’Shaughnessy KM, et al. 2004. Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J. Exp. Med. 200:957–65 86. Conde-Agudelo A, Villar J, Lindheimer M. 2004. World Health Organization systematic review of screening tests for preeclampsia. Obstet. Gynecol. 104:1367–91 87. Park CW, Park JS, Shim SS, et al. 2005. An elevated maternal plasma, but not amniotic fluid, soluble fms-like tyrosine kinase-1 (sFlt-1) at the time of mid-trimester genetic amniocentesis is a risk factor for preeclampsia. Am. J. Obstet. Gynecol. 193:984–89 88. Powers RW, Roberts JM, Cooper KM, et al. 2005. Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia. Am. J. Obstet. Gynecol. 193:185– 91 89. Thadhani R, Mutter WP, Wolf M, et al. 2004. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J. Clin. Endocrinol. Metab. 89:770–5 90. Taylor RN, Grimwood J, Taylor RS, et al. 2003. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am. J. Obstet. Gynecol. 188:177–82 91. Polliotti BM, Fry AG, Saller DN, et al. 2003. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet. Gynecol. 101:1266–74 www.annualreviews.org • Preeclampsia and Angiogenic Imbalance
77
ARI
7 December 2007
12:25
92. Levine RJ, Thadhani R, Qian C, et al. 2005. Urinary placental growth factor and risk of preeclampsia. JAMA 293:77–85 93. Buhimschi CS, Norwitz ER, Funai E, et al. 2005. Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia. Am. J. Obstet. Gynecol. 192:734–41 94. Espinoza J, Romero R, Nien JK, et al. 2007. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am. J. Obstet. Gynecol. 196:326 e1–13 95. Vatten LJ, Eskild A, Nilsen TI, et al. 2007. Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am. J. Obstet. Gynecol. 196:239 e1–6 96. Moore Simas T, Solitro M, Nadkarni S, et al. 2007. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am. J. Obstet. Gynecol. 197:244.e1–244.e8 96a. Li Z, Zhang Y, Ying Ma J, et al. 2007. Recombinant vascular endothial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 50:686–92 97. Lam C, Lim KH, Karumanchi SA. 2005. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension 46:1077–85 98. Karumanchi SA, Maynard SE, Stillman IE, et al. 2005. Preeclampsia: a renal perspective. Kidney Int. 67:2101–13 99. Karumanchi SA, Epstein FH. 2007. Placental ischemia and soluble fms-like tyrosine kinase 1—cause or consequence of preeclampisa? Kidney Int. 71(10):959–61
Annu. Rev. Med. 2008.59:61-78. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-05
78
Maynard
·
Epstein
·
Karumanchi
AR334-FM
ARI
18 December 2007
17:20
Annual Review of Medicine
Annu. Rev. Med. 2008.59:61-78. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Contents
Volume 59, 2008
The FDA Critical Path Initiative and Its Influence on New Drug Development Janet Woodcock and Raymond Woosley p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p1 Reversing Advanced Heart Failure by Targeting Ca2+ Cycling David M. Kaye, Masahiko Hoshijima, and Kenneth R. Chien p p p p p p p p p p p p p p p p p p p p p p p p 13 Tissue Factor and Factor VIIa as Therapeutic Targets in Disorders of Hemostasis Ulla Hedner and Mirella Ezban p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 29 Therapy of Marfan Syndrome Daniel P. Judge and Harry C. Dietz p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 43 Preeclampsia and Angiogenic Imbalance Sharon Maynard, Franklin H. Epstein, and S. Ananth Karumanchi p p p p p p p p p p p p p p p p p 61 Management of Lipids in the Prevention of Cardiovascular Events Helene Glassberg and Daniel J. Rader p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 79 Genetic Susceptibility to Type 2 Diabetes and Implications for Antidiabetic Therapy Allan F. Moore and Jose C. Florez p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 95 Array-Based DNA Diagnostics: Let the Revolution Begin Arthur L. Beaudet and John W. Belmont p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p113 Inherited Mitochondrial Diseases of DNA Replication William C. Copeland p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p131 Childhood Obesity: Adrift in the “Limbic Triangle” Michele L. Mietus-Snyder and Robert H. Lustig p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p147 Expanded Newborn Screening: Implications for Genomic Medicine Linda L. McCabe and Edward R.B. McCabe p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p163 Is Human Hibernation Possible? Cheng Chi Lee p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p177 Advance Directives Linda L. Emanuel p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p187 v
AR334-FM
ARI
18 December 2007
17:20
Genetic Determinants of Aggressive Breast Cancer Alejandra C. Ventura and Sofia D. Merajver p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p199 A Role for JAK2 Mutations in Myeloproliferative Diseases Kelly J. Morgan and D. Gary Gilliland p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p213 Appropriate Use of Cervical Cancer Vaccine Gregory D. Zimet, Marcia L. Shew, and Jessica A. Kahn p p p p p p p p p p p p p p p p p p p p p p p p p p p p p223 A Decade of Rituximab: Improving Survival Outcomes in Non-Hodgkin’s Lymphoma Arturo Molina p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p237
Annu. Rev. Med. 2008.59:61-78. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Nanotechnology and Cancer James R. Heath and Mark E. Davis p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p251 Cancer Epigenetics: Modifications, Screening, and Therapy Einav Nili Gal-Yam, Yoshimasa Saito, Gerda Egger, and Peter A. Jones p p p p p p p p p p p p267 T Cells and NKT Cells in the Pathogenesis of Asthma Everett H. Meyer, Rosemarie H. DeKruyff, and Dale T. Umetsu p p p p p p p p p p p p p p p p p p p p281 Complement Regulatory Genes and Hemolytic Uremic Syndromes David Kavanagh, Anna Richards, and John Atkinson p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p293 Mesenchymal Stem Cells in Acute Kidney Injury Benjamin D. Humphreys and Joseph V. Bonventre p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p311 Asthma Genetics: From Linear to Multifactorial Approaches Stefano Guerra and Fernando D. Martinez p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p327 The Effect of Toll-Like Receptors and Toll-Like Receptor Genetics in Human Disease Stavros Garantziotis, John W. Hollingsworth, Aimee K. Zaas, and David A. Schwartz p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p343 Advances in Antifungal Therapy Carole A. Sable, Kim M. Strohmaier, and Jeffrey A. Chodakewitz p p p p p p p p p p p p p p p p p p361 Herpes Simplex: Insights on Pathogenesis and Possible Vaccines David M. Koelle and Lawrence Corey p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p381 Medical Management of Influenza Infection Anne Moscona p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p397 Bacterial and Fungal Biofilm Infections A. Simon Lynch and Gregory T. Robertson p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p415 EGFR Tyrosine Kinase Inhibitors in Lung Cancer: An Evolving Story Lecia V. Sequist and Thomas J. Lynch p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p429 Adaptive Treatment Strategies in Chronic Disease Philip W. Lavori and Ree Dawson p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p443 vi
Contents
AR334-FM
ARI
18 December 2007
17:20
Antiretroviral Drug–Based Microbicides to Prevent HIV-1 Sexual Transmission Per Johan Klasse, Robin Shattock, and John P. Moore p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p455 The Challenge of Hepatitis C in the HIV-Infected Person David L. Thomas p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p473 Hide-and-Seek: The Challenge of Viral Persistence in HIV-1 Infection Luc Geeraert, Günter Kraus, and Roger J. Pomerantz p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p487
Annu. Rev. Med. 2008.59:61-78. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Advancements in the Treatment of Epilepsy B.A. Leeman and A.J. Cole p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p503 Indexes Cumulative Index of Contributing Authors, Volumes 55–59 p p p p p p p p p p p p p p p p p p p p p p p p525 Cumulative Index of Chapter Titles, Volumes 55–59 p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p529 Errata An online log of corrections to Annual Review of Medicine articles may be found at http://med.annualreviews.org/errata.shtml
Contents
vii
ANRV334-ME59-06
ARI
7 December 2007
12:29
Annu. Rev. Med. 2008.59:79-94. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Management of Lipids in the Prevention of Cardiovascular Events Helene Glassberg1 and Daniel J. Rader2 1
Division of Cardiovascular Medicine, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104; email:
[email protected]
2
Cardiovascular Institute; Institute for Diabetes, Obesity and Metabolism; and Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104; email:
[email protected]
Annu. Rev. Med. 2008. 59:79–94
Key Words
First published online as a Review in Advance on October 15, 2007
cholesterol, triglycerides, high-density lipoproteins, cardiovascular risk
The Annual Review of Medicine is online at http://med.annualreviews.org This article’s doi: 10.1146/annurev.med.59.121206.112237 c 2008 by Annual Reviews. Copyright All rights reserved 0066-4219/08/0218-0079$20.00
Abstract Lipid-modifying therapy has been proven to significantly reduce cardiovascular events and total mortality. Most of the data have come from statin trials. Statin therapy is generally well-tolerated and safe, and for patients who are at higher than average risk of cardiovascular disease, the benefit of lipid-modifying therapy far exceeds the risk. Careful risk assessment is a critical component of effective lipidmodifying therapy. In the foreseeable future, low-density lipoprotein cholesterol (LDL-C) will remain the primary therapeutic target, and combination therapy is likely to become the norm. The major questions are how low to treat and how to achieve increasingly aggressive targets in lipid-lowering therapy. Many patients on LDL-lowering therapy continue to have abnormalities of the triglyceride–highdensity lipoprotein (TG-HDL) axis, so additional drug therapy is often considered for such patients. In this review, we briefly discuss new developments in cardiovascular risk assessment, then discuss recent developments in treatment to reduce LDL, and finally discuss current concepts regarding therapy targeting the TG-HDL axis.
79
ANRV334-ME59-06
ARI
7 December 2007
12:29
INTRODUCTION CAD: coronary artery disease
Annu. Rev. Med. 2008.59:79-94. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
HDL-C: high-density lipoprotein cholesterol TG-HDL axis: balance of triglycerides and HDL-C. Even with successful LDL-lowering therapy, many patients have residual high triglyceride, low HDL-C, or both CHD: coronary heart disease FRS: Framingham Risk Score
Dyslipidemia is an important risk factor for coronary artery disease (CAD) and other atherosclerotic vascular disease. Elevated levels of atherogenic lipoproteins [low-density lipoproteins (LDL) and very-low-density lipoproteins (VLDL)] and reduced levels of antiatherogenic lipoproteins [high-density lipoproteins (HDL)] are targets for therapeutic intervention. It has been clearly demonstrated that lowering LDL cholesterol (LDLC) levels with diet and drugs significantly reduces the risk of cardiovascular events and total mortality, and guidelines for treatment to reduce LDL-C have become increasingly aggressive, particularly in high-risk patients. Evidence supporting treatment to lower triglycerides or raise HDL-C levels is much less abundant, and formal guidelines are nonexistent. The decision to employ drug therapy targeted to the “TG-HDL axis” is left to the clinical judgment of the physician. Accurate risk assessment is imperative so that patients receive an appropriate level of lipid-modifying drug therapy. In this review, we focus first on cardiovascular risk assessment as a critical determinant of the intensity of lipid-modifying therapy. We then discuss recent developments in treatment to reduce LDL and other atherogenic lipoproteins. Finally, we discuss current concepts regarding utilization of therapy that targets the TG-HDL axis.
SCREENING FOR ALL ADULTS The Adult Treatment Panel (ATP) III guidelines of the National Cholesterol Education Program (NCEP) of the National Heart Lung and Blood Institute (1) recommended that all adults over age 20 undergo a fasting full lipid panel to evaluate triglycerides, total cholesterol, HDL-C, and calculated LDL-C. [The LDL-C is calculated from the other lipid values using the following equation: LDL-C = total cholesterol – (triglycerides/5) – HDLC.] The guidelines also recommended the 80
Glassberg
·
Rader
clinical use of the “non-HDL-C” level as a secondary target of therapy in patients with fasting triglyceride levels >200 mg/dl. The guidelines strongly emphasize risk assessment and stratification as a guide to intensity of lipid-modifying drug therapy.
CARDIOVASCULAR RISK ASSESSMENT All decisions regarding lipid management are conditioned by the level of cardiovascular risk, including short-term, 10-year, and lifetime risk. Decisions such as whether to initiate lipid-modifying drug therapy, what target to set for the LDL-C level, and whether to employ combination therapy targeted to the TGHDL axis are all influenced by the clinician’s assessment of cardiovascular risk. The key categories of cardiovascular risk, as established by the NCEP ATPIII guidelines (1) and further modified by a subsequent update (2), are as follows: 1. Recent acute coronary syndrome 2. Pre-existing stable atherosclerotic cardiovascular disease 3. Diabetes mellitus, considered a “coronary heart disease (CHD) risk equivalent” condition 4. Absolute 10-year risk of a cardiovascular event >20% as determined by the Framingham Risk Score (FRS), also a CHD risk equivalent condition 5. Absolute FRS 10-year risk of 10%– 20%, considered “moderate risk” 6. Absolute FRS 10-year risk of <10%, considered “low risk” In addition, a very high LDL-C level, such as that seen in heterozygous familial hypercholesterolemia, confers a very high lifetime risk even though the FRS 10-year risk may be low, especially in a younger individual. Patients diagnosed with the metabolic syndrome are also at higher risk; therapeutic lifestyle changes and possibly more aggressive drug therapy are appropriate for them. The ATPIII guidelines also introduced diagnostic criteria for the metabolic syndrome,
Annu. Rev. Med. 2008.59:79-94. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-06
ARI
7 December 2007
12:29
a common condition usually associated with obesity. Indeed, the five criteria for diagnosis of metabolic syndrome include increased waist circumference. Other criteria are elevated blood pressure, elevated triglycerides, low HDL-C, and impaired fasting glucose (1). Patients who have at least three of the five criteria can be formally diagnosed as having the metabolic syndrome. More than one third of the adult US population meets sufficient criteria for diagnosis (3). Subsequent studies have established that the diagnosis of metabolic syndrome confers an increased cardiovascular risk above and beyond the individual traditional risk factors and the FRS (4, 5). Thus, clinicians should make an effort to formally diagnose the metabolic syndrome, and when treating dyslipidemia in patients who are so diagnosed, clinicians should bear in mind their elevated cardiovascular risk (see below). The FRS has limitations. It does not take family history into account, and thus a strong family history of premature CHD should be considered an important risk factor even if the FRS is low. Furthermore, a variety of other biomarkers have been proposed to add value beyond traditional risk factors in predicting future coronary events. Perhaps the most celebrated of these is C reactive protein (CRP) (6); others include apolipoprotein B (apoB), lipoprotein(a) [Lp(a)], lipoprotein particle size and number, and lipoproteinassociated phospholipase A2 (Lp-PLA2). Selective use of such tests may help to identify additional high-risk individuals who should be considered for drug therapy when their LDL-C is in a “gray zone.” Recognizing the need for an updated risk scoring system, Ridker and colleagues recently proposed the Reynolds Risk Score, which includes family history and CRP. Using this tool, they reclassified 40%–50% of women at intermediate risk into higher- or lower-risk categories (7). Whether this scoring system will be more widely adopted remains to be seen, but the concepts and data on which it is based are valid.
The use of noninvasive imaging of atherosclerotic disease is of conceptual interest (8, 9). Abundant data indicate that the carotid intimal medial thickness (IMT), measured by ultrasound, is predictive of coronary events. Accumulating data suggest that coronary artery calcification, measured by computed tomography, is also predictive, independent of traditional risk factors. The use of noninvasive imaging as a tool for cardiovascular risk assessment is likely to grow over the next several years.
REDUCING LDL-C The evidence supporting therapy to reduce LDL-C levels in the interest of improving cardiovascular outcomes and mortality is overwhelming. Lower is better—but how low is low, and how do we get there?
“Lower is Better” Statin trials have provided the major base of evidence for the benefit of LDL-lowering therapy; prior to the introduction of statins (HMG-CoA reductase inhibitors), the evidence was encouraging but limited. Placebocontrolled statin trials have consistently shown a significant reduction of cardiovascular events, and benefit extends even to patients whose LDL-C levels are average or below average. This was most strikingly demonstrated by the Heart Protection Study (10), which enrolled 20,536 subjects aged 40 to 80 years old with established CHD, other atherosclerotic vascular disease, or diabetes; the only lipid-related entry criterion was a total cholesterol level >135 mg/dl. Treatment with simvastatin 40 mg was associated with a highly significant 24% reduction in major coronary events, 25% reduction in stroke, and 13% reduction in total mortality. Benefit of simvastatin therapy was evident regardless of baseline cholesterol, even among the group with LDL-C <100 mg/dl at baseline. Other highly positive placebo-controlled statin trials in high-risk groups with average
www.annualreviews.org • Lipid Management and Cardiovascular Events
81
ARI
7 December 2007
12:29
LDL-C levels were the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm (ASCOT-LLA) with atorvastatin, which enrolled hypertensive patients with at least three other risk factors (11), and the Collaborative Atorvastatin Diabetes Study (CARDS), which enrolled type 2 diabetic patients (12). In a new generation of trials, a more intensively treated group was compared to a less intensively treated group. In the chronic CAD setting, the Treat to New Targets (TNT) trial (13) compared atorvastatin 10 mg or 80 mg daily in patients with stable CAD and LDL-C <130 mg/dl. Atorvastatin 80 mg (mean ontreatment LDL-C 77 mg/dl) was associated with a significant 22% reduction in major cardiovascular events compared with atorvastatin 10 mg (mean LDL-C 101 mg/dl). In the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) trial, simvastatin 20 mg was compared to atorvastatin 80 mg in stable CAD patients. Although the 11% decrease in the primary composite endpoint was not statistically significant ( p = 0.07), there was a highly significant reduction in secondary coronary disease endpoints (14). In the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE-IT) study in patients presenting with acute coronary syndromes, more intensive lowering of LDL (mean on-treatment LDL-C 62 mg/dl) with atorvastatin 80 mg was superior to less intensive lowering with pravastatin 40 mg (mean on-treatment LDL-C 95 mg/dl) at reducing death, myocardial infarction, or unstable angina requiring hospitalization (15). The Aggrastat to Zocor (A to Z) trial, which randomized acute coronary syndrome patients to simvastatin 40 mg versus placebo for four months, followed by titration to simvastatin 80 mg versus simvastatin, failed to demonstrate a significant difference between the two arms with regard to the primary endpoint, but a significant reduction in cardiovascular events during the follow-up period starting at four months was demonstrated (16). In the aggregate, these studies (10–16) reinforced the concept that “lower is better”
Annu. Rev. Med. 2008.59:79-94. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-06
82
Glassberg
·
Rader
with regard to reducing LDL-C, especially in patients at higher risk. The most recent full ATPIII guidelines, in 2001, preceded these studies, but an update was issued in 2004 (2) (Table 1) after some of them had been reported. The updated report recommended a new optional LDL target of <70 mg/dl for patients with established atherosclerotic vascular disease or diabetes, and an optional LDL target of <100 mg/dl for patients with intermediate risk (two or more risk factors and a FRS of 10%–20%). These optional guidelines have been rapidly adopted by cardiologists and a majority of internists. Indeed, it is considered “state of the art” preventive care to attempt to reduce LDL-C to <70 mg/dl in patients with atherosclerotic vascular disease or diabetes, and to <100 mg/dl in the majority of patients with two or more risk factors and/or a FRS >10%. Current debate centers on (a) whether LDL-C should be reduced even further than 70 mg/dl in very high risk patients, (b) whether even moderaterisk patients should be reduced to LDL-C <70 mg/dl, (c) which patients with average cholesterol levels should be started on statin therapy, and (d ) how early to initiate statin therapy. The finding that genetically low LDL-C levels (due to loss-of-function mutations in the PCSK9 gene) confer an eightfold reduction in lifetime risk of CHD (17) provided strong genetic evidence to support early and substantial LDL-C lowering.
Strategies for Achieving Aggressive LDL-C Targets Despite the remarkable consensus that highrisk patients should be treated aggressively, a substantial number of patients do not achieve their LDL-C goals. Although this failure is partly due to poor compliance, it is also due to the difficulty of achieving aggressive LDLC goals, particularly <70 mg/dl. Therapeutic lifestyle changes are an important component in the reduction of LDLC levels. Dietary saturated fat and cholesterol should be restricted; plant stanol and sterol
ANRV334-ME59-06
ARI
7 December 2007
12:29
Table 1 ATPIII LDL-C goals and cutpoints for therapeutic lifestyle changes (TLC) and drug therapy in different risk categories and proposed modifications based on recent clinical trial evidence Risk category CHDa
LDL-C goal equivalentsb
Initiate TLC mg/dlh
Consider drug therapyi ≥100 mg/dlj (<100 mg/dl: consider drug options)i
<100 mg/dl (optional goal: <70 mg/dl)f
≥100
Moderately high risk: 2+ risk factorsc (10-year risk 10% to 20%)d
<130 mg/dlg
≥130 mg/dlh
≥130 mg/dl (100–129 mg/dl; consider drug options)k
Moderate risk: 2+ risk factorsc (10-year risk <10%)d
<130 mg/dl
≥130 mg/dl
≥160 mg/dl
Lower risk: 0–1 risk factore
<160 mg/dl
≥160 mg/dl
≥190 mg/dl (160–189 mg/dl: LDL-lowering drug optional)
High risk: or CHD risk (10-year risk >20%)
Annu. Rev. Med. 2008.59:79-94. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
a
CHD (coronary heart disease) includes history of myocardial infarction, unstable angina, stable angina, coronary artery procedures (angioplasty or bypass surgery), or evidence of clinically significant myocardial ischemia. b CHD risk equivalents include clinical manifestations of noncoronary forms of atherosclerotic disease [peripheral arterial disease, abdominal aortic aneurysm, and carotid artery disease (transient ischemic attacks or stroke of carotid origin or >50% obstruction of a carotid artery)], diabetes, and 2+ risk factors with 10-year risk for hard CHD >20%. c Risk factors include cigarette smoking, hypertension (blood pressure ≥140/90 mm Hg or on antihypertensive medication), low HDL cholesterol (<40 mg/dl), family history of premature CHD (CHD in male first-degree relative <55 years of age; CHD in female first-degree relative <65 years of age), and age (men ≥45 years; women ≥55 years). d Electronic 10-year risk calculators are available at http://www.nhlbi.nih.gov/guidelines/cholesterol. e Almost all people with 0–1 risk factor have a 10-year risk <10%, and 10-year risk assessment in people at this risk level is thus not necessary. f Very high risk favors the optional LDL-C goal of <70 mg/dl, and in patients with high triglycerides, non-HDL-C <100 mg/dl. g Optional LDL-C goal <100 mg/dl. h Any person at high risk or moderately high risk who has lifestyle-related risk factors (e.g., obesity, physical inactivity, elevated triglyceride, low HDL-C, or metabolic syndrome) is a candidate for TLC to modify these risk factors regardless of LDL-C level. i When LDL-lowering drug therapy is employed, it is advised that intensity of therapy be sufficient to achieve at least a 30%–40% reduction in LDL-C levels. j If baseline LDL-C is <100 mg/dl, institution of an LDL-lowering drug is a therapeutic option on the basis of available clinical trial results. If a high-risk person has high triglycerides or low HDL-C, combining a fibrate or nicotinic acid with an LDL-lowering drug can be considered. k For moderately high-risk persons, when LDL-C level is 100–129 mg/dl at baseline or with TLC, initiation of an LDL-lowering drug to achieve an LDL-C level <100 mg/dl is a therapeutic option on the basis of available clinical trial results.
esters, psyllium, soy protein, and Chinese red yeast rice (which contains lovastatin) can all have modest cholesterol-lowering effects. Most other herbal approaches, such as ingestion of garlic and guggulipid, have not been shown to reduce LDL-C. No controlled studies have been performed in which several of these nonpharmacologic options have been combined to evaluate their additive or synergistic effects. Most patients who are more than 5%–10% above their LDL-C goal will require drug therapy to reach it. Statins are the mainstay of therapy and are the first choice in patients who require LDL-C reduction. By inhibiting cholesterol synthesis in the liver, they bring about compensatory upregulation of the hep-
atic LDL receptor, thus promoting LDL removal by the liver and reduced plasma LDLC levels. The six statins currently available are lovastatin, pravastatin, simvastatin, fluvastatin, atorvastatin, and rosuvastatin. A substantial number of patients in clinical practice do not achieve their LDL-C goal with the dose of statin they are started on, and doubling the dose produces a fairly predictable further reduction of only 6% (18). The clinician should be prepared to titrate statins appropriately and to use combination therapy in order to achieve LDL-C goals. There is a surprising lack of statin titration in clinical practice, and even when statins are titrated the results are often disappointing. Many patients require combination therapy to
www.annualreviews.org • Lipid Management and Cardiovascular Events
83
ANRV334-ME59-06
ARI
7 December 2007
Annu. Rev. Med. 2008.59:79-94. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
CAI: cholesterol absorption inhibitor
84
12:29
reach their LDL-C goal. Several options exist; the most common current approach relies on a new class of drugs known as cholesterol absorption inhibitors (CAIs). The small intestine mediates the absorption of cholesterol, which is derived from both the diet (about one third) and the liver via the bile (about two thirds). Inhibiting absorption results in reduced hepatic cholesterol stores and thus upregulation of hepatic LDL receptor expression, which in turn leads to reduction in LDLC levels. The first CAI, ezetimibe, has been on the market since 2003 (19). Ezetimibe 10 mg was shown to inhibit cholesterol absorption in humans by almost 60% (20). On average, ezetemibe reduces LDL-C levels by ∼18% as monotherapy (21), and to a similar extent when combined with a statin (22). Ezetimibe is mostly used in combination with statins to further reduce LDL-C levels, and a fixeddose combination of simvastatin and ezetimibe is available. No cardiovascular outcome data have yet been reported with ezetimibe, but a study called IMPROVE-IT comparing ezetimibe-simvastatin to simvastatin alone is currently under way. A substantial minority of patients do not achieve their LDL-C goal even on statin plus CAI, particularly high-risk patients with a high baseline LDL-C whose LDL-C target is <70 mg/dl. Bile acid sequestrants (cholestyramine, colestipol, colesevalam), which have been available for several decades, bind bile acids in the intestine, prevent their reabsorption, and accelerate their loss in the feces. The liver diverts cholesterol to bile acid synthesis, resulting in decreased hepatic cholesterol and upregulation of hepatic LDL receptor expression. Bile acid sequestrants reduce LDLC by up to ∼20% and are clearly additive to statin therapy with regard to LDL reduction (23). As monotherapy, bile acid sequestrants have been shown to reduce clinical cardiovascular events. Their tendency to increase plasma triglyceride levels has limited their use, as has the need to swallow a large number of pills or drink a slurry of the drug. However, for patients on high-dose statin plus ezetimGlassberg
·
Rader
ibe who are not yet at their LDL target, the addition of a bile acid sequestrant should be considered. Statins are overall safe and generally welltolerated. Approximately 3%–5% of patients develop muscle fatigue or pain on statin therapy. There is a much smaller risk of severe myopathy, defined as muscle pain plus substantial creatinine kinase (CK) elevation. An even rarer but potentially life-threatening effect is rhabdomyolysis, defined as myopathy with renal involvement (24). The risk of myopathy and rhabdomyolysis increases in a dose-dependent fashion with statins. Risk factors for statin-associated myopathy include advanced age, female gender, low body weight, renal insufficiency, and occult hypothyroidism. An important risk factor is concomitant administration of drugs that interfere with the cytochrome P450 (particularly 3A4) metabolism of statins, such as erythromycin-type antibiotics, antifungal agents, immunosuppressive drugs, amiodarone, gemfibrozil, and HIV protease inhibitors. Routine measurement of serum CK is unnecessary. If a patient taking a statin complains of muscle pain, a normal CK level does not exclude the possibility that the symptoms are due to the drug. Conversely, an elevated CK in an asymptomatic patient on a statin does not necessarily mandate discontinuation. In clinical practice, the biggest issue regarding patients on statins is not myopathy but myalgias. The CK is usually normal, and the relationship to the statin is often uncertain. Nevertheless, myalgias drive many patients to decide they are unable to take statins. There is substantial art involved on the part of the clinician in working with patients who have had myalgias on a statin. This includes attempting to determine the character of the muscle pain and its temporal relationship to statin administration, as well as trying other statins at low doses and sometime creative regimens. In many cases, the myalgias do not recur on a different (or even the same) statin. However, a subset of patients have recurrent symptoms and are labeled statin-intolerant.
Annu. Rev. Med. 2008.59:79-94. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-06
ARI
7 December 2007
12:29
It is particularly difficult for such patients to reach their target LDL-C level. Of course, the generally well-tolerated CAI ezetimibe is useful in this setting, as are bile acid sequestrants. Niacin, discussed in the next section, could also be considered. Some patients cannot achieve their LDLC goal even with combination drug therapy at the maximal tolerated dose. A subset of them are statin-intolerant, and another subset simply cannot achieve the LDL-C goal, usually because of a genetic disorder. Partial ileal bypass was developed as a surgical procedure to decrease LDL-C levels in the 1960s. Similar to the mechanism of the bile acid sequestrants, partial ileal bypass interrupts the enterohepatic circulation of bile acids, resulting in upregulation of the hepatic LDL receptor. The clinical utility of partial ileal bypass at this time is limited to hypercholesterolemic patients with established CAD who are unable to tolerate standard lipid-lowering medications and who do not wish to have LDL apheresis. LDL apheresis is the preferred option for refractory or drug-resistant hypercholesterolemia. The patient’s plasma is passed over columns that selectively remove LDL; then the LDL-depleted plasma is returned to the patient (25). Most patients have it performed biweekly, although severely hypercholesterolemic patients may have it weekly. Clinical trials have indicated that LDL apheresis can retard progression or cause regression of CAD in patients with severe drugresistant hypercholesterolemia (26, 27), and have even suggested a decrease in clinical cardiovascular events (27, 28). LDL apheresis is approved by the US Food and Drug Administration (FDA) and is reimbursed by most insurance plans. Candidates for LDL apheresis are patients who, on maximal tolerated combination drug therapy, either have CHD and LDL-C >200 mg/dl or have no CHD and LDL-C >300 mg/dl. New LDL-lowering therapies are clearly needed for those patients unable to achieve aggressive LDL goals on existing therapies.
TARGETING THE TG-HDL AXIS WITH DRUG THERAPY This section addresses two questions. First, is the TG-HDL axis an appropriate target for drug therapy? And if so, how should therapy be approached?
Outcome Studies The most common dyslipidemia associated with increased CHD risk is elevated triglycerides accompanied by low HDL-C (5). Indeed, even after patients have been treated with LDL-lowering therapy, many have residual high triglyceride, low HDL-C, or both. Abnormalities of the TG-HDL axis in statintreated patients are predictive of recurrent cardiovascular events. For example, in the Scandinavian Simvastatin Survival Study, the subset of 458 patients with both high triglyceride (>159 mg/dl) and low HDL (<39 mg/dl) had the highest event rate: 36% over the course of the study (29). Thus, the issue of whether treatment targeted to the TGHDL axis, such as fibrates, niacin, or omega-3 fatty acids, will further reduce the residual risk compared to statin therapy alone is of critical importance. Unfortunately, to date the only data available are from monotherapy studies that were not performed on the background of statin therapy, although several relevant studies are ongoing. Fibric acid derivatives, or fibrates, are agonists of PPARα. They include clofibrate, gemfibrozil, fenofibrate, and bezafibrate. Fibrates have the greatest effect on lowering triglycerides (up to 40%) and can also modestly raise HDL-C (5%–20% depending on the triglyceride levels), but they have relatively minimal effects on LDL-C. Randomized controlled clinical trials suggest that fibrate monotherapy reduces cardiovascular events, particularly in patients with insulin resistance and abnormalities of the TG-HDL axis (30). The Helsinki Heart Study compared gemfibrozil 1200 mg to placebo in men with elevated non-HDL-C >200 mg/dl and demonstrated
www.annualreviews.org • Lipid Management and Cardiovascular Events
85
ARI
7 December 2007
12:29
a significant 34% reduction in combined fatal and nonfatal myocardial infarction (the primary endpoint) (31). The Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (VA-HIT) tested the benefit of gemfibrozil 1200 mg in men with CAD who had average LDL-C levels (mean 112 mg/dl) but low HDL-C levels (mean 32 mg/dl). VAHIT showed a 22% reduction in the primary endpoint (nonfatal myocardial infarction and coronary death) compared to placebo (32). The Bezafibrate Infarction Prevention trial in patients with established CAD, LDL-C <180 mg/dl, and HDL-C <45 mg/dl randomized to either bezafibrate 400 mg daily or placebo failed to demonstrate a significant reduction in the primary endpoint of fatal or nonfatal myocardial infarction, but a post hoc analysis in the subgroup with high baseline triglycerides (>200 mg/dl) suggested a significant (39%) reduction in events (33). Most recently, the FIELD trial assessed the effect of fenofibrate 200 mg in diabetic patients with or without known CAD and mean baseline lipid values of LDL-C 118 mg/dl, HDL-C 42 mg/dl, and triglycerides 153 mg/dl (34). There was a nonsignficant 11% reduction in the primary outcome of first myocardial infarction or CHD death, although the reduction in some secondary endpoints was significant. It has been postulated that the limited effect seen with fenofibrate was possibly due to a greater “drop-in” of statin therapy in the placebo group. Interestingly, there has never been a fibrate trial targeted specifically to individuals with elevated triglyceride levels, even though fibrates are most effective in reducing triglycerides. A large placebo-controlled clinical outcome study called the Action to Control Cardiovascular Risk in Diabetes (ACCORD) is testing the effect of fenofibrate on the background of statin therapy in patients with type 2 diabetes mellitus. This study is important because it more closely mirrors current clinical practice. Nicotinic acid, or niacin, is the most effective pharmacologic agent available for raising HDL-C (up to ∼30%), and it also reduces
Annu. Rev. Med. 2008.59:79-94. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-06
86
Glassberg
·
Rader
triglycerides and LDL-C (35). Niacin acts on a G protein–coupled receptor in adipocytes called GPR109A to reduce lipolysis and release of free fatty acids, which is thought to contribute to its lipid-modifying effects (36). The only large randomized controlled outcome trial to evaluate niacin has been the Coronary Drug Project, which demonstrated a modest benefit. Immediate-release niacin decreased the risk of coronary events (CHD death or nonfatal myocardial infarction) by 15% and decreased the risk of nonfatal myocardial infarction by 26% compared with placebo (37). It was associated with reduced mortality at 15 years of follow-up (38). Several other clinical trials have found niacin to be effective alone or in combination with other drugs in slowing atherosclerotic disease progression. The ARBITER trial evaluated the effect of the addition of Niaspan 1000 mg daily versus placebo upon carotid intimal medial thickness (IMT) among patients with CAD who were at LDL goal on statin therapy (39). Niaspan raised HDL-C by 25% after 24 months of treatment and blunted the progression of IMT. In the HDL Atherosclerosis Treatment Study (HATS), 160 patients with CAD who had low HDL-C and normal LDL-C were randomized to simvastatin plus niacin versus double placebo, and the active treatment group was found to have reduced progression of angiographic disease (40). The composite clinical endpoint was reduced by 89% in patients treated with simvastatinniacin compared with double placebo ( p = 0.04), but the sample size was too small to warrant definitive statements regarding outcomes. Furthermore, the lack of a statinonly comparator group makes it difficult to discern the contribution of the niacin to the angiographic and outcome benefit. Two large clinical outcome studies are ongoing in which the effects of adding extendedrelease niacin to a statin are being compared with the statin alone: the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes (AIM-HIGH)
Annu. Rev. Med. 2008.59:79-94. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-06
ARI
7 December 2007
12:29
and the Heart Protection Study 2/THRIVE. These studies represent how niacin is used in clinical practice and address the incremental benefit of adding niacin to statin therapy. Omega-3 fatty acids reduce triglyceride levels and appear to reduce cardiovascular risk (41, 42). Both epidemiologic and experimental studies have demonstrated the benefit of both dietary fish and concentrated fish oils in the reduction of CHD events. Abundant data demonstrate a reduction in cardiovascular risk associated with dietary fish intake (43). A large randomized controlled trial demonstrated that daily intake of 1 g of omega3 fatty acids was associated with a significant reduction in cardiovascular events (44). It is not clear that the cardioprotective effect of omega-3 fatty acids is related to their triglyceride-lowering effects, as 1 g has relatively little effect on triglyceride levels but was shown to be cardioprotective.
Current Approaches to Targeting the TG-HDL Axis Therapeutically The treatment guidelines developed by NCEP ATPIII remain focused on LDL-C as the primary target for therapy but acknowledge that elevated triglyceride and low HDL-C are risk factors, even when LDLC is “treated to goal.” However, as noted above, clinical trial data supporting the treatment of the TG-HDL axis are less compelling. The NCEP ATPIII guidelines introduced the concept of non-HDL-C as a secondary target of therapy in patients with triglyceride levels >200 mg/dl. Non-HDLC is calculated simply as the total cholesterol minus the HDL-C and is intended to represent all of the atherogenic apoB-containing lipoproteins. The goals for non-HDL-C are 30 mg/dl higher than the goals for LDL-C. Thus, many patients with abnormalities of the TG-HDL axis have elevated non-HDL-C levels and require intensification of therapy to reduce non-HDL-C to recommended goals. The guidelines acknowledge that HDL-C can be considered a target of therapy at the dis-
cretion of the clinician but do not set specific HDL targets. Management of the patient with abnormalities of the TG-HDL axis should focus initially on therapeutic lifestyle changes. In general, patients should be advised to limit total fat intake to 30% of total calories, and limit the intake of simple carbohydrates, while increasing complex carbohydrates such as whole grains, fruits, and vegetables. Lowcarbohydrate diets have been shown to reduce triglyceride by up to 20% and in some instances also raise HDL-C by up to 20% (45, 46). However, longer-term data investigating broader cardiovascular surrogates and clinical outcomes are needed before these types of diets can be broadly recommended. Aerobic exercise independent of weight loss has been shown to modestly reduce triglyceride and increase HDL-C levels in a dose-dependent fashion. Finally, weight loss is important: Estimates from meta-analyses suggest that for every 4.5 kg (∼10 lb) of stable weight reduction, triglyceride levels are reduced by 6 mg/dl and HDL-C levels are increased by ∼2 mg/dl (5). Patients with persistent abnormalities in the TG-HDL axis despite attempts at therapeutic lifestyle changes are often at a level of cardiovascular risk that merits consideration of drug therapy. Of course, if the LDLC is also elevated or the patient has established atherosclerotic cardiovascular disease or type 2 diabetes, such that therapy for primary LDL reduction is indicated as discussed above, the decision to initiate statin therapy is straightforward. However, many patients with dyslipidemia related to the TGHDL axis do not have especially elevated LDL-C, so they do not qualify for LDLlowering therapy based on existing guidelines. In this setting, the decision of whether to initiate drug therapy, and if so, with which drug class, is based on clinical judgment and not addressed by formal guidelines. If the fasting triglycerides are especially elevated in a range predisposing to risk of acute pancreatitis (triglyceride >1000 mg/dl), then therapeutic lifestyle changes accompanied by primary
www.annualreviews.org • Lipid Management and Cardiovascular Events
87
ARI
7 December 2007
12:29
triglyceride-lowering drug therapy, generally a fibrate or omega-3 fatty acids, are clearly indicated. However, when the triglycerides are not in this range, and particularly when they are in the 200–500 mg/dl range, there are relatively few clinical trials to guide selection of drug therapy. No outcomes trials have been performed in which hypertriglyceridemia was a criterion for entry, and in fact most of the statin trials, and even some of the fibrate trials, have excluded individuals with significantly elevated triglyceride levels. However, the strongest data to suggest appropriate treatment of such patients come from the statin trials. For example, a subgroup analysis of the Scandinavian Simvastatin Survival Study found that subjects with both elevated triglyceride and low HDL benefited from simvastatin therapy (29), although all subjects had elevated LDL-C at entry. More compellingly, the Heart Protection Study did not exclude subjects based on their triglyceride levels, and a subgroup analysis showed that all strata of baseline triglyceride and HDL levels benefited from simvastatin (10). Thus, it is our opinion that a patient with dyslipidemia of the TG-HDL axis who has tried therapeutic lifestyle changes and is a high enough cardiovascular risk to merit consideration of drug therapy should be advised to start with statin therapy. The large body of data that now exists suggests that such patients will benefit from statin therapy even if their baseline LDL-C is average or low. The one exception may be in patients with extremely elevated triglyceride levels of >500 mg/dL, in whom triglyceride-lowering therapy should be initiated first. The more difficult clinical conundrum, however, is how to approach the patient who has already been treated with a statin but has persistent abnormalities of the TG-HDL axis. Many patients with dyslipidemia require therapy with more than one lipid-modifying drug (47). This situation raises the question of adding a second drug to modify the TGHDL axis. As noted above, no completed outcome trials address this question directly, and
Annu. Rev. Med. 2008.59:79-94. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-06
88
Glassberg
·
Rader
no guidelines recommend a course of action in this situation. The NCEP ATPIII guidelines do recommend that if LDL-C is at goal but triglyceride is >200 mg/dl, the clinician should calculate the non-HDL-C as a secondary target of therapy and attempt to reduced it to goal (i.e., 30 mg/dl greater than the LDL-C goal in the same patient, as mentioned above). In some cases, non-HDL-C might be reduced by intensifying statin therapy or adding a CAI. However, it may be reasonable in many cases to add a drug that acts on the TG-HDL axis in order to reduce nonHDL-C as well as raise HDL-C and reduce cardiovascular risk. However, data demonstrating effects of combination lipid-lowering therapy on clinical endpoints are sparse. Thus, the potential benefits of this approach in improving the lipid profile and reducing cardiovascular events must be weighed against the tolerability and safety of adding a second drug. Adding a fibrate to statin therapy. A relatively high-risk patient on a statin in whom the major remaining lipid abnormality is an elevated triglyceride level might be considered for the addition of a fibrate. The lipid effects of fibrates complement those of statins, and several controlled trials have documented the efficacy of adding a fibrate to a statin. For example, the addition of fenofibrate to simvastatin was compared with simvastatin alone in patients with combined hyperlipidemia (48). Combination therapy reduced median triglyceride levels by 43% compared with 20% for simvastatin monotherapy and increased HDL-C levels by 19% compared with 10% for simvastatin alone. However, although a statin-fibrate combination is more effective in treating the lipid profile in patients with mixed hyperlipidemia than either drug alone, there are no data indicating that addition of a fibrate to a statin further reduces cardiovascular risk. The major issue with the clinical use of this combination is safety, particularly related to myopathy (24). Indeed, cerivastatin was withdrawn because it increased the incidence
Annu. Rev. Med. 2008.59:79-94. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-06
ARI
7 December 2007
12:29
of myopathy and rhabdomyolysis, especially when combined with gemfibrozil (24). It appears that gemfibrozil affects the pharmacokinetics of most statins; fenofibrate has a more modest effect (49). This may be secondary to the differential effect of these two fibrates on the glucuronidation of statins, resulting in higher levels of statin metabolites with concomitant gemfibrozil use. The risk of myopathy with this combination can be minimized with appropriate patient selection and education (50). The American Heart Association and the American College of Cardiology released a joint clinical advisory (24) affirming the potential benefits of combination therapy with statin plus fibrate but suggesting caution in groups of patients at higher risk of myopathy, such as elderly (>70 years), frail patients with multiple medical problems; patients with underlying renal or hepatic insufficiency; or patients already taking multiple prescription medications. The ACCORD trial (discussed above) is the first definitive test of the cardiovascular benefit of adding a fibrate to a statin, and its eagerly awaited results represent the largest safety data set in the setting of a randomized controlled trial. Adding niacin to statin therapy. Adding niacin to a statin is considered in a relatively high-risk patient whose remaining major lipid abnormality is HDL-C (defined as <40 mg/dl, although many clinicians consider HDL-C <50 mg/dl to be low in women, and this cutpoint is used for the metabolic syndrome criteria). Several controlled trials have demonstrated the lipid efficacy of adding niacin to a statin (35, 51). Some of the best controlled comparative data come from the studies performed to support the approval of a fixed-dose combination tablet of lovastatin and extended-release niacin (niacin-ER). In a study of patients with hypercholesterolemia and low HDL-C levels, patients were randomized to two escalating doses of niacinER/lovastatin or escalating doses of atorvastatin (10–40 mg) and simvastatin (10–40 mg) over 16 weeks (52). At 16 weeks, the combi-
nation of 2000 mg ER-niacin and 40 mg lovastatin was superior in its effect on the TGHDL axis, lowering triglyceride by 49% and raising HDL-C by 32%. Thus the lipid efficacy of this combination is clear, although, as noted above, hard outcomes are still lacking. Important concerns are tolerability and effects on glucose metabolism. The most important tolerability issue with niacin is cutaneous flushing, which often deters physicians from prescribing niacin and patients from taking it. Engineering of niacin to delay its absorption helps, but does not eliminate this issue. A variety of other strategies, such as pretreating with aspirin and having a snack prior to taking niacin, can also reduce flushing. Most patients experience relatively rapid tachyphylaxis to the flushing effects of niacin if they are able to tolerate the flushing for a few weeks after initiation and after each dose increase. New approaches to reduce niacin-associated flushing are being investigated. The niacin receptor on adipocytes, called GPR109A (53), is also expressed on dendritic cells and macrophages in the skin; when activated by niacin, it is responsible for the release of vasodilatory prostaglandins such as PGD2 , which activate its receptor DP1 on vascular cells (54). Thus, one approach under development is to specifically block the PGD2 receptor that mediates flushing in the skin (55). It has long been noted that niacin therapy can have adverse effects on glycemic control in patients with type 2 diabetes or metabolic syndrome, motivating more cautious use of niacin in such patients. However, a few controlled trials of niacin in diabetics suggest this may not be a major problem for most patients (56). In the Arterial Disease Multiple Intervention Trial (ADMIT), niacin had relatively minimal effect on glycemic control in patients with well-controlled type 2 diabetes (57). In the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial (ADVENT), moderate-dose niacin was given to patients who had type 2 diabetes but no clinical cardiovascular disease (58). There
www.annualreviews.org • Lipid Management and Cardiovascular Events
89
ARI
7 December 2007
12:29
was a modest increase in hemoglobin A1C values from 7.2% to 7.5% in the niacin-treated subjects. Data in nondiabetics with impaired fasting glucose are limited, but some of these patients may experience an increase in fasting glucose with niacin therapy that approaches the mild diabetes range. Thus, the decision to add niacin to a statin in patients with type 2 diabetes or impaired fasting glucose must balance the lipid benefits against the possibility of slightly worsened glycemic control. With regard to the liver, although transaminases should be monitored when niacin is added to a statin, serious hepatotoxicity appears to be very rare with this combination. Some nonprescription sustained-release niacin preparations, which are classically administered twice a day, have been associated with several cases of severe hepatotoxicity (51).
Annu. Rev. Med. 2008.59:79-94. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-06
Adding omega-3 fatty acids to statin therapy. A few small studies have investigated the effects of statin–omega-3 combinations on lipids. It appears that the addition of fish oils to statin therapy has at least additive effects on the TG-HDL axis and is generally well-tolerated. For significant triglyceride reduction, the two active omega-3 fatty acids eicosapentanoic acid (EPA) and decohexanoic acid (DHA) generally need to be dosed up to ∼4 g/day. Most fish oil preparations are sold as dietary supplements without a prescription. An FDA-approved preparation of omega-3 fatty acids is the most highly concentrated of the preparations available, with 890 mg of DHA and EPA per 1-g capsule. The addition of omega-3 fatty acids might be considered as an alternative to adding a fibrate to a statin, particularly for a patient at increased risk for myopathy.
SUMMARY Lipid-lowering therapy has clearly reduced the risk of cardiovascular event and mortality, with the most abundant data generated from the statin trials. Statins are safe and generally well-tolerated. Tolerability is primarily limited by myalgias, and myopathy and rhabdomyolysis are rare. The benefit of appropriately used lipid-lowering therapy far exceeds the risk for those patients at above-average risk of cardiovascular disease. Thus, detailed risk assessment is critical to guide the intensity of the lipid-lowering therapy. This includes use of the FRS (and potentially the new Reynolds Risk Score), incorporation of family history, diagnosis of the metabolic syndrome, and use of additional blood markers and/or noninvasive vascular imaging to optimally assess future cardiovascular risk. Currently, LDL-C reduction remains the cornerstone of therapy, though how low to treat, how to achieve more aggressive targets, and how early to initiate therapy continue to be debated. Often, while treatment may result in adequate LDL lowering, abnormalities of the TG-HDL axis persist, and a major lacuna in our evidence base is the lack of completed trials demonstrating the benefit of adding TGHDL-modifying therapy to LDL-lowering therapy. Nevertheless, in high-risk patients, addition of a fibrate, niacin, or omega-3 fatty acids can be reasonably considered after a trial of therapeutic lifestyle changes. In such patients, the benefit must be weighed against the issues of tolerability and safety. The use of many different types of combination lipidmodifying therapy is likely to increase substantially over the next several years, particularly if ongoing outcome trials of combination therapy demonstrate efficacy in reducing cardiovascular outcomes.
DISCLOSURE STATEMENT Dr. Rader has received research funding from, served as a consultant to, and/or received honoraria from the majority of companies that have currently marketed drugs for the treatment of lipid disorders. Dr. Rader also consults with companies involved in developing new therapeutic agents for lipid disorders and holds equity in Aegerion Pharmaceuticals. 90
Glassberg
·
Rader
ANRV334-ME59-06
ARI
7 December 2007
12:29
Annu. Rev. Med. 2008.59:79-94. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
LITERATURE CITED 1. 2001. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486–97 2. Grundy SM, Cleeman JI, Merz CN, et al. 2004. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110:227–39 3. Ford ES, Giles WH, Dietz WH. 2002. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287:356–59 4. Reilly MP, Rader DJ. 2003. The metabolic syndrome: more than the sum of its parts? Circulation 108:1546–51 5. Ginsberg HN, Zhang YL, Hernandez-Ono A. 2006. Metabolic syndrome: focus on dyslipidemia. Obesity (Silver Spring) 14(Suppl. 1):41S–49S 6. Ridker PM, Rifai N, Rose L, et al. 2002. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. 347:1557–65 7. Ridker PM, Buring JE, Rifai N, et al. 2007. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 297:611–19 8. Fuster V, Fayad ZA, Moreno PR, et al. 2005. Atherothrombosis and high-risk plaque: Part II: approaches by noninvasive computed tomographic/magnetic resonance imaging. J. Am. Coll. Cardiol. 46:1209–18 9. Fuster V, Moreno PR, Fayad ZA, et al. 2005. Atherothrombosis and high-risk plaque: part I: evolving concepts. J. Am. Coll. Cardiol. 46:937–54 10. 2002. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7–22 11. Sever PS, Dahlof B, Poulter NR, et al. 2003. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361:1149–58 12. Colhoun HM, Betteridge DJ, Durrington PN, et al. 2004. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364:685–96 13. LaRosa JC, Grundy SM, Waters DD, et al. 2005. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352:1425–35 14. Pedersen TR, Faergeman O, Kastelein JJ, et al. 2005. High-dose atorvastatin vs usualdose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294:2437–45 15. Cannon CP, Braunwald E, McCabe CH, et al. 2004. Intensive vs moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350:1495–504 16. de Lemos JA, Blazing MA, Wiviott SD, et al. 2004. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292:1307–16 17. Cohen JC, Boerwinkle E, Mosley TH Jr., et al. 2006. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354:1264–72 18. Gotto AM. 1997. Cholesterol management in theory and practice. Circulation 96:4424– 30 www.annualreviews.org • Lipid Management and Cardiovascular Events
91
ARI
7 December 2007
12:29
19. Lipka LJ. 2003. Ezetimibe: a first-in-class, novel cholesterol absorption inhibitor. Cardiovasc. Drug Rev. 21:293–312 20. Garcia-Calvo M, Lisnock J, Bull HG, et al. 2005. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc. Natl. Acad. Sci. USA 102:8132–37 21. Bays HE, Moore PB, Drehobl MA, et al. 2001. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin. Ther. 23:1209–30 22. Davidson MH, Ballantyne CM, Kerzner B, et al. 2004. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int. J. Clin. Pract. 58:746–55 23. Zema MJ. 2005. Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia. Am. J. Ther. 12:306–10 24. Pasternak RC, Smith SC Jr., Bairey-Merz CN, et al. 2002. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J. Am. Coll. Cardiol. 40:567–72 25. Thompson GR. 2003. LDL apheresis. Atherosclerosis 167:1–13 26. Tatami R, Inoue N, Itoh H, et al. 1992. Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. Atherosclerosis 95:1–13 27. Thompson GR, Maher V, Matthews S, et al. 1995. Familial hypercholesterolaemia regression study: a randomised trial of low-density lipoprotein apheresis. Lancet 345:811–16 28. Sachais BS, Katz J, Ross J, et al. 2005. Long-term effects of LDL apheresis in patients with severe hypercholesterolemia. J. Clin. Apher. 20:252–55 29. Ballantyne CM, Olsson AG, Cook TJ, et al. 2001. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 104:3046–51 30. Steiner G. 2004. Fibrates in the metabolic syndrome and in diabetes. Endocrinol. Metab. Clin. North Am. 33:545–55, vi–vii 31. Frick MH, Elo O, Haapa K, et al. 1987. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 317:1237– 45 32. Rubins HB, Robins SJ, Collins D, et al. 1999. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N. Engl. J. Med. 341:410–18 33. 2000. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 102:21–27 34. Keech A, Simes RJ, Barter P, et al. 2005. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366:1849–61 35. Meyers CD, Kamanna VS, Kashyap ML. 2004. Niacin therapy in atherosclerosis. Curr. Opin. Lipidol. 15:659–65 36. Pike NB, Wise A. 2004. Identification of a nicotinic acid receptor: Is this the molecular target for the oldest lipid-lowering drug? Curr. Opin. Investig. Drugs 5:271–75 37. The Coronary Drug Project Research Group. 1975. Clofibrate and niacin in coronary heart disease. JAMA 231:360–81
Annu. Rev. Med. 2008.59:79-94. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-06
92
Glassberg
·
Rader
Annu. Rev. Med. 2008.59:79-94. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-06
ARI
7 December 2007
12:29
38. Canner PL, Berge KG, Wenger NK, et al. 1986. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J. Am. Coll. Cardiol. 8:1245– 55 39. Taylor AJ, Sullenberger LE, Lee HJ, et al. 2004. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebocontrolled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110:3512–17 40. Brown BG, Zhao XQ, Chait A, et al. 2001. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 345:1583– 92 41. Kris-Etherton PM, Harris WS, Appel LJ. 2003. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 23:e20–30 42. Hooper L, Thompson RL, Harrison RA, et al. 2006. Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. BMJ 332:752–60 43. Balk EM, Lichtenstein AH, Chung M, et al. 2006. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 189:19–30 44. 1999. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. Lancet 354:447–55 45. Foster GD, Wyatt HR, Hill JO, et al. 2003. A randomized trial of a low-carbohydrate diet for obesity. N. Engl. J. Med. 348:2082–90 46. Samaha FF, Iqbal N, Seshadri P, et al. 2003. A low-carbohydrate as compared with a low-fat diet in severe obesity. N. Engl. J. Med. 348:2074–81 47. Ansell BJ. 2005. Rationale for combination therapy with statin drugs in the treatment of dyslipidemia. Curr. Atheroscler. Rep. 7:29–33 48. Grundy SM, Vega GL, Yuan Z, et al. 2005. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am. J. Cardiol. 95:462– 68 49. Jones PH, Davidson MH. 2005. Reporting rate of rhabdomyolysis with fenofibrate + statin vs gemfibrozil + any statin. Am. J. Cardiol. 95:120–22 50. Wierzbicki AS, Mikhailidis DP, Wray R, et al. 2003. Statin-fibrate combination: therapy for hyperlipidemia: a review. Curr. Med. Res. Opin. 19:155–68 51. Carlson LA. 2005. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J. Intern. Med. 258:94–114 52. Bays HE, Dujovne CA, McGovern ME, et al. 2002. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the Advicor vs Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am. J. Cardiol. 91:667–72 53. Tunaru S, Kero J, Schaub A, et al. 2003. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat. Med. 9:352–55 54. Pike NB. 2005. Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid. J. Clin. Invest. 115:3400–3 55. Cheng K, Wu TJ, Wu KK, et al. 2006. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc. Natl. Acad. Sci. USA 103:6682–87 56. Shepherd J, Betteridge J, Van Gaal L. 2005. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. Curr. Med. Res. Opin. 21:665–82 www.annualreviews.org • Lipid Management and Cardiovascular Events
93
ANRV334-ME59-06
ARI
7 December 2007
12:29
Annu. Rev. Med. 2008.59:79-94. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
57. Elam MB, Hunninghake DB, Davis KB, et al. 2000. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. JAMA 284:1263–70 58. Grundy SM, Vega GL, McGovern ME, et al. 2002. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial. Arch. Intern. Med. 162:1568–76
94
Glassberg
·
Rader
AR334-FM
ARI
18 December 2007
17:20
Annual Review of Medicine
Annu. Rev. Med. 2008.59:79-94. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Contents
Volume 59, 2008
The FDA Critical Path Initiative and Its Influence on New Drug Development Janet Woodcock and Raymond Woosley p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p1 Reversing Advanced Heart Failure by Targeting Ca2+ Cycling David M. Kaye, Masahiko Hoshijima, and Kenneth R. Chien p p p p p p p p p p p p p p p p p p p p p p p p 13 Tissue Factor and Factor VIIa as Therapeutic Targets in Disorders of Hemostasis Ulla Hedner and Mirella Ezban p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 29 Therapy of Marfan Syndrome Daniel P. Judge and Harry C. Dietz p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 43 Preeclampsia and Angiogenic Imbalance Sharon Maynard, Franklin H. Epstein, and S. Ananth Karumanchi p p p p p p p p p p p p p p p p p 61 Management of Lipids in the Prevention of Cardiovascular Events Helene Glassberg and Daniel J. Rader p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 79 Genetic Susceptibility to Type 2 Diabetes and Implications for Antidiabetic Therapy Allan F. Moore and Jose C. Florez p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 95 Array-Based DNA Diagnostics: Let the Revolution Begin Arthur L. Beaudet and John W. Belmont p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p113 Inherited Mitochondrial Diseases of DNA Replication William C. Copeland p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p131 Childhood Obesity: Adrift in the “Limbic Triangle” Michele L. Mietus-Snyder and Robert H. Lustig p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p147 Expanded Newborn Screening: Implications for Genomic Medicine Linda L. McCabe and Edward R.B. McCabe p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p163 Is Human Hibernation Possible? Cheng Chi Lee p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p177 Advance Directives Linda L. Emanuel p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p187 v
AR334-FM
ARI
18 December 2007
17:20
Genetic Determinants of Aggressive Breast Cancer Alejandra C. Ventura and Sofia D. Merajver p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p199 A Role for JAK2 Mutations in Myeloproliferative Diseases Kelly J. Morgan and D. Gary Gilliland p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p213 Appropriate Use of Cervical Cancer Vaccine Gregory D. Zimet, Marcia L. Shew, and Jessica A. Kahn p p p p p p p p p p p p p p p p p p p p p p p p p p p p p223 A Decade of Rituximab: Improving Survival Outcomes in Non-Hodgkin’s Lymphoma Arturo Molina p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p237
Annu. Rev. Med. 2008.59:79-94. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Nanotechnology and Cancer James R. Heath and Mark E. Davis p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p251 Cancer Epigenetics: Modifications, Screening, and Therapy Einav Nili Gal-Yam, Yoshimasa Saito, Gerda Egger, and Peter A. Jones p p p p p p p p p p p p267 T Cells and NKT Cells in the Pathogenesis of Asthma Everett H. Meyer, Rosemarie H. DeKruyff, and Dale T. Umetsu p p p p p p p p p p p p p p p p p p p p281 Complement Regulatory Genes and Hemolytic Uremic Syndromes David Kavanagh, Anna Richards, and John Atkinson p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p293 Mesenchymal Stem Cells in Acute Kidney Injury Benjamin D. Humphreys and Joseph V. Bonventre p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p311 Asthma Genetics: From Linear to Multifactorial Approaches Stefano Guerra and Fernando D. Martinez p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p327 The Effect of Toll-Like Receptors and Toll-Like Receptor Genetics in Human Disease Stavros Garantziotis, John W. Hollingsworth, Aimee K. Zaas, and David A. Schwartz p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p343 Advances in Antifungal Therapy Carole A. Sable, Kim M. Strohmaier, and Jeffrey A. Chodakewitz p p p p p p p p p p p p p p p p p p361 Herpes Simplex: Insights on Pathogenesis and Possible Vaccines David M. Koelle and Lawrence Corey p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p381 Medical Management of Influenza Infection Anne Moscona p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p397 Bacterial and Fungal Biofilm Infections A. Simon Lynch and Gregory T. Robertson p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p415 EGFR Tyrosine Kinase Inhibitors in Lung Cancer: An Evolving Story Lecia V. Sequist and Thomas J. Lynch p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p429 Adaptive Treatment Strategies in Chronic Disease Philip W. Lavori and Ree Dawson p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p443 vi
Contents
AR334-FM
ARI
18 December 2007
17:20
Antiretroviral Drug–Based Microbicides to Prevent HIV-1 Sexual Transmission Per Johan Klasse, Robin Shattock, and John P. Moore p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p455 The Challenge of Hepatitis C in the HIV-Infected Person David L. Thomas p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p473 Hide-and-Seek: The Challenge of Viral Persistence in HIV-1 Infection Luc Geeraert, Günter Kraus, and Roger J. Pomerantz p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p487
Annu. Rev. Med. 2008.59:79-94. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Advancements in the Treatment of Epilepsy B.A. Leeman and A.J. Cole p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p503 Indexes Cumulative Index of Contributing Authors, Volumes 55–59 p p p p p p p p p p p p p p p p p p p p p p p p525 Cumulative Index of Chapter Titles, Volumes 55–59 p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p529 Errata An online log of corrections to Annual Review of Medicine articles may be found at http://med.annualreviews.org/errata.shtml
Contents
vii
Annu. Rev. Med. 2008.59:95-111. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-07
ARI
7 December 2007
12:34
Genetic Susceptibility to Type 2 Diabetes and Implications for Antidiabetic Therapy Allan F. Moore and Jose C. Florez Diabetes Unit (Department of Medicine) and Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts; the Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts; and the Department of Medicine, Harvard Medical School, Boston, Massachusetts; email: jcfl
[email protected]
Annu. Rev. Med. 2008. 59:95–111
Key Words
First published online as a Review in Advance on October 15, 2007
MODY, TCF7L2, KCNJ11, PPARG, pharmacogenetics, single-nucleotide polymorphism, genome-wide association
The Annual Review of Medicine is online at http://med.annualreviews.org This article’s doi: 10.1146/annurev.med.59.090706.135315 c 2008 by Annual Reviews. Copyright All rights reserved 0066-4219/08/0218-0095$20.00
Abstract Despite major advances in our knowledge of glycemic pathophysiology and the availability of multiple therapeutic options to confront type 2 diabetes, unraveling the complex link between genetic risk and environmental factors in this burgeoning epidemic has proven difficult. Linkage approaches have clarified the etiology of monogenic diabetic syndromes and congenital lipodystrophies, and candidate gene association studies have identified a number of common variants implicated in type 2 diabetes. This year we have witnessed the advent of genome-wide association scanning: As many as nine genetic loci have now been reproducibly associated with type 2 diabetes in five genome-wide scans. Of particular interest are preliminary explorations of the connections between genetic risk and pharmacologic response. An improved understanding of genetic mechanisms should allow us to test whether behavioral or pharmacologic therapies can be tailored and thus the tremendous disease burden inflicted by type 2 diabetes alleviated.
95
ANRV334-ME59-07
ARI
7 December 2007
Annu. Rev. Med. 2008.59:95-111. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
MODY: maturity-onset diabetes of the young
96
12:34
INTRODUCTION
MONOGENIC DIABETES
Diabetes mellitus affects more than 150 million people worldwide, and this number is expected to double within the next two decades. One in three Americans born in the year 2000 will develop the disease. Its complications include renal failure, blindness, amputation, myocardial infarction, and stroke. We have gained significant insight into the many advantages of tight blood glucose control, but the genetic susceptibility to the disease and the interaction between potential therapies and an individual’s genetic signature remain incompletely understood. The abundant evidence that supports the genetic basis of type 2 diabetes (T2D) is based on population, family, and twin studies. The prevalence of T2D varies widely across ethnic groups, with incidence rates as low as 1% in some rural Asian populations while Pima Indians and Polynesians have among the highest diabetic incidence rates in the world, reaching the 30%–50% range. Moreover, in the United States and the United Kingdom, rates of diabetes in minority ethnic groups are at least twofold higher than those of their white counterparts, and this difference is not eliminated when environmental factors are controlled for. Familial aggregation studies further bolster the notion of genetic susceptibility: The offspring of a diabetic parent has a 40% chance of developing diabetes in contrast to a population risk of ∼7%, and if both parents are affected, the risk rises to 70% (1). Similarly, a sibling of a diabetic patient has an approximate relative risk of 3 of developing diabetes later in life. Perhaps the strongest genetic evidence is derived from twin studies, which reveal concordance rates of 0.20 to 0.91 in monozygotic twins and 0.10 to 0.43 in dizygotic twins (2, 3). Despite this convincing evidence for an inborn susceptibility to T2D, the concordance rates are not 100%; the environment and chance contribute as well.
Some of the most compelling evidence that inherited variation can cause glycemic dysregulation comes from the clinical and genetic description of monogenic diabetes, including maturity-onset diabetes of the young (MODY), insulin resistance syndromes, mitochondrial diabetes, and neonatal diabetes. Although rare, these syndromes provide a framework for understanding and investigating the complex genetics of T2D.
Moore
·
Florez
Maturity-Onset Diabetes of the Young MODY was first described in 1960 as a unique type of non–insulin-dependent, autosomal dominant diabetes in thin, young adults (usually <25 years of age) who are not prone to ketoacidosis (4). It is thus distinguished from T2D by family history, younger onset, and absence of obesity. This syndrome accounts for approximately 1%–2% of diabetes cases, although MODY has been reported as responsible for as many as 5% of European diabetic cases (5). By using both linkage and candidate gene approaches, investigators have identified six different MODY genes to date, although ∼10% of MODY patients have no identifiable genetic mutation (a condition called MODY X). Despite differences in clinical presentation and treatment response, all six MODY syndromes share three features: (a) They result from mutated genes that are expressed in the pancreatic β cell; (b) these genes encode nuclear transcription factors (with the important exception of glucokinase); and (c) these mutations result in a significant loss of pancreatic β cell function and subsequent insulin production. MODY1 was identified through a linkage study of an American family (6). The syndrome results in severe, progressive β cell dysfunction and insulin dependence. MODY1 results from mutations in HNF4A on
Annu. Rev. Med. 2008.59:95-111. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-07
ARI
7 December 2007
12:34
chromosome 20, which affects the development and function of human pancreatic β cells. MODY1 is the third most common MODY subtype, with 31 mutations in 40 families described to date. MODY2 accounts for ∼20% of MODY cases. Whereas the other MODY syndromes are caused by mutations in transcription factors, MODY2 results from mutations in the glucokinase gene (GCK ) on chromosome 7p. Glucokinase catalyzes the phosphorylation of glucose and controls the first rate-limiting step of glycolysis. This enzyme functions as the glucose sensor of pancreatic β cells and regulates insulin production. Inactivating mutations of GCK result in mild, stable, lifelong fasting hyperglycemia because those affected lack an effective glucose sensor. Levels of insulin secretion in MODY2 patients are similar to levels seen in noncarriers of the mutation, although these levels are seen at higher serum glucose levels (7). Treatment is rarely required, and microvascular disease is unusual. As predicted by the pathophysiology, patients with GCK mutations do not respond to insulin or oral hypoglycemic agents because they decrease their endogenous insulin production in response to exogenous therapy. Some positive preliminary animal studies using GCK activators are emerging (8). MODY3 is the most common MODY subtype, with more than 193 mutations identified in 373 families (9). Diabetes usually develops in early adulthood but can develop later in life. Patients lose β cell function progressively with minimal insulin requirements at first, but eventual insulin dependence is the rule. The syndrome results from mutations in HNF1A (TCF1), which impair key steps of glucose transport, metabolism, and mitochondrial metabolism. Retinopathy and nephropathy are common in MODY3; however, macrovascular disease is not. MODY4 results from heterozygous mutations in the gene that encodes insulin promoter factor 1 (IPF1 or PDX1), a tran-
scription factor that regulates insulin gene transcription as well as islet and pancreatic development. Homozygous mutations in exon 1 of IPF1 give rise to pancreatic agenesis (10). MODY5, a more common MODY variant than originally suspected, is unique in that it is associated with renal anomalies. The syndrome was identified through the genetic screening of a Japanese cohort, which identified a nonsense mutation in HNF1B (TCF2) (11). HNF1B is highly expressed in the pancreas, liver, and kidney. Diabetes results from both hepatic insulin resistance and β cell loss (12). β cell dysfunction is more severe in MODY5 than in MODY3 and ketoacidosis has been reported (13). These patients typically require insulin therapy and do not respond to sulfonylureas. HNF1B mutations have been associated with renal dysfunction, genitourinary problems, abnormal liver function, and hyperuricemia (14). Finally, MODY6 has been shown to result from mutations in NEUROD1 (BETA2), which is important for pancreatic development and insulin gene transcription (15). Patients develop moderately severe and progressive β cell dysfunction. MODY6 is extremely rare, with only a few cases reported in the literature (16).
Insulin Resistance Syndromes and Lipodystrophies Insight into the genetic basis of diabetes has also been culled from several rare insulin resistance syndromes. These syndromes are characterized biochemically by hyperinsulinemia and insulin resistance in fat, muscle, and liver. The insulin receptor was a logical initial candidate gene for the severe hyperinsulinemia described in index patients. The most severe form of insulin resistance is leprechaunism (Donahue syndrome), named for the dysmorphic appearance of the affected infants. Patients may also show intrauterine growth retardation. The syndrome results www.annualreviews.org • Pharmacogenetics in Type 2 Diabetes
97
Annu. Rev. Med. 2008.59:95-111. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-07
ARI
7 December 2007
PPARG: gene encoding peroxisome proliferator-activated receptor γ (PPARγ), a nuclear hormone receptor that acts as a lipid sensor and induces a cascade of transcriptional events that lead to increased insulin sensitivity and adipocyte differentiation TNDM: transient neonatal diabetes mellitus PNDM: permanent neonatal diabetes mellitus DEND: developmental delay, epilepsy, neonatal diabetes
98
12:34
from homozygous mutations in the insulin receptor. Those affected rarely survive into the second year of life (17). The RabsonMendenall syndrome is characterized by pineal hyperplasia, acanthosis nigricans, accelerated growth, and dental dysplasia. Mutations in the insulin receptor allow incomplete receptor activation (18). The lipodystrophies are characterized by dysregulation of fat storage. Adipose tissue is deposited inappropriately in muscle and liver rather than the usual subcutaneous compartment. Congenital-generalized lipodystrophy (Berardinelli-Seip syndrome) results in loss of subcutaneous fat and hepatomegaly secondary to abnormal fat and glycogen deposition. Two genes have been implicated thus far: BSCL2 on chromosome 11, which encodes the protein seipin, an integral component of the endoplasmic reticulum; and AGPAT2, which encodes an enzyme in the synthesis of glycerophospholipids (19). Other forms of lipodystrophy result from mutations in the LMNA and PPARG genes. LMNA, initially identified through linkage analysis, is spliced to produce two proteins, lamin A and lamin C, which form part of the nuclear envelope responsible for nuclear trafficking (20). Perhaps the best known of the laminopathies is familial partial lipodystrophy (Dunnigan syndrome). Interestingly, adipose tissue is lost in the extremities as with other lipodystrophies but is preserved in the neck and face. Associated endocrinopathies include polycystic ovaries, hyperandrogenism, and hyperlipidemia. The peroxisome proliferatoractivated receptor γ (PPARγ) is a nuclear hormone receptor highly expressed in adipose tissue that acts as a lipid sensor and induces a cascade of transcriptional events that lead to increased insulin sensitivity and adipocyte differentiation. Mutations in its gene, PPARG, produce a truncated receptor protein that is unable to bind signaling ligands appropriately. Homozygous mutations result in severe insulin resistance, whereas heterozygotes have a mild phenotype.
Moore
·
Florez
Mitochondrial Diabetes Mitochondrial diabetes is another rare variant of monogenic diabetes. Maternally inherited diabetes and deafness (MIDD) is caused by an alanine-to-guanine mutation in the gene encoding the tRNA for leucine. This defect leads to ineffective oxidative phosphorylation.
Neonatal Diabetes Neonatal diabetes, which usually presents in the initial days or months of life, can be transient (resolving at a median of 12 weeks) or permanent. Most cases of transient neonatal diabetes mellitus (TNDM) result from imprinting mutations of the ZAC and HYNAI genes on chromosome 6q (21). This type of neonatal diabetes usually remits in childhood but is associated with an increased risk of T2D in adulthood. Permanent neonatal diabetes mellitus (PNDM), traditionally treated with insulin, has recently been associated with activating mutations in the KCNJ11 gene, which encodes the islet ATP-sensitive potassium channel Kir6.2 (22). Activating mutations in KCNJ11 result in constitutive opening of the inwardly rectifying potassium channel, hyperpolarization of the β cell membrane, and subsequent hypoinsulinemic diabetes. Conversely, loss-of-function polymorphisms have been associated with persistent hyperinsulinemia of infancy (23). Several novel heterozygous missense activating mutations in KCNJ11 have now been identified in TNDM. The severity of the mutation correlates with the clinical phenotype—some KCNJ11 defects result in PNDM, and even more severe genetic mutations result in the DEND syndrome (developmental delay, epilepsy, neonatal diabetes) (24). Mutations in this gene appear to be the most common cause of neonatal diabetes and account for about one third of PNDM cases (25). The closely associated sulfonylurea receptor (SUR1) also plays an important role in infant diabetes. Such a role was first proposed by Huopio et al. (26), who reported that the
ANRV334-ME59-07
ARI
7 December 2007
12:34
Annu. Rev. Med. 2008.59:95-111. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
missense mutation E1506K in ABCC8, the gene that encodes SUR1, resulted in congenital, autosomal dominant hyperinsulinemia in a Japanese family. The dominant mutation results in neonatal hyperinsulinemia and subsequent hypoglycemia, and the heterozygous form may increase adult susceptibility to common T2D. Consistent with these expectations, Babenko et al. (27) recently described a number of activating mutations in ABCC8 that affect SUR1 function and cause neonatal diabetes. The pharmacogenetic implications of these findings are discussed below.
COMMON TYPE 2 DIABETES Monogenic diabetes, as described above, results from single mutations that lead to profound phenotypes. The complex individual portfolio of susceptible and protective alleles in polygenic T2D is more difficult to discern, given the limited individual impact of a single genetic locus. Indeed, a full understanding of the complex gene-gene and gene-environment interactions at play in this disesase has proven quite challenging thus far.
MODY Genes To identify a connection between monogenic diabetes and common T2D, a natural starting point is to test whether common but less severe variants of monogenic diabetes might play a role in the pathogenesis of T2D. This hypothesis has been fairly comprehensively tested for the six known MODY genes, with suggestive but often conflicting results (28– 36). For example, common variants of HNF4A (MODY1) have been associated with T2D in both Finnish and Ashkenazi Jewish populations (28, 29). In addition, variants in GCK (MODY3) have been associated with elevated fasting blood glucose levels and possibly with common T2D, although the evidence here is somewhat weaker (36). Given the small effect of GCK mutations on fasting blood sugar (approximately 2 mmol/L), the mutation is un-
likely to have a substantial impact on T2D risk.
CAPN10 One of the earliest diabetes genes identified was CAPN10, which encodes the intracellular cysteine protease Calpain 10. A linkage signal in chromosome 2q in a Mexican-American cohort (LOD score 4.1) (37) eventually led to the identification of an adenosineto-guanosine polymorphism in intron 3 in CAPN10, which was associated with T2D. Although subsequent studies have not produced a consistent relationship between variation in CAPN10 and metabolic phenotypes, recent meta-analyses indicate that variants in CAPN10 may indeed confer a modest increase in T2D susceptibility (38–40). Interestingly, Calpain inhibitors increase insulin secretion and increase the metabolism of muscle glucose to glycogen in animal models (41).
Pharmacogenetics: the study of the interaction of therapies with target genes
PPARG A proline-to-alanine change in codon 12 of PPARG (P12A) was the first genetic variant to be definitively implicated in the common form of T2D (42). Deeb et al. (43) initially reported that the alanine allele was associated with increased insulin sensitivity and protection from T2D in a Finnish and secondgeneration Japanese cohort. Since this initial work, the preponderance of evidence has conclusively supported PPARG’s association with T2D, with an odds ratio (OR) of ∼1.2 (44). The risk of T2D conferred by this singlenucleotide polymorphism (SNP) has been studied prospectively in the Finnish Diabetes Prevention Study and the larger Botnia Prevention Study. In the Finnish study, >500 subjects with impaired glucose tolerance were randomized to placebo or lifestyle modification. The relative risk of developing diabetes was doubled in alanine carriers in the placebo arm, contradicting the prior evidence that the alanine allele was protective. In the larger Botnia study, comprising >2000 subjects, www.annualreviews.org • Pharmacogenetics in Type 2 Diabetes
99
ANRV334-ME59-07
ARI
7 December 2007
Annu. Rev. Med. 2008.59:95-111. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
DPP: Diabetes Prevention Program
12:34
proline homozygotes were 1.7 times more likely to develop diabetes than alanine carriers (45). Our study of 3548 participants enrolled in the Diabetes Prevention Program (DPP) also revealed a modest risk for the homozygous proline genotype (46). Interestingly, we uncovered a significant interaction between genotype and body mass index (BMI): The protective effect of the alanine allele was lost in subjects with a BMI greater than 35 kg/m2 . It is possible that this finding may explain some of the heterogeneity of results noted in the literature regarding this variant.
KCNJ11 The KCNJ11 gene, described above in the context of neonatal diabetes, encodes the β cell potassium channel and is functionally closely related to the sulfonylurea receptor SUR1, encoded by ABCC8. These genes are adjacent to each other on chromosome 11. Work on this locus has confirmed that a less drastic change in a gene implicated in a rare, monogenic subtype of diabetes can indeed contribute to its more common form: SNP E23K of KCNJ11 has now been convincingly associated with T2D. Although initial smaller studies failed to replicate the association of the E23K polymorphism with T2D, largescale studies and meta-analyses have consistently associated the lysine variant with T2D, with an OR of ∼1.15 (35, 47–52).
group of diabetes genetics investigators (reviewed in Reference 54). All of these studies demonstrate robust and convincing statistical evidence of association with diabetic risk and consistent effect sizes. The accumulated evidence from >50,000 subjects reveals a remarkable overall p value of <10−80 . The effect of the risk allele appears to be additive; one allele confers ∼40% risk whereas two copies confer 80% risk of diabetes (54). The precise mechanisms of this increased risk are poorly understood. TCF proteins are transcription factors that affect cell proliferation and differentiation via the Wnt signaling pathway. Tcf7l2-null mice have marked deficiencies in intestinal cells including enteroendocrine cells, which are responsible for incretin production. Incretins, including glucagon-like peptide 1 (GLP-1), influence gut mobility, satiety, and energy regulation, thus providing a plausible biological explanation for the role they may play in T2D. The TCF7L2 risk allele may result in a defective or poorly expressed protein that leads to decreased insulin secretion and consequent hyperglycemia. We tested the clinical implications of this hypothesis in the multiethnic cohort of the DPP and found that the risk allele was associated with impaired insulin secretion but not insulin resistance (55). These findings have been recently confirmed in a general population (56).
PHARMACOGENETICS TCF7L2 Investigators at deCODE Genetics in Iceland recently reported a strong association of a common allele in the gene of transcription factor 7–like 2 (TCF7L2) with an increased risk of T2D in three white populations (53). In this case-control study of 3774 subjects from Iceland, Denmark, and the United States, the estimated allelic risk was 1.56 ( p = 4.7 × 10−18 ). The effect size was greater than that of any diabetes gene identified to date. These results have subsequently been confirmed in multiple ethnic groups by virtually every other 100
Moore
·
Florez
Much of the work described above is motivated by the prospect that a clearer genetic understanding may lead to more effective strategies for diabetes prevention and treatment. Pharmacogenetics, the study of the interaction of therapies with target genes, is emerging as a fruitful discipline with testable hypotheses (57). The recently described drugresponse interaction between warfarin and variation in VKORC1 illustrates this tantalizing paradigm (58). In metabolic disease, treatment of leptin-deficient humans with recombinant leptin causes a dramatic reduction
Annu. Rev. Med. 2008.59:95-111. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-07
ARI
7 December 2007
12:34
in adiposity and normalization of appetite (58a). T2D is a promising disease exemplum in which pharmacogenetics can have a potentially tremendous impact, given the reasonably well-understood pathophysiology of glucose metabolism and the heavy burden of disease. Heterogeneity in response to diabetic medications, including thiazolidinediones (TZDs) and sulfonylurea therapy, is well known to many physicians who treat patients with T2D, and these variable response rates may result from heterogeneity at the genetic level. Approximately 5%–7% of diabetic patients treated with sulfonylurea monotherapy convert to insulin annually as a result of treatment failure (59). Although many genes have now been reproducibly associated with T2D, much less is known about gene-drug interactions. Similarly, the putative genetic predisposition of selected individuals to the development of side effects is presently unexplored.
Pharmacogenetics of Monogenic Diabetes Perhaps the most compelling evidence suggesting the validity of a pharmacogenetic approach in diabetes comes from elegant studies conducted in the newly described forms of PNDM. Even though mutated Kir6.2 β cell potassium channels are refractory to endogenous ATP, they can often respond to sulfonylureas, medications that bind to the SUR1 receptor and prompt channel closure. Sagen et al. (60) showed in 2004 that PNDM patients with Kir6.2 mutations could be effectively managed on a sulfonylurea without insulin therapy, with improved hemoglobin A1C levels. Two subsequent studies were published simultaneously in 2006 confirming this finding. Babenko et al. (27) identified ABCC8 mutations in nine families with neonatal diabetes and confirmed that sulfonylurea blockade was preserved. Pearson et al. (61) demonstrated that 44 out of 49 PNDM patients with Kir6.2 mutations could be successfully transitioned from
insulin to sulfonylurea therapy. Sulfonylurea treatment improved insulin secretion, and glycemic control was sustained at one year. A similar phenomenon can be observed in some MODY subtypes. MODY3 patients are uniquely sensitive among the MODY subtypes to sulfonylurea medications because the affected β cell potassium channel is downstream of the physiologic effects known to result from genetic mutations. In a randomized crossover trial in which adult responses to a sulfonylurea and metformin were compared between patients with HNF1A mutations and matched type T2D patients, the HNF1A group demonstrated a fivefold greater response to sulfonylurea than metformin. Their response to sulfonylurea was fourfold higher than that of the T2D patients (62).
TZD: thiazolidinedione
Pharmacogenetics of Polygenic Diabetes An early focus of T2D pharmacogenetic studies has been the common, functional P12A PPARG variant, since this nuclear receptor is the known drug target of TZD medications (63). TZDs are known to decrease glucose levels in T2D (64); however, clinical experience and multiple clinical trials indicate that there is a large percentage of nonresponders. In vitro studies reveal decreased binding of the variant receptor to the PPAR response element in the presence of increasing concentrations of TZDs (65). Four published studies have examined the effect of PPARG P12A on the response to ¨ TZDs. Bluher et al. (66) found that when 131 diabetic subjects were treated for 26 weeks with pioglitazone, the percentage of responders (defined as >20% decrease in fasting glucose or >15% decrease in hemoglobin A1C ) did not differ between proline homozygotes and alanine carriers. Similarly, in the TRIPOD (Troglitazone in Prevention of Diabetes) study, one third of subjects showed no increase in insulin sensitivity in response to troglitazone (400 mg daily); however, the P12A variant did not explain this failure (67). www.annualreviews.org • Pharmacogenetics in Type 2 Diabetes
101
ARI
7 December 2007
12:34
These same investigators continued their study on the same subjects by genotyping 131 common variants of PPARG and investigating their relationship to treatment response. Eight different polymorphisms were associated with response to troglitazone therapy (67a). In contrast with the above findings, when Kang et al. (68) examined the response of 198 T2D patients to rosiglitazone, they found that 15 carriers of the P12A polymorphism had a better response to TZD therapy than Pro12Pro homozygotes. Patients with the alanine allele had a larger reduction in fasting glucose and hemoglobin A1C than those without the allele, although the sample size was small. On the other hand, we were unable to show an effect of PPARG P12A or five of the other PPARG polymorphisms implicated by Snitker et al. (67) on response to troglitazone therapy in the 340 participants randomized to troglitazone in the DPP (46). Thus, knowledge of allelic variation at this locus does not yet offer a rationale for therapeutic choices. The impact of the KCNJ11 genetic variant E23K on the effectiveness of sulfonylurea therapy is also unclear. Sesti et al. (69) genotyped KCNJ11 in 525 white T2D patients and investigated whether failure to respond to sulfonylurea therapy (defined as fasting plasma glucose >300 mg/dl despite combined sulfonylurea-metformin therapy and appropriate diet) was due, in part, to the risk allele. The authors found carriers to have a relative risk of failure of 1.45 compared to E23E homozygotes. Also, the risk allele was associated with an earlier onset of diabetes and worse metabolic control in nonresponders. This group also performed in vitro experiments of human islet secretory function in response to glucose and glibenclamide, a second-generation sulfonylurea. After 24-h exposure to high glucose concentration followed by stimulation with glibenclamide, insulin release was 30% lower in K allele carriers. These results stand in contrast to those of the UK Prospective Diabetes Study (UKPDS), in which the authors found no
Annu. Rev. Med. 2008.59:95-111. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-07
102
Moore
·
Florez
significant association of the E23K variant with response to sulfonyurea therapy in 364 newly diagnosed T2D patients (47). The disparity between these results may follow from different definitions of treatment failure, durations of therapy, specific sulfonylureas used, patient clinical characteristics, or statistical fluctuations. In the DPP, although metformin was effective in lowering the risk of diabetes for E23E homozygotes, it failed to protect carriers of the risk lysine allele. In addition, K23K homozygotes randomized to metformin did not show the expected improvement in insulin sensitivity at one year (70). This effect is poorly understood and will require validation with additional physiologic studies in an independent cohort. Although the precise molecular mechanism by which TCF7L2 contributes to T2D is still under investigation, it is apparent that this variant confers a defect in insulin secretion, possibly by affecting GLP-1 metabolism (55, 56, 71–73). In regard to a possible drug × genotype interaction, the recently published Go-DARTS study genotyped 6516 UK participants for TCF7L2 and found the T allele overrepresented in individuals requiring insulin treatment and underrepresented in the patients being managed by diet alone. The authors concluded that TCF7L2 variants may be associated with increased disease severity and therapeutic failure (74). Another recent publication from the same group reported the effect of TCF7L2 genotypes on therapeutic response in 901 diabetic patients treated with sulfonylurea and 945 patients treated with metformin. Carriers of the risk TCF7L2 variants were more likely to fail to sulfonylurea but not metformin therapy as measured by a hemoglobin A1C > 7% within 3–12 months after treatment initiation (74a). This finding further supports the hypothesis that TCF7L2 variants are important in β cell function. Finally, studies from the DPP on participants with impaired glucose tolerance and elevated fasting glucose reveal that the lifestyle preventive intervention was effective
Annu. Rev. Med. 2008.59:95-111. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-07
ARI
7 December 2007
12:34
in reducing the genetic risk conferred by the high-risk homozygous genotype to the level of their wild-type counterparts (55). A possible interaction between this locus and insulin secretagogues, incretin mimetics, or dipeptidyl peptidase IV inhibitors has not yet been investigated. One exciting new area of active research involves variability in medication transport and metabolism. Recent work by Shu et al. (75) has introduced the hepatic transport of metformin as yet another area in which genetic variability may play a significant role in therapy response . This group showed that the organic cation transporter 1 (OCT1), which participates in the hepatic uptake of metformin, may contribute to variation in response to metformin. These authors reported a reduced effect of metformin on AMP kinase phosphorylation in Oct1-deficient mouse hepatocytes and poor absorption of metformin in Oct1-deficient mice. They also showed that the OCT1 reduced-function allele in healthy human subjects is predictive of higher glucose levels during an oral glucose tolerance test. Thus, this complementary area of pharmacogenetic investigation holds great promise in explaining the human variability in drug response.
GENOME-WIDE ASSOCIATION SCANS The most dramatic recent advance in T2D genomics is the availability of data from genome-wide association scans (GWASs), enabled by the development and affordability of high-throughput genotyping platforms, the compilation of SNPs in public databases, the assembly of large patient cohorts, the completion of the HapMap, and the generation of sophisticated analytical tools. GWASs query the genome while remaining agnostic to biological plausibility, and these surveys currently provide 70%–80% coverage of human common genomic variation. Five GWASs, as well as a partial metaanalysis that encompasses three of them, have
been published in the past year (Table 1). The scans have both confirmed known T2D loci and introduced at least six novel diabetes genes. Of note, TCF7L2 has been replicated as the genetic locus with unequivocally the strongest signal. The first GWAS was performed on a French population in February 2007. It reproduced the powerful impact of TCF7L2 (OR 1.65, p < 1.0 × 10−7 ) and also identified HHEX (OR 1.21, p = 9.1 × 10−6 ) and SLC30A8 (OR 1.26, p = 5.0 × 10−7 ) as potential novel T2D loci. SLC30A8, a zinc transporter gene initially cloned and sequenced in 2004, is expressed exclusively in pancreatic β cells, where it transports zinc from the cytoplasm into insulin secretory vesicles (76). This is a critical step in the final biosynthetic pathway of insulin production and secretion. HHEX is thought to be involved in β cell development or function (77). Two other loci reported by these investigators have not yet been replicated in subsequent work. Following this initial report, four wellpowered GWAS surveys were published simultaneously. In a Nature Genetics report, the deCODE group and collaborators confirmed again the strong signal of TCF7L2 (OR 1.38, p = 1.9 × 10−10 ) and replicated the HHEX and SCL30A8 findings. CDKAL1 (CDK5 regulatory subunit associated protein 1–like 1) was also identified by these investigators (OR 1.2, p = 18 × 10−4 ). This gene affects CDK5/CDK5R1 activity, and in so doing, may lead to β cell degeneration. Further, they found that the insulin response of homozygotes was ∼20% lower than that of heterozygotes or noncarriers, confirming the biological plausibility of this finding (78). Simultaneously with the deCODE paper, the Diabetes Genetics Initiative (DGI) (79), the Wellcome Trust Case Control Consortium (WTCCC), (80) and the Finland– United States Investigation of NIDDM Genetics (FUSION) (81) each published a GWAS in Science. The studies represent, in aggregate, more than 32,000 samples and have www.annualreviews.org • Pharmacogenetics in Type 2 Diabetes
GWAS: genome-wide association scan
103
ANRV334-ME59-07
ARI
Table 1
7 December 2007
12:34
Genetic loci associated with type 2 diabetes that have achieved genome-wide significance Sladek et al. (77) (n = 6794)
Markera
Chr
Position
Nearest gene
Notes
Risk allele
deCODE (78) (n = 10,056)
OR (95% CI)
p value
OR (95% CI)
p value
1.38
1.9×10−10
1.2
7.7 × 10−9
Annu. Rev. Med. 2008.59:95-111. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Previously known rs7903146
10
114748339
TCF7L2
Transcription factor; risk allele impairs insulin secretion
T
1.65
3.3 × 10−10
rs5219
11
17366148
KCNJ11
Kir6.2 potassium channel; risk allele impairs insulin secretion
T
1.34
0.074
rs1801282
3
12368125
PPARG
Nuclear C hormone receptor; target for thiazolidinediones
1.22
0.11
GWAS-identified rs4402960
3
186994389
IGF2BP2
Growth factor binding protein; pancreatic development
T
rs10811661
9
22124094
CDKN2B Cyclindependent kinase inhibitor and p15 tumor suppressor; islet development
T
rs7754840
6
20769229
CDKAL1
Homologous to CDK5RAP1, CDK5 inhibitor; islet glucotoxicity sensor
C
rs1111875
10
94452862
HHEX
Pancreatic transcription factor; pancreatic development
C
1.21
8.6 × 10−6
1.17
0.001
rs13266634
8
118253964
SLC30A8 β cell zinc transporter ZnT8; insulin biosynthesis
C
1.18
5.0 × 10−7
1.19
0.001
a b
Proxies include: for rs7754840, rs10946398; for rs7903146, rs7901695; and for rs5219, rs5215. Meta-analysis of DGI, WTCCC, and FUSION.
104
Moore
·
Florez
ANRV334-ME59-07
ARI
7 December 2007
12:34
Table (Continued ) DGI (79) (n = 13,781)
Annu. Rev. Med. 2008.59:95-111. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
OR (95% CI)
p value
WTCCC (80) (n = 13,965) OR (95% CI)
p value
FUSION (81) (n = 4808) OR (95% CI)
p value
Meta-analysisb (n = 32,554) OR (95% CI)
p value
1.38 (1.31–1.46)
2.3 × 10−31
1.37 (1.25–1.49)
6.7 × 10−13
1.34 (1.21–1.49)
1.4 × 10−8
1.37 (1.31–1.43)
1.0 × 10−48
1.15 (1.09–1.21)
1.0 × 10−7
1.15 (1.05–1.25)
1.3 × 10−3
1.11 (1.02–1.21)
0.014
1.14 (1.10–1.19)
6.7 × 10−11
1.09 (1.01–1.16)
0.019
1.23 (1.09–1.41)
1.3 × 10−3
1.20 (1.07–1.33)
1.4 × 10−3
1.14 (1.08–1.20)
1.7 × 10−6
1.17 (1.11–1.23)
1.7 × 10−9
1.11 (1.05–1.16)
1.6 × 10−4
1.18 (1.08–1.28)
2.4 × 10−4
1.14 (1.11–1.18)
8.9 × 10−16
1.20 (1.12–1.28)
5.4 × 10−8
1.19 (1.11–1.28)
4.9 × 10−7
1.20 (1.07–1.36)
2.2 × 10−3
1.20 (1.14–1.25)
7.8 × 10−15
1.08 (1.03–1.14)
2.4 × 10−3
1.16 (1.10–1.22)
1.3 × 10−8
1.12 (1.03–1.22)
9.5 × 10−3
1.12 (1.08–1.16)
4.1 × 10−11
1.14 (1.06–1.22)
1.7 × 10−4
1.13 (1.07–1.19)
4.6 × 10−6
1.10 (1.01–1.19)
0.025
1.13 (1.08–1.17)
5.7 × 10−10
1.07 (1.00–1.16)
0.047
1.12 (1.05–1.18)
7.0 × 10−5
1.18 (1.09–1.29)
7.0 × 10−5
1.12 (1.07–1.16)
5.3 × 10−8
www.annualreviews.org • Pharmacogenetics in Type 2 Diabetes
105
ARI
7 December 2007
12:34
been combined in an initial meta-analysis of the best results. These GWASs confirmed the known TCF7L2, KCNJ11, and PPARG loci as well as the recently published HHEX and SCL30A8 associations. They independently discovered the CDKAL1 association and also identified the novel diabetes loci IGF2BP2 (OR 1.14, p = 8.9 × 10−16 ) and CDKN2B (OR 1.2, p = 7.8 × 10−15 ). Taken together, these studies provide strong evidence for the potential power of GWASs. The following considerations emerge from this sizeable advancement in our knowledge of the genetic etiology of T2D:
Annu. Rev. Med. 2008.59:95-111. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-07
1. All of the genetic effects are modest, with a ceiling of effect (produced by the combination of allele frequency and genetic risk) hovering around TCF7L2. 2. The collaborative integration of multiple datasets and consequent very large sample sizes will be essential to confirm or refute individual findings, extend the search for statistical associations further down the p-value distribution, explore phenotypic covariates, and assess epistatic interactions. 3. Novel biology remains to be discovered in relation to the effects of inherited DNA variation on human phenotypic diversity in general and metabolic traits in particular.
4. Association studies, if adequately powered, can indeed help characterize the genetic architecture of complex diseases. 5. This rapid progress has been greatly facilitated by the generous and disinterested posting of anonymized genomic data and analytical tools in the public domain.
CONCLUSIONS Genetic studies of T2D have been extremely productive. Multiple genes have been identified in the past ten years, and a series of GWAS surveys were released in the first months of 2007. This growing ensemble captures only a small fraction of the genetic risk of T2D. Moreover, the precise metabolic consequences of these novel genetic discoveries are yet to be determined, and whether these results will affect clinical practice must be tested empirically. Understanding the complex interactions among genetic profiles, individual lifestyles, and environmental factors lies at the core of effective diabetes treatment. Thus, although this body of work represents a tremendous accomplishment, it is but a springboard. The hope is that improved genetic understanding may one day enhance the health and life span of the diabetic patients we treat.
DISCLOSURE STATEMENT The authors are not aware of any biases that might be perceived as affecting the objectivity of this review.
LITERATURE CITED 1. Groop L, Tuomi T. 1997. Non-insulin-dependent diabetes mellitus—a collision between thrifty genes and an affluent society. Ann. Med. 29:37–53 2. Barnett AH, Eff C, Leslie RD, et al. 1981. Diabetes in identical twins. A study of 200 pairs. Diabetologia 20:87–93 3. Ghosh S, Schork N. 1996. Genetic analysis of NIDDM. The study of quantitative traits. Diabetes 45:1–14 4. Fajans SS, Conn JW. 1960. Tolbutamide-induced improvement in carbohydrate tolerance of young people with mild diabetes mellitus. Diabetes 9:83–88 106
Moore
·
Florez
Annu. Rev. Med. 2008.59:95-111. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-07
ARI
7 December 2007
12:34
5. Ledermann HM. 1995. Maturity-onset diabetes of the young (MODY) at least ten times more common in Europe than previously assumed? Diabetologia 38:1482 6. Bell GI, Xiang KS, Newman W, et al. 1991. Gene for noninsulin-dependent diabetes mellitus (maturity-onset diabetes of the young subtype) is linked to DNA polymorphism on human chromosome 20q. Proc. Natl. Acad. Sci. USA 88:1484–88 7. Velho G, Blanch´e H, Vaxillaire M, et al. 1997. Identification of 14 new glucokinase mutations and description of the clinical profile of 42 MODY-2 families. Diabetologia 40:217–24 8. Sarabu R, Grimsby J. 2005. Targeting glucokinase activation for the treatment of type 2 diabetes—a status review. Curr. Opin. Drug. Discov. Dev. 8:631–37 9. Ellard S, Colclough K. 2006. Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha (HNF1A) and 4 alpha (HNF4A) in maturity-onset diabetes of the young. Hum. Mutat. 27:854–69 10. Stoffers DA, Zinkin NT, Stanojevic V, et al. 1997. Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. Nat. Genet. 15:106– 10 11. Horikawa Y, Iwasaki I, Hara M, et al. 1997. Mutation in hepatocyte nuclear factor-1β gene (TCF2) associated with MODY. Nat. Genet. 17:384–85 12. Brackenridge A, Pearson ER, Shojaee-Moradie F, et al. 2006. Contrasting insulin sensitivity of endogenous glucose production rate in subjects with hepatocyte nuclear factor-1β and -1α mutations. Diabetes 55:405–11 13. Bingham C, Ellard S, Cole TR, et al. 2002. Solitary functioning kidney and diverse genital tract malformations associated with hepatocyte nuclear factor-1β mutations. Kidney Int. 61:1243–51 14. Pearson ER, Badman MK, Lockwood CR, et al. 2004. Contrasting diabetes phenotypes associated with hepatocyte nuclear factor-1α and -1β mutations. Diab. Care 27:1102–7 15. Malecki MT, Jhala US, Antonellis A, et al. 1999. Mutations in NEUROD1 are associated with the development of type 2 diabetes mellitus. Nat. Genet. 23:323–28 16. Kristinsson SY, Thorolfsdottir ET, Talseth B, et al. 2001. MODY in Iceland is associated with mutations in HNF-1α and a novel mutation in NeuroD1. Diabetologia 44:2098–103 17. Krook A, Brueton L, O’Rahilly S. 1993. Homozygous nonsense mutation in the insulin receptor gene in infant with leprechaunism. Lancet 342:277–78 18. Moller DE, Flier JS. 1988. Detection of an alteration in the insulin-receptor gene in a patient with insulin resistance, acanthosis nigricans, and the polycystic ovary syndrome (type A insulin resistance). N. Engl. J. Med. 319:1526–29 19. Windpassinger C, Auer-Grumbach M, Irobi J, et al. 2004. Heterozygous missense mutations in BSCL2 are associated with distal hereditary motor neuropathy and silver syndrome. Nat. Genet. 36:271–76 20. Shackleton S, Lloyd DJ, Jackson SN, et al. 2000. LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat. Genet. 24:153–56 21. Temple IK, Gardner RJ, Mackay DJ, et al. 2000. Transient neonatal diabetes: widening the understanding of the etiopathogenesis of diabetes. Diabetes 49:1359–66 22. Gloyn AL, Pearson ER, Antcliff JF, et al. 2004. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N. Engl. J. Med. 350:1838–49 23. Thomas Y, Ye Y, Lightner E. 1996. Mutation of the pancreatic islet inward rectifier Kir6.2 also leads to familial persistent hyperinsulinemic hypoglycemia of infancy. Hum. Mol. Genet. 5:1809–12 www.annualreviews.org • Pharmacogenetics in Type 2 Diabetes
107
ARI
7 December 2007
12:34
24. Gloyn AL, Reimann F, Girard C, et al. 2005. Relapsing diabetes can result from moderately activating mutations in KCNJ11. Hum. Mol. Genet. 14:925–34 25. Hattersley AT, Ashcroft FM. 2005. Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. Diabetes 54:2503–13 26. Huopio H, Otonkoski T, Vauhkonen I, et al. 2003. A new subtype of autosomal dominant diabetes attributable to a mutation in the gene for sulfonylurea receptor 1. Lancet 361:301– 7 27. Babenko AP, Polak M, Cave H, et al. 2006. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N. Engl. J. Med. 355:456–66 28. Love-Gregory LD, Wasson J, Ma J, et al. 2004. A common polymorphism in the upstream promoter region of the hepatocyte nuclear factor-4α gene on chromosome 20q is associated with type 2 diabetes and appears to contribute to the evidence for linkage in an Ashkenazi Jewish population. Diabetes 53:1134–40 29. Weedon MN, Owen KR, Shields B, et al. 2004. Common variants of the hepatocyte nuclear factor-4α P2 promoter are associated with type 2 diabetes in the U.K. population. Diabetes 53:3002–6 30. Winckler W, Graham RR, de Bakker PIW, et al. 2005. Association testing of variants in the hepatocyte nuclear factor 4α gene with risk of type 2 diabetes in 7883 people. Diabetes 54:886–92 31. Winckler W, Burtt NP, Holmkvist J, et al. 2005. Association of common variation in the HNF1α gene region with risk of type 2 diabetes. Diabetes 54:2336–42 32. Holmkvist J, Cervin C, Lyssenko V, et al. 2006. Common variants in HNF-1α and risk of type 2 diabetes. Diabetologia 49:2882–91 33. Bonnycastle LL, Willer CJ, Conneely KN, et al. 2006. Common variants in MaturityOnset Diabetes of the Young genes contribute to risk of type 2 diabetes in Finns. Diabetes 55:2534–40 34. Winckler W, Weedon MN, Graham RR, et al. 2007. Evaluation of common variants in the six known Maturity-Onset Diabetes of the Young (MODY) genes for association with type 2 diabetes. Diabetes 56:685–93 35. Love-Gregory L, Wasson J, Lin J, et al. 2003. E23K single nucleotide polymorphism in the islet ATP-sensitive potassium channel gene (Kir6.2) contributes as much to the risk of type II diabetes in Caucasians as the PPARγ Pro12Ala variant. Diabetologia 46:136–37 36. Weedon MN, Frayling TM, Shields B, et al. 2005. Genetic regulation of birth weight and fasting glucose by a common polymorphism in the islet cell promoter of the glucokinase gene. Diabetes 54:576–81 37. Hanis CL, Boerwinkle E, Chakraborty R, et al. 1996. A genome-wide search for human noninsulin-dependent (type 2) diabetes genes reveals a major susceptibility locus on chromosome 2. Nat. Genet. 13:161–66 38. Weedon MN, Schwarz PEH, Horikawa Y, et al. 2003. Meta-analysis and a large association study confirm a role for calpain-10 variation in type 2 diabetes susceptibility. Am. J. Hum. Genet. 73:1208–12 39. Song Y, Niu T, Manson JE, et al. 2004. Are variants in the CAPN10 gene related to risk of type 2 diabetes? A quantitative assessment of population and family-based association studies. Am. J. Hum. Genet. 74:208–22 40. Tsuchiya T, Schwarz PEH, Bosque-Plata LD, et al. 2006. Association of the calpain-10 gene with type 2 diabetes in Europeans: results of pooled and meta-analyses. Mol. Genet. Metab. 89:174–84 41. Sreenan SK, Zhou YP, Otani K, et al. 2001. Calpains play a role in insulin secretion and action. Diabetes 50:2013–20
Annu. Rev. Med. 2008.59:95-111. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-07
108
Moore
·
Florez
Annu. Rev. Med. 2008.59:95-111. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-07
ARI
7 December 2007
12:34
42. Altshuler D, Hirschhorn JN, Klannemark M, et al. 2000. The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat. Genet. 26:76–80 43. Deeb SS, Fajas L, Nemoto M, et al. 1998. A Pro12Ala substitution in PPARγ 2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat. Genet. 20:284–87 44. Florez JC, Hirschhorn JN, Altshuler D. 2003. The inherited basis of diabetes mellitus: implications for the genetic analysis of complex traits. Annu. Rev. Genom. Hum. Genet. 4:257–91 45. Lyssenko V, Almgren P, Anevski D, et al. 2005. Genetic prediction of future type 2 diabetes. PLOS Med. 2:e345 46. Florez JC, Jablonski KA, Sun MW, et al. 2007. Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. J. Clin. Endocrinol. Metab. 92:1502–9 47. Gloyn AL, Hashim Y, Ashcroft SJ, et al. 2001. Association studies of variants in promoter and coding regions of β-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53). Diabet. Med. 18:206–12 48. Gloyn AL, Weedon MN, Owen KR, et al. 2003. Large-scale association studies of variants in genes encoding the pancreatic β-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes 52:568–72 49. Nielsen E-MD, Hansen L, Carstensen B, et al. 2003. The E23K variant of Kir6.2 associates with impaired post-OGTT serum insulin response and increased risk of type 2 diabetes. Diabetes 52:573–77 50. Barroso I, Luan J, Middelberg RPS, et al. 2003. Candidate gene association study in type 2 diabetes indicates a role for genes involved in β-cell function as well as insulin action. PLOS Biol. 1:e20 51. Florez JC, Burtt N, de Bakker PIW, et al. 2004. Haplotype structure and genotypephenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region. Diabetes 53:1360–68 52. van Dam RM, Hoebee B, Seidell JC, et al. 2005. Common variants in the ATP-sensitive K+ channel genes KCNJ11 (Kir6.2) and ABCC8 (SUR1) in relation to glucose intolerance: population-based studies and meta-analyses. Diabet. Med. 22:590–98 53. Grant SFA, Thorleifsson G, Reynisdottir I, et al. 2006. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat. Genet. 38:320–23 54. Florez JC. 2007. The new type 2 diabetes gene TCF7L2. Curr. Opin. Clin. Nutr. Metab. Care 10:391–96 55. Florez JC, Jablonski KA, Bayley N, et al. 2006. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N. Engl. J. Med. 355:241–50 56. Loos RJF, Franks PW, Francis RW, et al. 2007. TCF7L2 polymorphisms modulate proinsulin levels and β-cell function in a British Europid population. Diabetes 56:1943–47 57. Roden DM, Altman RB, Benowitz NL, et al. 2006. Pharmacogenomics: challenges and opportunities. Ann. Intern. Med. 145:749–57 58. Rieder MJ, Reiner AP, Gage BF, et al. 2005. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352:2285–93 58a. Farooqi IS, Jebb SA, Langmack G, et al. 1999. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N. Engl. J. Med. 341:879–84 59. UKPDS. 1998. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–53 www.annualreviews.org • Pharmacogenetics in Type 2 Diabetes
109
ARI
7 December 2007
12:34
60. Sagen JV, Raeder H, Hathout E, et al. 2004. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. Diabetes 53:2713–18 61. Pearson ER, Flechtner I, Njolstad PR, et al. 2006. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N. Engl. J. Med. 355:467–77 62. Pearson ER, Starkey BJ, Powell RJ, et al. 2003. Genetic cause of hyperglycemia and response to treatment in diabetes. Lancet 362:1275–81 63. Lehmann JM, Moore LB, Smith-Oliver TA, et al. 1995. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J. Biol. Chem. 270:12953–56 64. Inzucchi SE, Maggs DG, Spollett GR, et al. 1998. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N. Engl. J. Med. 338:867–73 65. Masugi J, Tamori Y, Mori H, et al. 2000. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-γ2 on thiazolidinedioneinduced adipogenesis. Biochem. Biophys. Res. Commun. 268:178–82 ¨ 66. Bluher M, Lubben G, Paschke R. 2003. Analysis of the relationship between the Pro12Ala variant in the PPAR-γ2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes. Diab. Care 26:825–31 67. Snitker S, Watanabe RM, Ani I, et al. 2004. Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-γ2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study. Diab. Care 27:1365–68 67a. Wolford JK, Yeatts KA, Dhanjal SK, et al. 2005. Sequence variation in PPARG may underlie differential response to troglitazone. Diabetes 54:3319–25 68. Kang ES, Park SY, Kim HJ, et al. 2005. Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor γ2 gene on rosiglitazone response in type 2 diabetes. Clin. Pharmacol. Ther. 75:202–8 69. Sesti G, Laratta E, Cardellini M, et al. 2006. The E23K variant of KCNJ11 encoding the pancreatic β-cell KATP channel subunits Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 91:2334–39 70. Florez JC, Jablonski KA, Kahn SE, et al. 2007. Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program. Diabetes 56:531–36 71. Damcott CM, Pollin TI, Reinhart LJ, et al. 2006. Polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene are associated with type 2 diabetes in the Amish: replication and evidence for a role in both insulin secretion and insulin resistance. Diabetes 55:2654– 59 72. Saxena R, Gianniny L, Burtt NP, et al. 2006. Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. Diabetes 55:2890–95 73. Wang J, Kuusisto J, V¨anttinen M, et al. 2007. Variants of transcription factor 7-like 2 (TCF7L2) gene predict conversion to type 2 diabetes in the Finnish Diabetes Prevention Study and are associated with impaired glucose regulation and impaired insulin secretion. Diabetologia 50:1192–200 74. Kimber CH, Doney AS, Pearson ER, et al. 2007. TCF7L2 in the Go-DARTS study: evidence for a gene dose effect on both diabetes susceptibility and control of glucose levels. Diabetologia 50:1186–91
Annu. Rev. Med. 2008.59:95-111. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-07
110
Moore
·
Florez
Annu. Rev. Med. 2008.59:95-111. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-07
ARI
7 December 2007
12:34
74a. Pearson ER, Donnelly LA, Kimber CH, et al. 2007. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes 56:2178–82 75. Shu S, Sheardown SA, Brown C, et al. 2007. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J. Clin. Invest. 117:1422–31 76. Chimienti F, Devergnas S, Favier A, et al. 2004. Identification and cloning of a β-cell specific zinc transporter, Zn T8, localized into insulin sectretory granules. Diabetes 53:2330– 37 77. Sladek R, Rocheleau G, Rung J, et al. 2007. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445:828–30 78. Steinthorsdottir V, Thorleifsson G, Reynisdottir I, et al. 2007. A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Science 39:770–75 79. Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University and Novartis Institutes for BioMedical Research. 2007. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316:1331–36 80. Zeggini E, Weedon MN, Lindgren CM, et al. 2007. Replication of genome-wide association signals in U.K. samples reveals risk loci for type 2 diabetes. Science 316:1336–41 81. Scott LJ, Mohlke KL, Bonnycastle LL, et al. 2007. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316:1341–45
www.annualreviews.org • Pharmacogenetics in Type 2 Diabetes
111
AR334-FM
ARI
18 December 2007
17:20
Annual Review of Medicine
Annu. Rev. Med. 2008.59:95-111. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Contents
Volume 59, 2008
The FDA Critical Path Initiative and Its Influence on New Drug Development Janet Woodcock and Raymond Woosley p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p1 Reversing Advanced Heart Failure by Targeting Ca2+ Cycling David M. Kaye, Masahiko Hoshijima, and Kenneth R. Chien p p p p p p p p p p p p p p p p p p p p p p p p 13 Tissue Factor and Factor VIIa as Therapeutic Targets in Disorders of Hemostasis Ulla Hedner and Mirella Ezban p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 29 Therapy of Marfan Syndrome Daniel P. Judge and Harry C. Dietz p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 43 Preeclampsia and Angiogenic Imbalance Sharon Maynard, Franklin H. Epstein, and S. Ananth Karumanchi p p p p p p p p p p p p p p p p p 61 Management of Lipids in the Prevention of Cardiovascular Events Helene Glassberg and Daniel J. Rader p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 79 Genetic Susceptibility to Type 2 Diabetes and Implications for Antidiabetic Therapy Allan F. Moore and Jose C. Florez p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 95 Array-Based DNA Diagnostics: Let the Revolution Begin Arthur L. Beaudet and John W. Belmont p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p113 Inherited Mitochondrial Diseases of DNA Replication William C. Copeland p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p131 Childhood Obesity: Adrift in the “Limbic Triangle” Michele L. Mietus-Snyder and Robert H. Lustig p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p147 Expanded Newborn Screening: Implications for Genomic Medicine Linda L. McCabe and Edward R.B. McCabe p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p163 Is Human Hibernation Possible? Cheng Chi Lee p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p177 Advance Directives Linda L. Emanuel p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p187 v
AR334-FM
ARI
18 December 2007
17:20
Genetic Determinants of Aggressive Breast Cancer Alejandra C. Ventura and Sofia D. Merajver p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p199 A Role for JAK2 Mutations in Myeloproliferative Diseases Kelly J. Morgan and D. Gary Gilliland p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p213 Appropriate Use of Cervical Cancer Vaccine Gregory D. Zimet, Marcia L. Shew, and Jessica A. Kahn p p p p p p p p p p p p p p p p p p p p p p p p p p p p p223 A Decade of Rituximab: Improving Survival Outcomes in Non-Hodgkin’s Lymphoma Arturo Molina p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p237 Annu. Rev. Med. 2008.59:95-111. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Nanotechnology and Cancer James R. Heath and Mark E. Davis p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p251 Cancer Epigenetics: Modifications, Screening, and Therapy Einav Nili Gal-Yam, Yoshimasa Saito, Gerda Egger, and Peter A. Jones p p p p p p p p p p p p267 T Cells and NKT Cells in the Pathogenesis of Asthma Everett H. Meyer, Rosemarie H. DeKruyff, and Dale T. Umetsu p p p p p p p p p p p p p p p p p p p p281 Complement Regulatory Genes and Hemolytic Uremic Syndromes David Kavanagh, Anna Richards, and John Atkinson p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p293 Mesenchymal Stem Cells in Acute Kidney Injury Benjamin D. Humphreys and Joseph V. Bonventre p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p311 Asthma Genetics: From Linear to Multifactorial Approaches Stefano Guerra and Fernando D. Martinez p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p327 The Effect of Toll-Like Receptors and Toll-Like Receptor Genetics in Human Disease Stavros Garantziotis, John W. Hollingsworth, Aimee K. Zaas, and David A. Schwartz p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p343 Advances in Antifungal Therapy Carole A. Sable, Kim M. Strohmaier, and Jeffrey A. Chodakewitz p p p p p p p p p p p p p p p p p p361 Herpes Simplex: Insights on Pathogenesis and Possible Vaccines David M. Koelle and Lawrence Corey p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p381 Medical Management of Influenza Infection Anne Moscona p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p397 Bacterial and Fungal Biofilm Infections A. Simon Lynch and Gregory T. Robertson p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p415 EGFR Tyrosine Kinase Inhibitors in Lung Cancer: An Evolving Story Lecia V. Sequist and Thomas J. Lynch p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p429 Adaptive Treatment Strategies in Chronic Disease Philip W. Lavori and Ree Dawson p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p443 vi
Contents
AR334-FM
ARI
18 December 2007
17:20
Antiretroviral Drug–Based Microbicides to Prevent HIV-1 Sexual Transmission Per Johan Klasse, Robin Shattock, and John P. Moore p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p455 The Challenge of Hepatitis C in the HIV-Infected Person David L. Thomas p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p473 Hide-and-Seek: The Challenge of Viral Persistence in HIV-1 Infection Luc Geeraert, Günter Kraus, and Roger J. Pomerantz p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p487
Annu. Rev. Med. 2008.59:95-111. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Advancements in the Treatment of Epilepsy B.A. Leeman and A.J. Cole p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p503 Indexes Cumulative Index of Contributing Authors, Volumes 55–59 p p p p p p p p p p p p p p p p p p p p p p p p525 Cumulative Index of Chapter Titles, Volumes 55–59 p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p529 Errata An online log of corrections to Annual Review of Medicine articles may be found at http://med.annualreviews.org/errata.shtml
Contents
vii
ANRV334-ME59-08
ARI
7 December 2007
13:56
Annu. Rev. Med. 2008.59:113-129. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Array-Based DNA Diagnostics: Let the Revolution Begin Arthur L. Beaudet and John W. Belmont Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas 77030; email:
[email protected],
[email protected]
Annu. Rev. Med. 2008. 59:113–29
Key Words
First published online as a Review in Advance on October 25, 2007
microarray, chromosomal imbalance, genotyping, mutation analysis, DNA sequencing
The Annual Review of Medicine is online at http://med.annualreviews.org This article’s doi: 10.1146/annurev.med.59.012907.101800 c 2008 by Annual Reviews. Copyright All rights reserved 0066-4219/08/0218-0113$20.00
Abstract Advances in the fabrication of DNA microarrays as well as transformations in detection chemistries have vastly increased the throughput for genotyping, DNA sequencing, and array-based copy number analysis (ABCNA). Rapid changes in technology are not only affecting research but also revolutionizing DNA diagnostics. Here we focus on the application of high-throughput ABCNA and genotyping. Targeted and genome-wide ABCNA has led to the discovery of extensive DNA copy number variation in the population and the delineation of many previously unrecognized submicroscopic chromosomal aberrations (genomic disorders). High-throughput singlenucleotide polymorphism (SNP) genotyping is being widely applied in genome-wide association studies (GWASs) with recent successes in identification of common variants that confer risk for common adult diseases. Future applications of high-throughput genotyping and array-based DNA sequencing technology will undoubtedly involve research and diagnostic analyses of rare mutations and perhaps ultimately enable full individual genome sequencing.
113
ANRV334-ME59-08
ARI
7 December 2007
13:56
HIGH-THROUGHPUT ANALYSIS OF COPY NUMBER VARIATION Feature: a spot on an array, whether BAC, oligonucleotide, PCR product, or other
Annu. Rev. Med. 2008.59:113-129. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Array CGH: array comparative genomic hybridization ABCNA: array-based copy number analysis Chromosomal microarray analysis (CMA): a clinically friendly term to encompass copy number analysis, including array CGH but also non-CGH platforms such as Affymetrix and Illumina when used to determine copy number BAC: bacterial artificial chromosome Copy number variant (CNV): alternative structure in genomic DNA that typically includes deletions (reduced copy number) and duplications (more copies) in adjacent segments of DNA. The presence of these deleted/ duplicated segments can vary among individuals; they are, therefore, a type of polymorphism
114
Microarrays of increasing complexity are becoming available at decreasing cost per feature. This has made it feasible to perform genome-wide analysis of copy number variation for research purposes and for clinical diagnosis. Two distinct platforms are available: Some methods use array comparative genomic hybridization (array CGH), in which direct comparison to a control is essential, whereas others determine relative copy number for a region quantitatively within a single genome without the use of an internal control in a cohybridization. All of these methods quantify copy number differences within a human sample for the purposes of research or clinical diagnosis. As a group, they all offer quantitative array-based copy number analysis (ABCNA), and in a clinical setting, they can be described as chromosomal microarray analysis (CMA). Some commercial platforms for array CGH use large insert clones such as bacterial artificial chromosomes (BACs) (Perkin-Elmer and BlueGnome), but platforms using oligonucleotides (Agilent Technologies and Nimblegen) are increasingly preferred (1). The two major commercial platforms that do not use CGH (Affymetrix and Illumina) grew out of arrays that were originally designed for typing single-nucleotide polymorphisms (SNPs). These platforms now offer combined SNP genotyping and copy number analysis.
GENOME ARCHITECTURE The enormous extent of copy number variation in the human genome has only recently been appreciated. Although copy number variation in the human genome has been known for decades for loci such as the αglobin and color pigment genes, the 1991 discovery that genomic duplications encompassing the PMP22 gene are the cause of the most common form of Charcot-MarieTooth disease (2) opened the much broader Beaudet
·
Belmont
vista of what have been called genomic disorders (3, 4). Genomic disorders are clinical phenotypes caused by abnormal dosage or dysregulation of one or more genes resulting from rearrangement of the genome. It has become clear that low copy repeats (LCRs) mediate deletions, duplications, and inversions. The extent of LCRs in the genome was extensively documented by Eichler and colleagues using bioinformatic methods (5). These genomic LCRs are genomic sequences of substantial length that are typically 98–99% identical in sequence. Copy number variants (CNVs) often occur within a region flanked by LCRs, but many CNVs occur independently of LCRs. LCRs can contain one or more intact functional genes within the repeat, although this is often not the case. The location of LCRs has been used to identify regions of the genome that will be particularly susceptible to deletion and duplication (6). A CNV whose less common form accounts for at least 1% of the alleles in the population can be defined as a copy number polymorphism by analogy to the standard definition of a polymorphism.
FUNCTIONAL SIGNIFICANCE OF COPY NUMBER VARIANTS From current data, it is clear that some CNVs represent single-region genomic disorders with very high or complete penetrance. These may involve a single gene within the CNV that mediates most or all of the phenotype (e.g., Charcot-Marie-Tooth disease type 1A and duplication of PMP22) or multiple genes contributing to the phenotype (as for Williams syndrome). It also seems likely, but is not proven, that the majority of CNVs in the genome are benign and have minimal or no detectable effect on the phenotype. However, it is also clear that some CNVs mediate a single gene/region disorder with incomplete penetrance [e.g., deletions of PMP22 causing HNPP (hereditary neuropathy with liability to pressure palsies), in which many individuals with the genotype are asymptomatic
Annu. Rev. Med. 2008.59:113-129. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-08
ARI
7 December 2007
13:56
throughout life]. Of enormous interest at this moment is the role of CNVs in common diseases of complex etiology, in which the CNV may be only one of a group of genetic variations contributing to the phenotype. One can also imagine that CNVs might contribute to phenotypic variation within the normal population, affecting skin pigmentation, height, behavioral differences, musicality, mathematical ability, and a myriad of other human traits. It is known that deletion of the P locus in association with Prader-Willi syndrome and Angelman syndrome can cause hypopigmentation. It is known that deletion of the imprinted IGF2 locus on the paternal chromosome can lead to short stature and that duplication can lead to increased stature or gigantism.
METHODOLOGY As noted above, many different methods are available for analysis of copy number variation, some of which utilize the principles of array CGH (Figure 1). Much of the early work with array CGH has utilized large insert BAC arrays. Unlike oligonucleotide arrays, which for the most part have been produced by large commercial entities, large insert BAC arrays can be produced by academic labs and small companies. Another advantage of BAC arrays is that they can obtain a result from a miniscule amount of starting DNA because the hybridization signal can come from tens of kilobases (kb) of DNA. Oligonucleotide arrays have the great advantage that they can be chosen to be free of repetitive sequences, and they interrogate a very specific region. Oligonucleotides used in the various platforms typically range from 20 to 80 nucleotides. Oligonucleotides offer the possibility of strand-specific detection, which can be useful in certain circumstances. A disadvantage of BAC arrays is that they contain repetitive human sequences and require the use of Cot-1 DNA to suppress hybridization of repetitive sequences, and even then the signal-to-background ratio is
not as robust as for oligonucleotide arrays. Except for the Illumina platform, which attaches oligonucleotides to microspheres, the BACs or oligonucleotides are attached to a flat surface of glass or silica. The oligonucleotide platforms that offer SNP detection have potential advantages in terms of detection of uniparental disomy (UPD) and loss of heterozygosity (LOH). SNP detection offers the possibility to determine the parent of origin for a de novo deletion or duplication, and to determine paternity, in addition to detection of UPD and LOH. Detection of LOH is particularly important for analysis of tumors. The platforms that combine copy number quantitation and SNP detection offer the opportunity to do genome-wide studies that might detect disease susceptibilities related either to a CNV or a SNP. It is obvious that CNVs have a much higher mutation rate than SNPs. This has substantial implications for linkage and association studies that go far beyond what can be reviewed here, but the linkage disequilibrium (LD) and heritability found with CNVs has been subjected to an initial evaluation (7). The availability of wholegenome amplification (WGA) allows an enormous increase in the amount of research and diagnostic analysis that can be done with a small clinical sample. WGA is particularly useful for large collaborative studies analyzing a collection of samples that is available to multiple investigators. WGA can be applied to single-cell analysis, a strategy that potentially can be used for preimplantation genetic diagnosis.
LD: linkage disequilibrium WGA: whole-genome amplification
RESEARCH APPLICATIONS Current research has focused on simply defining the extent of copy number variation in the human genome. A number of publications have analyzed a series of normal individuals with generally similar results (5, 8, 9). One of the most extensive studies of 270 individuals identified 1447 CNVs covering 360 megabases (Mb) or 12% of the human genome. These CNVs encompass www.annualreviews.org • Array Diagnostics
115
ANRV334-ME59-08
ARI
7 December 2007
13:56
a.
Label patient DNA Label control DNA with Cy3 with Cy5
Mix
Hybridize DNA to genomic clone microarray
Annu. Rev. Med. 2008.59:113-129. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Analyze Cy3/Cy5 fluorescence ratio of patient to control
Cy3/Cy5 ratio >1 Cy3/Cy5 ratio <1 Deletion Duplication
Oligo array no dye reversal
b. BAC array with dye reversal -1.5
-1
-0.5
0
0.5
1
Oligos within a BAC region 1.5
RP11-487A2
0 Figure 1 Array CGH methodology and a comparison of BAC and oligonucleotide arrays. (a) For array comparative genomic hybridization, a patient’s DNA is labeled with green dye (left) and a control DNA is labeled with red dye (right). The DNA preparations are mixed and cohybridized to an array of BACs or oligonucleotides on a glass slide. The DNA bound to each spot is quantified using a laser scanner. In the patient’s DNA, normal regions will be indicated by a yellow balanced color; regions of duplication will be identified by greener spots, and regions of deletion will be identified by redder spots. (b) A patient sample with a small deletion affecting one BAC is shown on a BAC array (left) and on an oligonucleotide array simulating a BAC configuration (middle). Data for individual oligonucleotides within the BAC are also shown (right). The deviation of the abnormality relative to background is greater for the oligonucleotide array than for the BAC array.
hundreds of functional genes, and as many as 2908 RefSeq genes were identified using multiple platforms. A substantial fraction of these CNVs are very rare and 116
Beaudet
·
Belmont
were seen on only one chromosome in 270 individuals. The immediate future promises to be very exciting for research on the role of CNVs
Annu. Rev. Med. 2008.59:113-129. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-08
ARI
7 December 2007
13:56
in human evolution and diversity as well as research related to disease susceptibility and normal human variation. Although the population genetics of copy number variation is largely unexplored, one early report has shown extensive differences among African, European, and Asian populations (8). The extent to which CNVs contribute to complex disease traits and to normal human variation is virtually unexplored at this time. Any gene located within a CNV might be completely insensitive to copy number or dosage with either deletion or duplication. This is thought generally to be true for heterozygous deficiency of many genes encoding enzymes associated with inborn errors of metabolism, where heterozygous individuals are generally assumed to have a normal phenotype, although subtle phenotypic variations may be more common than is widely appreciated. There is very extensive knowledge of medical disorders in which haploinsufficiency for a gene generates a distinct phenotype with very high penetrance and some amount of variation in expression. These genes are extremely dosage-sensitive. There is less information about dosage sensitivity related to duplication, although the experience with CMT-1A makes it clear that duplications can affect phenotypes on the basis of sensitivity to excessive dosage. It seems quite likely that many genes would have intermediate levels of sensitivity to dosage variation, that the effect would depend on the genotype at other loci and on the environment (i.e., the mutations have incomplete penetrance), and that there would be extensive phenotypic variability among individuals symptomatic from a given deletion or duplication (i.e., the mutations show variation in expression).
CLINICAL APPLICATIONS Copy number analysis is already in use for identification of genomic mutations causing mental retardation, developmental delay, dysmorphic features, and other syndromic abnor-
malities. The majority of studies have used array CGH, but some have used oligonucleotide platforms that detect both SNPs and copy number independent of a CGH strategy. This literature has been reviewed recently (10). There are already two reports summarizing the experience with 1000–3000 clinical pediatric samples (11, 12), and the unpublished experience amounts to tens of thousands of clinical samples. It is overwhelmingly clear that ABCNA can detect a wide range of genomic abnormalities that are not detectable by conventional Giemsa banded karyotype. ABCNA methods are particularly advantageous for detection of duplications, which are difficult to detect even with metaphase fluorescence in situ hybridization (FISH). ABCNA methods provide the equivalent of hundreds or even thousands of FISH tests in a single clinical assay, with enormous cost savings compared to performing each FISH test individually. The frequency with which abnormalities of diagnostic significance are detected in various patient populations is quite variable, depending on the extent of previous cytogenetic evaluation and on the heterogeneity of the populations studied. The rate of discovery of causative abnormalities also depends on the complexity of the array platform being used, and there has been considerable debate about the advantages and disadvantages of targeted arrays versus tiling path arrays. We have estimated that ABCNA will detect a causal abnormality in ∼12%–18% of children with multiple congenital anomalies and/or developmental delay–mental retardation, with 3%–5% of these abnormalities being detected by a banded karyotype and 9%–13% detected by ABCNA but not by karyotype (10). The question of whether to use targeted arrays or tiling arrays in the clinic has been hotly debated. Targeted arrays typically focus on regions of known disease pathology, such as all known deletion and duplication syndromes. Targeted arrays additionally often have relatively dense coverage of subtelomeric www.annualreviews.org • Array Diagnostics
117
ARI
7 December 2007
13:56
and pericentromeric regions. These targeted arrays can establish an etiologic abnormality in a great number of patients who have a normal karyotype. The targeted arrays typically focus on CNV regions that are known to give phenotypic abnormalities with near 100% penetrance while avoiding regions of common CNVs where the clinical significance is unknown. Often, clinicians using ABCNA encounter a CNV on which there is minimal previous information. At least four sources of information bear on the clinical interpretation of such CNVs. First, if the CNV is de novo in the child and not present in either parent, it is statistically much more likely to be the cause of the child’s disabilities. Second, if the CNV is in a region known to be highly polymorphic in the normal population, it is less likely to be of clinical significance. Databases of CNVs are currently available on most genome browsers. Third, the size of the deletion or duplication matters. In general, the presumably benign CNVs are smaller than the disease-causing CNVs; the median sizes of CNVs from two platforms in one study were 228 kb and 81 kb (8), whereas disease-causing mutations are often many megabases in size. Finally, the gene content of a region can help to determine the clinical significance. If it is known that point mutations causing haploinsufficiency produce a phenotype with high penetrance, a deletion can be presumed to be the cause of that phenotype, even if a genomic deletion of the region has not been reported previously. Deletions or duplications encompassing large numbers of genes are statistically more likely to be disease-causing, since there is a probability that at least one gene in the region is dosagesensitive. In contrast to targeted arrays, tiling arrays offer much greater density of analysis and a greater chance of detecting a clinically causative abnormality if any is present. However, high-density tiling arrays typically detect 20–30 CNVs in a normal individual compared to a consensus genome. The majority of these CNVs will be common variants that are very likely to be benign on the basis of cur-
Annu. Rev. Med. 2008.59:113-129. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-08
118
Beaudet
·
Belmont
rent databases. However, some CNVs, perhaps 2–10, will be rare, and analysis of parents will be indicated to determine whether any of the variants are de novo rather than inherited. The use of targeted arrays for study of children with various disabilities can now be considered an advanced standard of care, although only ∼10% of chromosomal studies will include ABCNA in 2007. This proportion is increasing rapidly and will soon be the majority. It is probably most cost-effective to start with targeted arrays and regard tiling arrays as the next generation of technology. In most cases, parents should be studied for abnormalities detected by targeted arrays. A reasonable case can be made that all cases with normal results on targeted arrays could go on to tiling arrays. The clinician might well go directly to the highest-density tiling array that is available within an acceptable cost, and assume that it will be necessary to study parents in all cases. The use of ABCNA in the clinical evaluation of autism and in autism research deserves special mention. It is well known that chromosomal deletions and duplications involving virtually every chromosome can cause an autism phenotype, most often in combination with mental retardation and dysmorphic features (13). Some recent investigations using ABCNA to study autism populations have found higher rates of diagnostic abnormalities than previously expected, namely 28% in a study of dysmorphic patients (14) and 10% in a population of which presumably only a portion were dysmorphic (15). It has been argued (16) that these results predict that a substantial fraction of all autism is caused by classical mutations (both genomic and point mutations), most of which are de novo and associated with substantially reduced reproductive fitness. The use of ABCNA rather than karyotypic analysis is attractive for prenatal diagnosis because ABCNA can detect many more abnormalities. The potential advantages of such an approach have been reviewed (17), but substantial disagreement has been expressed (18).
ANRV334-ME59-08
ARI
7 December 2007
13:56
We believe that it is inevitable that ABCNA will replace karyotype for routine analysis of prenatal samples and that invasive prenatal diagnosis will be offered to all pregnant patients, at least until such analysis might become possible using a noninvasive sample from the mother (17).
Annu. Rev. Med. 2008.59:113-129. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
HIGH-THROUGHPUT GENOTYPING OF COMMON POLYMORPHISMS Microarray genotyping is making possible a new generation of powerful genetic association studies that escape the need for selection of candidate genes. In genetic association studies, cases are compared with either population- or family-based controls. The principles underlying genetic association studies have been reviewed recently (18a) and are not repeated here. Direct tests of association assess whether a particular variant plays a causal role in disease by comparing the frequency of the variant in a set of cases to that in the controls. Even in the absence of a direct test of association, the correlation between adjacent polymorphisms—called linkage disequilibrium (LD)—allows a subset of common markers to serve as surrogates for the variants that alter gene functions. The International HapMap Project has provided a very high-resolution LD map that has allowed selection of an efficient set of SNPs to capture a high fraction of genetic correlations (these are called tag SNPs). Given some knowledge of the LD patterns in the genome, sets of hundreds of thousands of markers can be selected that “cover” the most common variants in the population. The availability of the LD map and the technical capacity to genotype the necessary markers has now made genomewide association studies (GWASs) feasible. These new studies allow an unbiased search for associations that do not depend on any pre-existing knowledge of the genes or pathways involved.
GENOTYPING PLATFORMS Several technologies now allow SNPs to be genotyped rapidly, with high accuracy and very low cost. Robust chemistries that can analyze standard sets of up to 1.8 million SNPs and nonpolymorphic positions in a single assay are now available (Figure 2). These assays require scalable, multiplex assay chemistries coupled to an array-based address system to allow readout. The detection chemistry must have extremely high specificity for single-nucleotide variations, i.e., very low error rates in detection of both homozygous and heterozygous positions in SNPs. The very low molar concentration of unique DNA sequences in the diploid human genome requires coupled amplification systems to obtain useful signal-to-noise ratios. An important general principle for achieving singlebase specificity is the detection of physically coincident events (19). This is exactly the route taken by the polymerase chain reaction (PCR) assay, in which specific annealing of both primers is required for the reaction to take place. More complex multistep specificity and universal amplification strategies are employed in highly parallel genotyping assays to allow both single-base specificity and the sensitivity necessary for picking out the locus-specific signal from the complex mixture. Whole-genome sampling and amplification (WGSA) (Affymetrix; Figure 2a) allows parallel amplification of short DNA segments (100–1100 bp) that are then labeled and hybridized to oligonucleotide probe arrays (20). The oligonucleotides are specific for each of the two SNP alleles and the resulting hybridization intensities can be used to derive the genotypes. These assays are fixed in the sense that the investigator uses the information from a standardized array but cannot add SNPs for particular purposes. An alternative approach, incorporated in the Infinium assays (Illumina; Figure 2b,c) involves detection of allele-specific primer extension or single-base extension products on a
www.annualreviews.org • Array Diagnostics
GWAS: genome-wide association study
119
ANRV334-ME59-08
ARI
7 December 2007
13:56
a.
Restriction digest target DNA StyI
StyI
Sty1
gDNA
Adaptor ligation Genomic Sampling PCR
Hybridize to allele-specific 25-mer probe oligos, wash, and stain with fluorescent tagged streptavidin
End label b b b
b
Annu. Rev. Med. 2008.59:113-129. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Fragment size 100-1100 bp
b.
Target DNA gDNA
Immunostaining Whole-genome amplification
b
CG
T
A
B
Denature
Anneal
b
G
T
A
B
CG
T
A
B
Allele specific primer extension
c.
Whole-genome amplify target DNA
AA A-DNP SNP1
CC C-bio SNP2
AC P A-DN C-bio SNP3
Detect hapten-labeled bases by immunostaining Figure 2 High-throughput genotyping of known variants. (a) Whole-genome sampling assay. This chemistry is used by the Affymetrix whole-genome products. (b) Allele-specific primer extension with immunodetection of incorporated label (Infinium I). (c) Single-base extension with hapten-labeled nucleotides (Infinium II). Infinium I and II chemistries are used by the Illumina genotyping platform. 120
Beaudet
·
Belmont
Annu. Rev. Med. 2008.59:113-129. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-08
ARI
7 December 2007
13:56
self-assembling high-density microbead array (21). In the Infinium assays, genomic DNA is first subjected to WGA, and those products are hybridized to an array of locus-specific 50-mer capture probes. Either primer extension or single-base extension reactions on the array surface are used for allele discrimination. Signal amplification by means of antibody methods familiar to users of ELISA assays are used to enhance the sensitivity. A distinct advantage of this class of assays is that the “assay conversion” (percentage of SNPs that actually allow inference of the genotype in the final assay mixture) is very high.
RECENT SUCCESSES IN GENOME-WIDE ASSOCIATION STUDIES There has been deserved skepticism among geneticists about the likelihood that association studies will identify the genetic loci underlying common diseases. The validity of case-control study results has often been undermined by inadequate sample sizes, mismatching of cases and controls, inadequate understanding of the variation in patterns of LD across the genome, and the necessity to select candidate genes. This very discouraging picture began to change a few years ago with the publication of association studies that tested genomic regions first identified in linkage analyses. In these cases, the preliminary linkage studies provided crucial information not only about the possible location of the disease loci but also about the likely magnitude of locus-specific effects and other features of the genetic architecture in the specific diseases being studied. The successful identification of genetic variants underlying type I diabetes and inflammatory bowel disease provides some timely examples. This route was also helpful in identifying genes for less common but complex diseases such as Hirschsprung anomaly and nonsyndromic cleft lip and palate.
With the dramatic increase in the number of SNPs identified in targeted and shotgun resequencing efforts (>15 million recorded in the dbSNP database), it has become possible to test direct associations to large numbers of SNPs that alter protein function. There are about 58,500 known SNPs whose positions in the protein-coding exons lead to nonsynonymous amino acid substitutions (nsSNPs). Two recent genome-wide surveys of nsSNPs illustrate how this approach can be successful. Smyth et al. (22) demonstrated that variants in the innate immunity viral RNA receptor gene (IFIH1) on chromosome 2q24.3 confer risk for type 1 diabetes. The identification of this locus reinforced our previous understanding that autoimmune responses following viral infection are central pathways in that disease. In another example of genome-wide testing of possibly functional polymorphisms, Hampe et al. (23) screened for association of Crohn’s disease with almost 20,000 nsSNPs. This led to the discovery of an important role for the ATG16L1 locus, which encodes a component of a large protein complex essential for autophagy. Autophagy is the intracellular process in which membrane-bound autophagosomes deliver cytoplasmic elements to lysosomes for degradation. A unifying theme in inflammatory bowel disease research appears to be impairment of the handling of intracellular bacterial pathogens. The availability of genotyping platforms that can inexpensively analyze 100,000 to one million SNP markers in a single DNA sample allows studies to take an “agnostic” approach to genomic association. Without any prior information about genes or pathways, it is possible to ask whether any gene shows strong association with a disease. Since 2005 there have been several studies that did not rely on linkage analysis to focus attention on a single genomic region. Examples of disorders studied in this way include age-related macular degeneration, obesity, coronary artery disease, type I diabetes, and type II diabetes. In perhaps the earliest example of success with www.annualreviews.org • Array Diagnostics
121
ARI
7 December 2007
13:56
the GWAS strategy, several groups independently demonstrated a large risk effect for age-related macular degeneration caused by a common variant in the complement factor H gene (24). This gene was previously unsuspected, and its exact role in the disorder is not yet clear. Very large studies, perhaps best exemplified by the Wellcome Trust Case Control Consortium (WTCCC), have shown that an integration of epidemiological studies with genetic analysis can identify the most important common variants contributing to disease. In the WTCCC studies, ∼2000 DNA samples from each of seven common diseases—bipolar disorder, coronary artery disease, Crohn’s disease, rheumatoid arthritis, types I and II diabetes, and hypertension— were compared to 3000 common control individuals. The study yielded strong confirmations of several genes that had been previously associated, showing a total of 24 associations that reached genome-wide significance ( p < 5 × 10−7 ). In addition to those associations, 58 more had suggestive significant associations (10−5 < p < 5 × 10−7 ). Some of these have been validated in powerful replication studies (25–27). This multistage process, in which the initial genome screen is used to identify the most promising loci for further testing, is expected to be very useful in the future. The WTCCC and several just-published studies using genome-wide association analysis have now provided strong evidence that GWAS can identify the variants that increase risk of disease with relatively small locus-specific effects. Table 1 is not meant to be a comprehensive list of diseases and loci but merely summarizes some of the largest and highest-impact studies (22–44). Several broad conclusions can be inferred from these studies. First, as previously suspected, there appear to be certain key pathways in each disease, and genetic variants af-
Annu. Rev. Med. 2008.59:113-129. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-08
122
Beaudet
·
Belmont
fecting a pathway can interact to increase risk. Second, the locus-specific risks are typically very low. This requires that both primary and replication studies be very large in order to achieve the statistical power necessary to detect and validate associations. Third, most of the risk genes identified were not strong functional candidates, highlighting the necessity for an unbiased genome-wide approach. Fourth, the functional consequences of SNP variants identified to date are often regulatory, so simply scanning for amino acid substitutions or sequencing of exons will have only limited effectiveness.
HIGH-THROUGHPUT GENOTYPING AND ANALYSES OF KNOWN MUTATIONS Genotyping platforms that are useful for testing SNPs can also be adapted to testing for much rarer genetic variants that have strong causal roles in disease. The literature is not yet extensive but points toward much greater use of these assays in the future. The molecular inversion probe (MIP) assay (45, 46), array-based primer extension (APEX), and GoldenGate assays (47) are examples that exploit a combination of linked specificity steps with a universal PCR. MIP uses padlock probes whereas GoldenGate uses allele-specific primer extension for singlebase interrogation. Both MIP and GoldenGate use universal PCR to amplify the diverse locus-specific assays, a process that allows multiplexing at a level in which thousands of genomic loci are interrogated in parallel in the same reaction. The amplicons in this PCR reaction all contain short, unique “address tags” that are used as indicators for the individual assays. Both MIP and GoldenGate are read out through hybridization of the multiplex PCR products to a standardized array of oligonucleotides that are complementary to the address sequences. Arrayed mutation
Annu. Rev. Med. 2008.59:113-129. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-08
ARI
7 December 2007
13:56
Table 1
Findings of some genome-wide association studies
Disease
Genotyping strategy
Gene
Function
References
breast cancer
500K tag SNP
FGFR2
increased expression of receptor tyrosine kinase
29
coronary heart disease
500K tag SNP
9p21
unknown
28, 30
dry age-related macular degeneration
100K tag SNP
CFH
inflammation
24
exudative age-related macular degeneration
100K tag SNP and positional tag SNP
HTRA1
increased expression of a secreted serine protease
31, 32
inflammatory bowel disease (Crohn’s)
300K tag SNP
IL23R
IL23 signaling
28, 33
nonsynonymous SNPs
ATG16L1
autophagosome pathway
23
positional cloning and 500K tag SNP
CARD15/NOD2
caspase recruitment
28, 34
300K tag SNP and 500K tag SNP
5p13.1
gene desert modulates expression of PTGER4
28, 35
Positional tag SNPs and 500K tag SNP
5q31
cytokine gene cluster
28, 36
500K tag SNP and replication
IRGM
GTP-binding protein that induces autophagy
25, 28
MST1
phagocytosis
25, 28
NKX2–3
intestinal lymphoid development
25, 28
PTPN2
T cell phosphatase regulator of inflammatory responses
25, 28
100K tag SNP
INSIG2
insulin-induced gene 2
37
replication
FTO
unknown
38, 39
prostate cancer
300K tag SNPs
8q24
unknown
40, 41
rheumatoid arthritis
500K tag SNP
HLA-DRB1
antigen presentation
28
500K tag SNP
PTPN22
signal transduction
28
nonsynonymous SNPs, 500K tag SNP, replication
IF1H1
innate immunity viral RNA receptor
22, 26, 28
500K tag SNP, replication
12q24, SH2B3
signal transduction via pleckstrin homology domain
26, 28
500K tag SNP, replication
ERBB3
growth factor receptor
26, 28
500K tag SNP, replication
16p13
unknown
26, 28
500K tag SNP, replication
PTPN2
T cell protein tyrosine phosphatase
26, 28
candidate, 500K tag SNP
INS
insulin
28
candidate, 500K tag SNP
PTPN22
signal transduction
28
candidate, 500K tag SNP
CD25
IL2 receptor subunit
28
candidate, 500K tag SNP
CTLA4
T cell activation
28
obesity
type I diabetes
(Continued )
www.annualreviews.org • Array Diagnostics
123
ANRV334-ME59-08
Table 1
ARI
7 December 2007
13:56
(Continued ) Genotyping strategy
Gene
Function
References
type II diabetes
500K tag SNP, replication
CDKAL1
cyclin-dependent kinase 5 (CDK5) regulatory subunit associated protein 1–like 1
27, 28, 42, 43
500K tag SNP, replication
CDKN2A/ CDKN2B
regulator of pancreatic beta cell replication
27, 28, 42, 43
500K tag SNP, replication
IGF2BP2
insulin-like growth factor binding protein
27, 42, 43
500K tag SNP, replication
HHEX IDE
homeobox transcription factor, insulin degrading enzyme
27, 28, 42–44
100K and 300K (Illumina) tag SNP, replication
SLC30A8
zinc transporter
27, 42–44
500K tag SNP, replication
TCF7L2
transcription factor
27, 28, 42, 44
300K tag SNP
FTO
unknown
42
300K tag SNP
PPARG
peroxisome proliferator-activated receptor-gamma
42
300K tag SNP
KCNJ11
potassium channel
42
Annu. Rev. Med. 2008.59:113-129. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
Disease
assays have been developed for mutations in specific genes, such as ABCA4 (48), for disorders with extensive locus heterogeneity, exemplified by Leber’s congenital amaurosis (49) and nonsyndromic congenital deafness (50). We believe that such assays could play a major role in clinical diagnosis and carrier testing for the majority of known Mendelian diseases.
NEXT-GENERATION DNA SEQUENCING ON ARRAYS New technologies that promise to dramatically increase the throughput and reduce the cost of DNA sequencing are being intensely investigated (51). Unlike Sanger sequencing, which produces sequence data by controlled termination of the polymerase, the new techniques derive the sequence as nucleotides are sequentially added by the polymerase. Two of these chemistries have now been developed into early-stage high-throughput sequencing
124
Beaudet
·
Belmont
instruments (Figure 3). The first of these uses pyrosequencing chemistry. Pyrosequencing works by detecting the release of pyrophosphate as nucleotides are added to a DNA primer hybridized to template DNA (52). DNA polymerase can extend the primer when there is a complementary dNTP available but stops when only a noncomplementary base is present. DNA synthesis is reinitiated following the addition of the next complementary dNTP. Pyrophosphate is released as the base is added to the growing DNA chain and detected by enzyme amplification. The sequencing instrument controls the order of dNTP addition to the reaction. The order of base addition combined with the light emission is then decoded as the sequence. The 454 Life Sciences Corporation exploits pyrosequencing on an array of ∼300,000 microscopic (40 μm) wells (Figure 3a). The wells each contain a single sepahrose bead on which are coupled the reaction products of a single molecule of template DNA, which itself has been amplified in
ARI
7 December 2007
13:56
an oil-water emulsion (53). An advantage of clonal amplification is that it neatly deals with the problem of heterozygosity. The pyrosequencing reaction is monitored in a fiber optic system. Read lengths of ∼250 nucleotides are feasible. Another general method of sequencing is called cyclic reversible termination (CRT). CRT uses cycles of base addition, imaging, and deprotection to follow the sequence of DNA synthesized on an unknown template. Fluorescence CRT exploits fluorescentdye-labeled reversible terminator nucleotides (Figure 3b). These specialized nucleotides have a protecting group that terminates DNA synthesis. The fluorescent label can then be imaged. Catalytic removal of the protecting group allows another cycle of base addition and imaging. An instrument and reagents that exploit this method have been introduced by Solexa, Inc. Solexa’s method combines this chemistry with in situ amplification of large numbers of single DNA molecules. Two recent studies are among the first to exploit next-generation sequencing methods. In a survey of mutations in epidermal growth factor receptor (EGFR), an oncogene known to be important in a variety of cancers, specific mutations were identified in tumors and archived paraffin block samples using 454 pyrosequencing (54). This method holds promise for very sensitive detection of low-level genetic mosaicism that may be important in many neoplastic diseases. In another recent study, array sequencing on the Solexa instrument was used to identify methylation patterns in the genome (55). Those investigators systematically surveyed the distribution of 20 methylations of histone, lysine, and arginine across the genome, introducing a very powerful way to obtain a genome-wide view of chromatin control of gene expression. Simultaneous sequence analysis of >1 million molecules per assay is possible. The general goal of a “$1000 genome” articulated by the
National Human Genome Research Institute no longer seems like a pipedream. Although there will be some lag in clinical application, it is highly likely that mutation scanning of large numbers of genes or even complete genome sequencing will be feasible in the near future.
a.
Beads with capture oligos
Distribution of beads to picoliter wells
Emulsion PCR
PPi
dNMP
light
Annu. Rev. Med. 2008.59:113-129. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-08
ATP Luciferase
PPi + APS Sulfurylase
Read out with fiber optic coupling to individual wells
b.
• Attach single molecules to surface • Amplify on surface to form clusters • 32M clusters per run
Pyrosequencing reaction
anchor primers
incorporation 4-color fluorescent-labeled dNTPs
imaging
deprotection Figure 3 Next-generation sequencing methods. (a) Pyrosequencing microfabricated picoliter reactors. This technology has been developed by 454 Life Sciences Corporation. (b) Sequencing by synthesis. Clusters of amplified DNA products are formed by a bridge PCR method using paired anchor oligos. Sequencing is accomplished by cycles of incorporation, imaging, and deprotection. This method is used by the Solexa/Illumina instrument.
www.annualreviews.org • Array Diagnostics
125
ANRV334-ME59-08
ARI
7 December 2007
13:56
SUMMARY POINTS 1. Array-based analysis of genomic DNA has now entered clinical practice as a method to test for submicroscopic chromosomal aberrations. 2. Array methods for high-throughput genotyping of known genetic variants are being extensively used to identify genetic associations with complex common diseases. 3. Unbiased genome-wide association studies (GWASs), in which very large numbers of SNPs serve as proxies for the most common genetic variants in the population, are now technically feasible. They are proving to be a very powerful way to identify and replicate robust associations of variants with diseases such as breast and prostate cancer, autoimmune diseases, and cardiovascular disease. Annu. Rev. Med. 2008.59:113-129. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
4. Next-generation methods for DNA sequencing rely on scaling new and established sequencing chemistries in highly parallel array formats. Array-based sequencing should lead to research and clinical applications in both inherited and neoplastic diseases.
DISCLOSURE STATEMENT The authors are faculty members in the Department of Molecular and Human Genetics at Baylor College of Medicine (BCM), which generates revenue by offering extensive genetic laboratory testing including use of arrays for genomic copy number analysis. BCM has a collaborative marketing agreement with Athena Diagnostics and currently uses arrays manufactured by Agilent Technologies.
LITERATURE CITED 1. Ylstra B, van den Ijssel P, Carvalho B, et al. 2006. BAC to the future! or oligonucleotides: a perspective for micro array comparative genomic hybridization (array CGH). Nucleic Acids Res. 34:445–50 2. Lupski JR, de Oca-Luna RM, Slaugenhaupt S, et al. 1991. DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell 66:219–32 3. Lupski JR, Stankiewicz P. 2006. Genomic Disorders—The Genomic Basis of Disease. Totowa, NJ: Humana Press. 427 pp. 4. Lupski JR, Stankiewicz P. 2005. Genomic disorders: molecular mechanisms for rearrangements and conveyed phenotypes. PLoS Genet. 1:e49 5. Sharp AJ, Locke DP, McGrath SD, et al. 2005. Segmental duplications and copy-number variation in the human genome. Am. J. Hum. Genet. 77:78–88 6. Sharp AJ, Hansen S, Selzer RR, et al. 2006. Discovery of previously unidentified genomic disorders from the duplication architecture of the human genome. Nat. Genet. 38:1038–42 7. Locke DP, Sharp AJ, McCarroll SA, et al. 2006. Linkage disequilibrium and heritability of copy-number polymorphisms within duplicated regions of the human genome. Am. J. Hum. Genet. 79:275–90 8. Redon R, Ishikawa S, Fitch KR, et al. 2006. Global variation in copy number in the human genome. Nature 444:444–54 9. Komura D, Shen F, Ishikawa S, et al. 2006. Genome-wide detection of human copy number variations using high-density DNA oligonucleotide arrays. Genome Res. 16:1575– 84 126
Beaudet
·
Belmont
Annu. Rev. Med. 2008.59:113-129. Downloaded from arjournals.annualreviews.org by Kennesaw State University on 10/06/08. For personal use only.
ANRV334-ME59-08
ARI
7 December 2007
13:56
10. Stankiewicz P, Beaudet AL. 2007. Use of array CGH in the evaluation of dysmorphology, malformations, developmental delay, and idiopathic mental retardation. Curr. Opin. Genet. Dev. 17:182–92 11. Lu X, Shaw CA, Patel A, et al. 2007. Clinical implementation of chromosomal microarray analysis: summary of 2513 postnatal cases. PLoS ONE 2:e327 12. Shaffer LG, Kashork CD, Saleki R, et al. 2006. Targeted genomic microarray analysis for identification of chromosome abnormalities in 1500 consecutive clinical cases. J. Pediatr. 149:98–102 13. Vorstman JA, Staal WG, van Daalen E, et al. 2006. Identification of novel autism candidate regions through analysis of reported cytogenetic abnormalities associated with autism. Mol. Psychiatry 11(1):18–28 14. Jacquemont ML, Sanlaville D, Redon R, et al. 2006. Array-based comparative genomic hybridisation identifies high frequency of cryptic chromosomal rearrangements in patients with syndromic autism spectrum disorders. J. Med. Genet. 43:843–49 15. Sebat J, Lakshmi B, Malhotra D, et al. 2007. Strong association of de novo copy number mutations with autism. Science 316:445–49 16. Beaudet AL. 2007. Autism: highly heritable but not inherited. Nat. Med. 13:534–36 17. Van den Veyver IB, Beaudet AL. 2006. Comparative genomic hybridization and prenatal diagnosis. Curr. Opin. Obstet. Gynecol. 18:185–91 18. Shuster E. 2007. Microarray genetic screening: a prenatal roadblock for life? Lancet 369:526–29 18a. Hirschhorn JN, Daly MJ. 2005. Genome-wide association studies for common diseases and complex traits. Nat. Rev. Genet. 6:95–108 19. Fan JB, Chee MS, Gunderson KL. 2006. Highly parallel genomic assays. Nat. Rev. Genet. 7:632–44 20. Kennedy GC, Matsuzaki H, Dong S, et al. 2003. Large-scale genotyping of complex DNA. Nat. Biotechnol. 21:1233–37 21. Peiffer DA, Le JM, Steemers FJ, et al. 2006. High-resolution genomic profiling of chromosomal aberrations using Infinium whole-genome genotyping. Genome Res. 16:1136–48 22. Smyth DJ, Cooper JD, Bailey R, et al. 2006. A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. Nat. Genet. 38:617–19 23. Hampe J, Franke A, Rosenstiel P, et al. 2007. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat. Genet. 39:207–11 24. Klein RJ, Zeiss C, Chew EY, et al. 2005. Complement factor H polymorphism in agerelated macular degeneration. Science 308:385–89 25. Parkes M, Barrett JC, Prescott NJ, et al. 2007. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn’s disease susceptibility. Nat. Genet. 39:830–32 26. Todd JA, Walker NM, Cooper JD, et al. 2007. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat. Genet. 39:857–64 27. Zeggini E, Weedon MN, Lindgren CM, et al. 2007. Replication of genome-wide association signals in U.K. samples reveals risk loci for type 2 diabetes. Science 316:1336–41 28. Wellcome Trust Case Control Consortium. 2007. Genome-wide association study of 14000 cases of seven common diseases and 3000 shared controls. Nature 447:661–78 29. Hunter DJ, Kraft P, Jacobs KB, et al. 2007. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic pos